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Abstract 
It is now well documented that the immune and skeletal systems are closely 
related and share many of the same regulatory pathways, such as cytokines, 
transcription factors and signalling pathways – a relationship that is now referred to as 
osteoimmunology. The immunomodulation of bone remodelling, a life-long and 
indispensable process in bone metabolism, is the foundation of this relationship. Bone 
remodelling is a process that consists of bone resorption, driven by osteoclasts, and 
bone formation, driven by osteoblasts, two states that are finely balanced under normal 
physiological conditions. The immune response under pathological conditions (i.e. , 
inflammation) results in dysregulated bone remodelling in conditions such as 
rheumatoid arthritis (RA), periodontitis, and apical periodontitis. The study of immune 
modulation of bone remodelling under inflammatory conditions promises to give us a 
better understanding of the mechanisms responsible for the bone loss associated these 
diseases and opens the door to new therapeutic approaches.    
Sphingosine-1-phosphate (S1P), together with its receptor, sphingosine-1-
phosphate receptor 1 (S1PR1), acts as a regulator of both the immune response and 
bone remodelling processes and, therefore, plays a vital role in osteoimmunology. 
S1P-S1PR1 signalling induces both osteoclastogenesis and osteogenesis, which 
suggest it has an intriguing dual role in inflammatory bone remodelling. Whereas 
dysregulated S1P-S1PR1 signalling is linked to bone loss in destructive inflammatory 
bone diseases such as RA, its role during infections has not been studied in any detail. 
Consequently, very little is known about the role of S1P-S1PR1 signalling in infection-
induced inflammatory bone remodelling, which forms the topic of this thesis. 
In this thesis, the status of S1P-S1PR1 signalling in an infection-induced bone 
destructive disease, namely apical periodontitis, were investigated. It was noted that 
S1P-S1PR1 signalling was abnormally activated and associated with the expression of 
RANKL, a key factor in osteoclastogenesis. An animal model of apical periodontitis 
further confirmed the role of S1P-S1PR1 signalling in inducing infectious 
inflammatory bone loss. 
Although there was a link between S1P-S1PR1 signalling and enhanced RANKL 
production to induced bone loss, it was still unknown what triggered the activation in 
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response to infection-induced inflammatory conditions. Using an in vitro co-culture 
system, the interaction between macrophages and bone marrow-derived mesenchymal 
stromal cells (BMSCs) in response to lipopolysaccharides (LPS) stimulation was 
found. Increased S1P production in BMSCs could activate S1PR1 and activated 
S1PR1 subsequently led to increased RANKL expression in BMSCs, which eventually 
resulted in induced osteoclastogenesis and bone loss.  
Furthermore, since bone remodelling consists of osteoclastogenesis and 
osteogenesis, we sought to determine the status of osteogenesis under the effects of 
infection-induced inflammation environment. Interestingly, osteogenic markers were 
found to be upregulated in BMSCs co-cultured with macrophages, especially under 
the infection-induced inflammatory condition. Using siRNA techniques to block 
S1PR1 expression, it was demonstrated that osteogenesis was due to S1P-S1PR1 
signalling activation in the inflammatory condition. Therefore, the interactions 
between macrophages and BMSCs could activate S1P-S1PR1 signalling and lead to 
increased osteogenesis in inflammatory conditions.  
Taken together, the data from this study demonstrates that S1P-S1PR1 signalling 
is abnormally activated in infection-induced inflammation, which is likely to be 
partially due to the interactions between macrophages and BMSCs. The S1P-S1PR1 
signalling appears to have a crucial role in inflammatory bone remodelling by 
stimulating RANKL expression in BMSCs and, therefore, facilitating 
osteoclastogenesis, while on the other hand also inducing osteogenesis. This study 
adds to our understanding of the pathogenesis of bone destruction or abnormal bone 
formation in infectious inflammatory diseases, knowledge that will aid in the future 
development of new therapies for the treatment of conditions such as periodontitis. 
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Chapter 1: Introduction 
1.1 BACKGROUND 
The skeletal system undergoes a constant life-long process of adaptation, which 
consists of osteoclast-driven resorption and osteoblast-driven formation (Raggatt & 
Partridge, 2010). This dynamic turnover of bone is termed bone remodelling and plays 
a key role in maintaining bone strength and integrity (Hadjidakis & Androulakis, 2006). 
Under physiological conditions, bone remodelling is highly regulated and maintained 
in a balanced state by the immune system such that the amount of bone formation 
equals that of bone resorption (Arron & Choi, 2000). Under pathological conditions 
such as inflammation, this balance is disrupted; the over-activated immune response 
results in over-induced osteoclastogenesis and dysregulated osteogenesis, which 
eventually breaks the balance of remodelling, as seen in rheumatoid arthritis (RA) 
(Rodan & Martin, 2000), periodontitis (Taubman, Valverde, Han, & Kawai, 2005), 
and apical periodontitis (Wang & Stashenko, 1993). Therefore, studying this 
inflammatory response will help us reach a better understanding of the pathogenesis  
of destructive inflammatory bone diseases and the search for new therapeutic 
approaches for these diseases. 
Among the immune-related factors, one of the most important sphingolipid 
metabolites, sphingosine-1-phosphate (S1P) together with its receptor sphingosine-1-
phosphate receptor 1 (S1PR1), plays a vital role in the regulation of both the immune 
response and the bone remodelling process (Maceyka, Harikumar, Milstien, & Spiegel, 
2012; Rivera, Proia, & Olivera, 2008). The S1P-S1PR1 signalling activates the 
immune response and hence facilitates osteoclastogenesis, however, it is also found to 
induce osteogenesis. This suggests that the role of S1P-S1PR1 in remodelling is more 
complicated and intriguing than first thought, especially under inflammatory 
conditions (Pederson, Ruan, Westendorf, Khosla, & Oursler, 2008; Sato, Iwasaki, 
Kitano, Tsunemi, & Sano, 2012). This signalling has been found to be abnormally 
activated in destructive inflammatory bone diseases such as RA which is involved in 
the aberrantly-induced immune response and osteoclastogenesis during the onset and 
development of RA (Kitano et al., 2006). The mechanism governing the role of S1P-
S1PR1 in RA is still unclear and in need of further research, as is its the role of in 
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infection-induced bone loss. Invading pathogens have been found to affect the status 
of S1P-S1PR1 signalling and consequently lead to dysregulated immune modulation 
(Arish et al., 2015), further complicating the picture. Hence, it is of great importance 
to study the role of S1P-S1PR1 signalling in infection-induced inflammatory bone 
remodelling. 
 
1.2 PURPOSES 
The main purpose of this study is to investigate the involvement of S1P-S1PR1 
signalling in infection-induced bone loss in apical periodontitis, to detect the cell-cell 
interaction (i.e. macrophages and bone marrow stem cells) based on S1P-S1PR1 
signalling in infectious inflammatory condition, and to reveal the possible roles and 
mechanisms of this signalling in inflammatory bone remodelling. The main questions 
to be addressed are the follows: 
• What is the status of S1P-S1PR1 signalling in inflammatory destructive 
bone disease caused by infection? Is it related to the induced bone loss?  
• What makes the status of this signalling abnormal under the infection-
induced inflammatory condition?    
• How does the S1P-S1PR1 signalling affect bone remodelling in the 
infection-induced inflammatory condition? 
    
1.3 POSSIBLE OUTCOMES AND SIGNIFICANCE  
Despite many previous studies, it is still unclear how S1P-S1PR1signalling 
affects bone remodelling during inflammation, especially in the infection-induced 
diseases. Furthermore, it is not fully understood how this signalling becomes activated 
during inflammation and what kind of cells are involved in this activation. Based on 
this, it is hypothesized that the S1P-S1PR1 signalling is dysregulated during infection-
induced bone destruction, which results in dysregulated bone remodelling under 
inflammatory conditions. This study will, therefore, shed some light on the 
pathogenesis of destructive bone diseases, and also provide potential new therapeutic 
approaches for the prevention and treatment of these diseases.    
 Dissecting the Role of Sphingosine 1-Phosphate--Sphingosine 1-Phosphate Receptor 1 in Inflammatory Bone 
Remodelling 19 
1.4 THESIS OUTLINE 
The content of each chapter (except for Chapter 1) included in this thesis are 
listed below: 
Chapter 2, is an in-depth review of the available literature on S1P-S1PR1 
signalling and osteoimmunology (the interaction of the immune and skeletal systems). 
In this review, the bi-directional regulation between cells from immune and skeletal 
systems is highlighted, with particular emphasis given to how this interaction affects 
the process and balance of bone remodelling. Then, the direct effects of S1P-S1PR1 
signalling on osteoclastogenesis, osteogenesis, and osteoclast-osteoblast coupling is 
illustrated. The role of this signalling in immune modulation is explained, as well as 
the possible impacts of these modulations on bone remodelling. Finally, the 
significance of the S1P-S1PR1 signalling in destructive bone diseases, and the 
available therapeutic approaches based on this signalling are evaluated. 
In Chapter 3, the status of S1P-S1PR1 signalling was examined and found to be 
abnormally activated in the apical periodontitis lesions. The animal model further 
confirmed the activation of S1P-S1PR1 signalling and its possible relation with over-
activated osteoclastogenesis. This relationship was verified by modulation of the S1P-
S1PR1 signalling to reduce bone loss. Taken together, it was found that the S1P-
S1PR1 signalling was induced during infection-stimulated inflammation, and was 
actively involved in the pathogenesis of bone loss by enhancing osteoclastogenesis.  
In Chapter 4, the interaction between macrophages and bone marrow-derived 
mesenchymal stromal cells (BMSCs) was considered to be involved in the activation 
of S1P-S1PR1 signalling during infections. To uncover how this activation happens, 
an in vitro co-culture system of macrophages and BMSCs was stimulated with 
lipopolysaccharide (LPS), a component of the outer membrane of Gram-negative 
bacteria which triggers a strong immune response in mammals, in order to mimic 
infection. Under these circumstances, the secreted factors derived from macrophages 
were found to induce the S1P production of BMSCs, which acted in an autocrine 
manner to activate S1PR1 in BMSCs. S1PR1 was found to result in enhanced RANKL 
(an indispensable factor in osteogenesis) production in BMSCs. In this Chapter, the 
interaction between macrophages and BMSCs, when exposed to LPS, resulted in the 
activation of S1P-S1PR1 signalling in BMSCs, which eventually induced 
osteoclastogenesis by stimulating RANKL expression. 
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In Chapter 5, the possible impacts of S1P-S1PR1 signalling on osteogenesis 
during infection-induced inflammation were investigated. Osteogenic markers were 
up-regulated in BMSCs co-cultured with macrophages, especially under the infection-
induced low inflammatory condition. The expression of osteogenic markers was 
reduced when S1PR1 was blocked in BMSCs in the co-culture system, which indicated 
that S1P-S1PR1 has an essential role in promoting osteogenesis during low infection-
induced inflammation. 
Chapter 6 summarized the findings and discussed future perspectives based on 
what are the limitations of this study. 
 
 
 Dissecting the Role of Sphingosine 1-Phosphate--Sphingosine 1-Phosphate Receptor 1 in Inflammatory Bone 
Remodelling 21 
Chapter 2: Literature Review 
Suggested Statement of Contribution of Co-Authors for Chapter by 
Published Paper 
 
In the case of this chapter 
Title: S1P-S1PR1 signalling: the “Sphinx” in osteoimmunology 
Date, status, journal: Nov 2016, Submitted, Nature Reviews Rheumatology 
 
Contributor Statement of contribution 
Lan Xiao 
 
Involved in the concept and design of the project, wrote the 
manuscript. 
Yinghong Zhou Involved in the conception and design of the project, and 
reviewed the manuscript. 
Thor Friis Assisted with manuscript preparation. 
Yin Xiao Involved in the conception and design of the project, and 
reviewed the manuscript. 
 
 
Principal Supervisor Confirmation 
I have sighted email or other correspondence from all Co-authors confirming their 
certifying authorship. 
Name:    Prof Yin Xiao               Signature:                                
Date:  27th July 2016 
 
 Dissecting the Role of Sphingosine 1-Phosphate--Sphingosine 1-Phosphate Receptor 1 in Inflammatory Bone 
Remodelling 22 
S1P-S1PR1 signalling: the “Sphinx” in osteoimmunology 
2.1 ABSTRACT 
Bone remodelling is strictly regulated by immune modulators to maintain the balance 
between bone resorption and formation. This fundamental interaction between the 
immune and skeletal systems is described as osteoimmunology, a process achieved 
through a number of modulators. Among these modulators is the pleiotropic 
sphingolipid metabolite, S1P, which together with its cognate receptors, the S1PRs, 
are a known regulators of the immune system, which are also directly involved in the 
process of bone remodelling. S1P-S1PR1 signalling is considered essential for 
osteoimmunology, being a pathway capable of inducing an inflammatory response that 
stimulates osteoclastogenesis, as well as osteogenesis. Its role in bone remodelling is 
far from straight forward, especially under pathological conditions, such as 
inflammation. In this review, we highlight the dual role of S1P-S1PR1 signalling in 
bone remodelling and immune-modulation with an emphasizing on how osteo-
immune regulators are affected by inflammation, an issue with relevance to conditions 
such as rheumatoid arthritis and periodontitis. 
 
2.2 INTRODUCTION 
It has been long realized that the immune and skeletal systems are closely linked. 
The process of bone remodelling is a primary process required for bone homeostasis 
and consists of osteoclasts-driven bone resorption and osteoblasts-driven bone 
formation (Raggatt & Partridge, 2010). The immune progenitor cells-derived 
osteoclasts and mesenchymal stem cells-derived osteoblasts are linked via immune 
modulators and are, therefore, the fundamental cell types of these two interconnected 
systems. This relationship was first termed osteoimmunology to describe the 
interaction of cells from the immune and skeletal systems (Arron & Choi, 2000). 
Further studies within the realm of osteoimmunology have revealed that a complex 
system of mutual regulation exists between cells from the immune and skeletal systems. 
At one level, the immune response greatly affects osteoclast-osteoblast coupling and 
therefore mediates the balance between bone resorption and formation, whereas on 
another level, cells from skeletal system also have a profound effect on the 
differentiation and function of immune cells.     
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Sphingosine-1-phosphate (S1P) is one of the most important sphingolipid 
metabolites and has a number of roles that are essential in a diverse range of cellular 
processes during both physiological and pathophysiological conditions (Maceyka, et 
al., 2012). S1P is produced by various cell types and acts not only as an intracellular 
second messenger, but also an extracellular first messenger in both an autocrine and 
paracrine manner. It does this by binding with a class of G-protein-coupled receptors, 
known as sphingosine-1-phosphate receptors, of which there is currently five known 
subtypes, S1PR1 through to S1PR5, (Spiegel & Milstien, 2011). Of these receptors, 
S1PR1 is expressed in most types of mammalian cells (Aarthi, Darendeliler, & 
Pushparaj, 2011) and considered to be multifunctional in many biological processes. 
The S1P-S1PR1 signalling has long been addressed as a key regulator in immune 
response due to its involvement in the chemotaxis, activation, differentiation and 
function of immune cells (Rivera, et al., 2008). The elevated concentration of S1P, 
coupled with an up-regulation of S1PR1 expression locally within inflammatory 
tissues in many diseases, as well as the therapeutic effects of S1PR1 modulators, is an 
indication of the important role of S1P-S1PR1 signalling in inflammation (Maceyka, 
et al., 2012).  
S1P-S1PR1 signalling is considered to be a catalyst of inflammation by inducing 
osteoclastogenesis whilst reducing osteogenesis; however, the fact that this pathway is 
also active during bone regeneration (Pederson, et al., 2008; Sato, et al., 2012) suggests 
a complex and rather intriguing role in bone remodelling. This review attempts to 
highlight the interactions between the immune and skeletal systems, how these 
interactions effect bone remodelling, and what is known about the role of S1P-S1PR1 
signalling in the emerging field of osteoimmunology. 
 
2.3 BONE REMODELLING & OSTEOIMMUNOLOGY 
2.3.1 Bone biology 
Bone is the main constituent of the vertebrate skeletal system and supports and 
protects a number of organs in the body (Steele & Bramblett, 1988). Bone plays an 
essential role in calcium metabolism, acting as the main repository of calcium, and 
also acts as reservoir of growth factors and cytokines. Bone marrow is a crucial organ, 
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not only for the capacity of haematopoiesis and fat storage, but also for its role as an 
important immune organ where immune cells develop and differentiate (Taichman, 
2005). The major cellular components of bone are osteoclasts, osteoblasts, and 
osteocytes. Besides cells, bone also consists of collagen and osteoid, as well as 
inorganic mineral deposits (Kini & Nandeesh, 2012). 
 
2.3.2 Bone remodelling 
     The skeleton undergoes a life-long and continuous process of remodelling, in 
which old bone is resorbed by osteoclasts and new bone replaced by osteoblasts 
(Raggatt & Partridge, 2010). Nearly 10% of the skeletal mass in an adult human is 
remodelled annually (Takayanagi, 2007). This dynamic bone turnover reshapes the 
skeleton during growth, maintains calcium homeostasis, repairs micro damages, and 
enables bone to adapt to different biomechanical forces. Bone remodelling, therefore, 
plays a key role in maintaining its strength and integrity (Hadjidakis & Androulakis, 
2006).  
     Osteoclasts and osteoblasts are the major players in the bone remodelling 
process. The hematopoietic stem cells (HSCs)-derived osteoclasts are considered the 
only cells capable of resorbing bone (Kini & Nandeesh, 2012). Osteoclast precursors 
fuse with each other to form a giant, multinucleated cell—the osteoclast (Boyle, 
Simonet, & Lacey, 2003). Osteoclastogenesis depends on receptor activator of nuclear 
factor-kappa B ligand (RANKL), a cytokine in the tumour necrosis factor (TNF) 
family (Lacey et al., 1998). RANKL activates its cognate receptor, receptor activator 
of nuclear factor-kappa B (RANK), initiating osteoclastogenic signals (Fig 1). The 
RANKL-RANK axis, together with the downstream NF-κB signalling pathway, is 
indispensable in osteoclastogenesis (Kong et al., 1999; Theill, Boyle, & Penninger, 
2002). Another key factor in osteoclast formation is macrophage colony-stimulating 
factor (M-CSF), which is critical in regulating survival and proliferation of osteoclast 
precursors (Yoshida et al., 1990). M-CSF also up-regulates RANK expression in 
osteoclast precursors, making the cells more sensitive to RANKL, thereby contributing 
to RANKL-RANK-derived osteoclastogenesis (Ross & Teitelbaum, 2005). 
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Figure 1. The RANKL-RANK axis mediated osteoclastogenic signals. RANK is activated when 
combining with its ligand RANKL. Activated RANK then triggers the down-stream osteoclastogenic 
signalling cascades. Activated TRAF6 induces the MAPK, IKK and NF-κB signalling, which 
eventually result in activation of NFATc1 and osteoclastogenesis. RANKL: receptor activator of nuclear 
factor factor-kappa B ligand. RANK: receptor activator of nuclear factor-kappa B. TRAF6: tumour-
necrosis factor (TNF) receptor-associated factor 6. IKK: inhibitor of nuclear factor kappa-B kinase. 
MAPK: mitogen-activated protein kinase. NF-κB: nuclear factor kappa B. AP-1: activator protein1. 
ErK: extracellular signal regulated kinase. JNK: c-Jun N-terminal kinase. NFATc1: nuclear factor of 
activated T-cells, cytoplasmic 1. 
 
     Osteoclastogenesis interacts with osteoblasts–the major producer of RANKL 
and M-CSF (Udagawa et al., 1990)–indicating that osteoclasts and osteoblasts are 
related “coupling” cells that link osteoclastogenesis to osteogenesis. Osteoblasts are 
derived from MSCs and are the main cell type responsible for bone formation (Kini & 
Nandeesh, 2012). The typical markers of osteogenesis include early stage markers 
such as alkaline phosphatase (ALP), type I collagen (COL1), runt-related transcription 
factor 2 (RUNX2), bone sialoprotein (BSP), and late stage markers such as osteopontin 
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(OPN) and osteocalcin (OCN). The Wnt/β-catenin and TGF-β signalling pathways, as 
well as the signal transducer and activator of transcription 3 (STAT3) signalling, are 
also considered to be crucial in the process of bone formation (Logan & Nusse, 2004; 
O’Brien, Gubrij, Lin, Saylors, & Manolagas, 1999; Urist, 1965). Besides RANKL and 
M-CSF, osteoblasts also produce osteoprotegerin (OPG), which, conversely, plays a 
“protective” role in bone by acting as a decoy receptor of RANKL and interrupts its 
binding to RANK, thereby impeding osteoclastogenesis (Simonet et al., 1997). Hence, 
osteoclasts and osteoblasts are interconnected by the RANKL/RANK/OPG axis, with 
the ratio of RANKL to OPG determining the balance between bone resorption and 
formation (Fonseca et al., 2004).  
     Under normal physiological conditions, bone remodelling is a strictly regulated 
process that must maintain bone formation at a rate equal to that of bone resorption 
(Arron & Choi, 2000). Skeletal pathologies arise when this balance is disrupted. The 
most common of such disorders is when bone remodelling is skewed towards 
resorption–that is, when osteoclastogenesis is aberrantly stimulated so the rate of bone 
resorption exceeds bone formation, resulting in a net bone loss, as seen in 
inflammatory diseases, such as rheumatoid arthritis (RA) (Rodan & Martin, 2000), 
periodontitis (Taubman, et al., 2005), and apical periodontitis (Wang & Stashenko, 
1993). Hence, studying the mechanisms of physiological/pathological remodelling 
could help us find therapeutic approaches against these diseases.  
 
2.3.3 Osteoimmunology 
     Evidence of the relationship between the immune and skeletal systems became 
apparent with the finding that IL-1, secreted by antigen-stimulated immune cells, 
played a positive role in osteoclastogenesis (Dewhirst, Stashenko, Mole, & 
Tsurumachi, 1985). Since then, many more studies have demonstrated the role of 
immune system on bone remodelling (Fig 2) (Takayanagi, 2007). Furthermore, cells 
derived from skeletal system, such as MSCs, are capable of regulating immune 
response (Nauta & Fibbe, 2007). Such findings gave birth to osteoimmunology, a field 
that is concerned with cellular and molecular interactions between immune and 
skeletal systems. 
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Regulations of the immune system on bone remodeling 
Classic examples of osteoimmunology are inflammatory bone diseases, such as 
RA, in which a dysregulated immune response causes excessive osteoclastogenesis 
and bone destruction (Firestein, 2003). The adaptive immune cells–T-helper cells–play 
a critical role by producing RANKL, the key factor in osteoclastogenesis, and also  
produce other factors that regulate bone remodelling. Cytokines derived from type 1 
helper T (Th1) cells, such as IFNγ and granulocyte-macrophage colony-stimulating 
factor (GM-CSF), suppress osteoclastogenesis by interrupting the RANK signalling 
(Fig 1) (Kim, Day, & Morrison, 2005; Lari et al., 2007; Miyamoto et al., 2001; 
Takayanagi et al., 2000). Other cytokines derived from type 2 helper T (Th2) cells, 
such as interleukin-4 (IL-4) and IL-10, also inhibit RANK signalling and osteoclast 
differentiation (Abu-Amer, 2001; Moreno, Kaczmarek, Keegan, & Tondravi, 2003; 
Park-Min et al., 2009). IL-6, which is produced by Th2 cells and M1 macrophages, 
induces osteoclastogenesis by promoting RANKL production, as well as stimulating 
IL-1 production, which amplifies the inflammatory response (Hashizume, Hayakawa, 
& Mihara, 2008; Kudo et al., 2003; Kurihara, Bertolini, Suda, Akiyama, & Roodman, 
1990). IL-6 also induces the differentiation of type 17 helper T (Th17) cells, which 
secrete the pro-inflammatory cytokine IL-17 (Kimura, Naka, & Kishimoto, 2007; 
Korn et al., 2008), which in turn promote RANKL secretion and osteoclastogenesis 
(Lubberts et al., 2003; Van Den Berg & Miossec, 2009)  
The immune-suppressive regulatory T (Treg) cells(Sakaguchi, Yamaguchi, 
Nomura, & Ono, 2008), inhibit osteoclastogenesis in a direct cell-to-cell contact-
dependent manner, by binding of cytotoxic T-lymphocyte-associated protein 4 
(CTLA-4) on Treg cells with CD80 and CD86 on osteoclast precursors; Treg cells also 
reduce osteoclastogenesis by secreting IL-4 and IL-10 (Zaiss et al., 2007). Another 
Treg cell-derived factor, TGF-β, has pleiotropic effects on osteoclastogenesis. On one 
hand, TGF-β can induce osteoclast differentiation by promoting RANK expression 
and regulate activator protein 1 (AP-1) signalling (Galvin, Gatlin, Horn, & Fuson, 
1999; Quinn et al., 2001), a key downstream effector of RANK (Fig 1). However, in 
osteoclast-osteoblast co-cultures, TGF-β can also suppress RANKL expression in 
osteoblasts, effectively applying the breaks on osteoclastogenesis (Quinn, et al., 2001).  
Cells from the innate immune system also contribute to the regulation of 
osteoclastogenesis. Macrophages, the major components of innate immunity, 
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constitute three sub-populations of cells: (1) non-activated M0 macrophages; (2) pro-
inflammatory M1 macrophages, which are classically activated by LPS or Th1 cell 
cytokines such as IFNγ; and (3) M2 macrophages, which is alternatively activated by 
Th2 cell cytokines, such as IL-4 or IL-13, and are classified as anti-inflammatory 
macrophages (Horwood, 2015; Mantovani et al., 2004; Mills, Kincaid, Alt, Heilman, 
& Hill, 2000; Murray et al., 2014). The M1 macrophages express IL-1α and IL-1β, 
TNF-α, nitric oxide (NO), and reactive oxygen species (ROS), whereas M2 
macrophages are characterized by the expression of IL-10, TGF-β, and arginase-1 
(Arg1) (Ho & Sly, 2009; Mantovani, et al., 2004; Tjiu et al., 2009). Macrophages are 
precursors of osteoclasts (Takeshita, Kaji, & Kudo, 2000) and secrete factors that 
actively affect osteoclastogenesis. The M1 macrophages express IL-1α and IL-1β 
which activates RANK signalling thereby inducing osteoclastogenesis, under both 
physiological and pathological conditions (Wei, Kitaura, Zhou, Ross, & Teitelbaum, 
2005; Zwerina et al., 2007). M1 macrophages also express TNF-α, which stimulates 
osteoclast differentiation by activating the NF-κB signalling (Kobayashi et al., 2000; 
Lam et al., 2000). In osteoblasts, TNF-α promotes RANKL expression, which also 
affects osteoclastogenesis (Kitaura et al., 2004; Zou, Hakim, Tschoep, Endres, & 
Bar‐Shavit, 2001). Whereas M1 macrophages secrete high levels of IL-12 and low 
levels of IL-10, M2 macrophages do the opposite: secreting high levels of IL-10 and 
low levels of IL-12 (Ho & Sly, 2009; Mantovani, et al., 2004; Tjiu, et al., 2009). IL-
10 is a negative regulator of osteoclastogenesis (Park-Min, et al., 2009) and IL-12 
suppresses osteoclast differentiation, by inducing the expression of IFNγ and GM-CSF, 
both of which downregulate RANK signalling (Nagata, Kitaura, Yoshida, & 
Nakayama, 2003).  
Compared with its role in osteoclastogenesis, the role of immune system in 
osteogenesis is not as clear cut. It has been reported that pro-inflammatory T cells and 
IFNγ can promote osteogenesis (Croes et al., 2016), whereas a mouse knockout study 
has shown that interferon gamma receptor 1 (IFNGR1) knockout resulted in lower 
bone density and inferior osteogenic capacity of MSCs (Duque et al., 2009), indicative 
of a positive role for IFNγ in osteogenesis; however, T cells and IFNγ can inhibit in 
vivo osteogenesis by downregulating RUNX2 (Liu et al., 2011). IL-17, another pro-
inflammatory cytokine with a seemingly contradictory role in osteogenesis, has been 
shown to enhance ALP activity and induce bone formation in vitro and in vivo (Huang 
 Dissecting the Role of Sphingosine 1-Phosphate--Sphingosine 1-Phosphate Receptor 1 in Inflammatory Bone 
Remodelling 29 
et al., 2009; Ono et al., 2016), but also inhibit osteogenesis in a calvarial defect model 
in rat (Kim et al., 2014). Treg cell-derived TGF-β has been identified as an activator 
of osteogenesis by promoting osteoblast differentiation and enhanced mineralization 
(Bonewald & Dallas, 1994). 
There are also conflicting results from studies of macrophage-derived cytokines. 
The M1-derived cytokines, IL-1 and TNF-α, have been identified as negative 
regulators of in vitro osteogenesis, since they impede the ALP activity and mRNA 
expression of ALP, COL1A1, RUNX2, OCN and OPN (Nanes, 2003; Perrien et al., 
2002). However, IL-1 is reported to induce in vitro osteogenesis via the Wnt-
5a/receptor tyrosine kinase–like orphan receptor 2 (Wnt-5a/Ror2) pathway ; moreover, 
in vivo bone formation is inhibited following antagonism of IL-1 receptor, suggesting 
IL-1 is required in osteogenesis (Ma et al., 2003; Sonomoto et al., 2012). It has also 
been suggested that TNF-α can facilitate bone formation, in spite of its suppression of 
RUNX2 and COL1, by enhancing the expression and activity of ALP and the 
expression of bone morphogenetic protein 2 (BMP-2) via the NF-κB pathway, (Hess, 
Ushmorov, Fiedler, Brenner, & Wirth, 2009). Conflicting results such as these indicate 
that the roles of IL-1 and TNF-α in osteogenesis remain unresolved. The conflict 
results might be due to the different doses and duration of stimulation of these factors. 
The opposite results between in vitro and in vivo studies imply that except for MSCs, 
other cells such as immune cells also take indispensable roles in in vivo osteogenesis; 
for this reason, it might be inaccurate to simply investigate the effect of some certain 
factors on MSCs in vitro, instead, more efforts should be put into the research on the 
interplay between MSCs and immune cells during osteogenesis. 
IL-6, which is classified as an M1 cytokine, can also enhance in vivo ALP 
activity via the immune signal mediator STAT3, a further indication of the ability of 
IL-6 to affect osteogenesis (Bellido, Borba, Roberson, & Manolagas, 1997; Blanchard, 
Duplomb, Baud’huin, & Brounais, 2009; Cho et al., 2007; Itoh et al., 2006; Sammons, 
Ahmed, El-Sheemy, & Hassan, 2004). Oncostatin M (OSM) is another M1 
inflammatory cytokine that acts via STAT3 and has a role in osteogenesis where it 
serves as a coupling factor between pre-osteoclasts and pre-osteoblasts by activating 
RUNX2. Studies with OSM or OSM receptor (OSMR) deficient mice show reduced 
bone healing, evidence for its role in osteogenesis (Guihard et al., 2012; Song, Jeon, 
Kim, Jung, & Kim, 2007). Besides secreting osteogenic factors, macrophages also 
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recruit MSCs. For example, the Osteoactivin (OA)/Glycoprotein non-metastatic 
melanoma protein B (GPNMB), a transmembrane glycoprotein mainly secreted by M2 
macrophages, is a chemotactic agent that stimulates the migration of MSCs (Wu, 
Sondag, Malcuit, Kim, & Safadi, 2015).   
In fractures, the acute inflammatory phase–characterized by the infiltration of 
M1 macrophages–is indispensable for bone healing. Secreted factors of M1 
macrophages, especially OSM can induce significant osteogenesis, whereas 
conditioned media (CM) from M2 macrophages does not elicit such a strong 
osteogenic effect despite being associated with tissue repair (Guihard, et al., 2012). 
The effect on osteogenic differentiation of pre-osteoblasts by direct co-culture with 
M0, M1, or M2 macrophages show that with any one of these will enhance osteogenic 
potential. Furthermore, the conversion of M1 to M2 macrophages significantly 
improves mineralization in the co-culture system (Loi et al., 2016). These similar 
studies all support the indispensable role of macrophages in osteogenesis. It could be 
presumed that the transient activation of M1 macrophages is essential for the early 
osteoblast activation, while M2 macrophages is indispensable for the later 
mineralization. It is now thought that inflammatory signals at the injury site serve as 
chemoattractant that causes macrophages to migrate to the defect. Once in place, the 
macrophages proliferate, polarize, and release functional factors, which then recruit 
MSCs to the injury site and induce bone formation (Takayanagi, 2007).  
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Figure 2. The immuno-regulation on bone remodelling. The two major players in bone remodelling 
– osteoclasts and osteoblasts are coupled through the RANKL-RANK-OPG axis, that osteoblasts-
derived RANKL combines with its ligand RANK in osteoclasts and plays an indispensable role in 
osteoclastogenesis; OPG (which is also derived from osteoblasts) reduces osteoclastogenesis by 
impairing the RANKL-RANK signalling. The immune system greatly takes part in osteoclastogenesis 
by producing RANKL; also, the immune-related factors either affect pre-osteoclasts, or interacts with 
osteoblasts to induce RANKL production to regulate osteoclastogenesis. On the other hand, the immuo- 
regulators also affect the process of osteogenesis. RANKL: receptor activator of nuclear factor factor-
kappa B ligand. RANK: receptor activator of nuclear factor-kappa B. OPG: osteoprotegerin.  
 
Immune-regulation mediated by cells from the skeletal system  
Skeletal system also exerts a regulatory effect on immune system. It is well 
recognised that MSCs, the non-hematopoietic multipotent stem cells that play a central 
role in osteogenesis, are capable of immunomodulation. MSCs are able to suppress the 
differentiation and function of cells from both innate and adaptive immune system, 
with the exception of Treg cells. MSCs are reported to affect macrophage polarization 
by inducing the M2 subsets; interfere with T cell proliferation, cytokine production 
and polarization, especially inducing the Treg cells differentiation whereas reducing 
that of Th17 cells. The similar reduction has also been found in the activation of 
dendritic cells (DCs), B cells and NK cells (Aggarwal & Pittenger, 2005; Fibbe, Nauta, 
& Roelofs, 2007; Gur-Wahnon, Borovsky, Beyth, Liebergall, & Rachmilewitz, 2007; 
Nauta & Fibbe, 2007; Németh et al., 2009). These immune-suppressing functions of 
MSCs are achieved either through direct cell-cell contact or secretion of soluble 
immune-modulators, some of which are produced constantly while others are 
produced when MSCs are exposed to inflammatory factors or activated immune cells 
(Bunnell, Betancourt, & Sullivan, 2010). The direct cell-cell contact suppression is 
achieved through the programmed death 1 (PD-1) pathway (Augello et al., 2005). The 
immune suppressive factors include prostaglandin E2 (PGE2), TGF-β, IL-10, 
indoleamine 2,3-dioxygenase (IDO), human leukocyte antigen G (HLA-G), 
hepatocyte growth factor (HGF), leukemia inhibitory factor (LIF), IL-1 receptor 
antagonist (IL-1RA), monocyte chemotactic protein 1 (MCP1), galectin-1, galectin-3, 
semaphorin-3A, TNF-α-induced protein 6 (TNAIP6) (Auletta, Deans, & Bartholomew, 
2012; Bunnell, et al., 2010).  
When toll-like receptors (TLRs) are activated by LPS, IFN-α/γ, or TNF-α, MSCs 
may exert immune-suppressive effects such as converting M1-like macrophages to 
M2-like macrophages by secreting PGE2 (Chen et al., 2010; Maggini et al., 2010; 
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Németh, et al., 2009). However, MSCs can also respond by producing pro-
inflammatory cytokines (Bunnell, et al., 2010), such as IL-1β and IL-6, or chemokine 
IL-8, which attract the migration of neutrophils and augment inflammatory response 
(Raicevic et al., 2010). It has emerged that similar to macrophages, human MSCs also 
polarizes into two distinct phenotypes: pro-inflammatory MSC1 and 
immunosuppressive MSC2 (Waterman, Tomchuck, Henkle, & Betancourt, 2010). 
TLR signalling plays an active role in this polarization, in which acute and low-level 
activation of TLR4 directs MSCs toward MSC1 phenotype, whereas TLR3 activation 
induces an MSC2 phenotype. MSC1 phenotype can also be induced by IFNs or direct 
contact with certain pro-inflammatory cells. Polarized MSCs are thought to play roles 
similar to that of M1 and M2 macrophages in tissue repair (Verreck, de Boer, 
Langenberg, van der Zanden, & Ottenhoff, 2006), with MSC1s contributing to early 
stage inflammation and MSC2s contributing to late tissue regeneration. 
Based on these findings, it is speculated that during physiological bone healing, 
the inflammatory signals at the injury site attract macrophages to migrate to the defect 
by means of a chemotactic response. Once in place, the macrophages polarize towards 
M1 phenotype and release functional factors, which play an indispensable role in the 
initial stage of bone formation by recruiting MSCs to the injury site and inducing 
osteogenesis. On the other hand, the MSCs-derived immune-suppression gradually 
induces the transition from M1 to M2 phenotypes. The importance of this transition 
implies that M2 macrophages might play an indispensable role in the later stage of 
bone formation. The critical mutual regulation between macrophages and 
osteoblasts/pre-osteoblasts should take a great part in osteogenesis; hence, studying on 
this interaction should be meaningful to bone regeneration.  
Over all, the skeletal and immune systems, which share a variety of regulatory 
molecules and mechanisms, exert mutual regulation of each other, and this interaction 
eventually maintains the physiological status of body. Cells from each system exert 
regulatory functions to maintain the homeostasis of bone. In addition, studies into the 
factors that are involved in the interplay between these two systems should give us a 
better understanding of osteoimmunology. Among these factors, the multifunctional 
sphingolipid metabolites-S1P, together with its receptors (i.e. S1PR1), not only acts as 
a key regulator in immune-regulation, but also directly affects the process of bone 
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remodelling, therefore, making the S1P-S1PR1 signalling essential for 
osteoimmunology.  
 
2.4 S1P-S1PR1 SIGNALLING & OSTEOIMMUNOLOGY 
2.4.1 The function of S1P and its receptor S1PR1 
Sphingolipid is a key component of mammalian cell membranes and undergo 
metabolism in response to certain stimulations (Rivera, et al., 2008). The sphingolipid 
is first cleaved to produce ceramide, which is then deacylated by ceramidases (CERase) 
to produce sphingosine. Phosphorylation of sphingosine forms the multifunctional 
bioactive lipid S1P, a mediator of a number of cellular processes, such as cell 
proliferation, survival, differentiation, migration, as well as cytokine and chemokine 
production (Spiegel & Milstien, 2011). The phosphorylation of sphingosine is based 
on sphingosine kinase 1 and 2 (SPHK1 and SPHK2). S1P can be reversibly degraded 
by S1P phosphatases (SPPs), or irreversibly degraded by S1P lyase (SPL) (Hannun & 
Obeid, 2008; Mechtcheriakova et al., 2007; Peest et al., 2008). SPHK1 is mainly 
present in the cytoplasm which, after being activated by certain stimuli, is translocated 
to the cell membrane where it can catalyse the phosphoration of sphingosine and result 
in the production of S1P (Pitson, 2011). SPHK1 is activated by factors such as TNF-α 
and IL-1β, as well as LPS. This activation was found to be dependent on extracellular 
signal regulated kinase (Erk) signalling (Billich et al., 2005; Hammad et al., 2008; Xia 
et al., 1998). Whereas SPHK1 is mainly responsible for the production of secreted S1P, 
SPHK2 induces the nuclear S1P production and, therefore, plays a role in the 
regulation of gene transcription (Hait et al., 2009).  
After its synthesis, S1P is readily degraded by SPL and SPPs in most mammalian 
cells, except in erythrocytes, which lack SPL and SPPs (Rosen, Gonzalez-Cabrera, 
Sanna, & Brown, 2009). Platelets also produced copious amounts of S1P due to an 
absence of SPL (Ito et al., 2007). This explains the discrepancy, under normal 
physiological conditions, between circulating S1P levels in the blood versus that of 
solid tissues, with S1P concentration being significantly higher in peripheral blood 
(micro-molar range) than in solid tissues. S1P is also maintained at relatively high 
level (greater than 100 nano-molars) in the lymph circulation, which is mainly due to 
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the presence of lymphatic endothelial cells (Pappu et al., 2007; Schwab et al., 2005; 
Venkataraman et al., 2008). Cells from the macrophage–monocyte lineage are also 
recognized as important producers of S1P (Ryu et al., 2006). Especially, under 
inflammatory conditions, SPHK1 is abnormally activated and produces high levels of 
S1P that is released into the local microenvironment. TNF-α also induces SPHK1 led 
production of S1P in human umbilical vein endothelial cells (HUVEC) and L929 
fibroblasts (Pettus et al., 2003; Xia, et al., 1998). Other inflammatory factors such as 
IL-1β and IFN-γ have also been shown to activate SPHK1 (Alvarez, Milstien, & 
Spiegel, 2007; Billich, et al., 2005), which partially explains the high S1P levels in the 
inflammatory tissues (Ledgerwood et al., 2008). Furthermore, the vascular leakage 
accompanied by inflammation may release S1P from blood to tissues, thereby raising 
the S1P concentrations within the inflammatory tissues (Kono & Proia, 2015). 
Intracellular S1P is considered a second messenger, which contributes to the 
suppression of apoptosis (Spiegel & Milstien, 2003), whereas the extracellular S1P 
regulates pleiotropic biological functions by binding with its cognate G-protein-
coupled receptors in an autocrine or/and paracrine manner (Sanchez & Hla, 2004). To 
date, the five known S1P receptors couple with diverse heterotrimeric G-protein 
subunits (known as Gαi, Gαq/11 and Gα12/13) following activation, thereby directing 
many diverse signalling pathways (Davis & Kehrl, 2009). Of these receptors, S1PR1 
is considered to be most widely expressed and found in most tissues, especially the 
lungs, brain, and immune organs (Cahalan et al., 2011; Chae, Proia, & Hla, 2004; Kono 
et al., 2014). S1PR1 is expressed by a variety of cells, and following activation S1P, 
interacts with Gαi which then activates the downstream signalling molecules (Fig 3), 
such as phospholipase C (PLC), phosphoinositide 3-kinase (PI3K), Ras guanosine 
triphosphatase (GTPase) and Rac GTPase. These molecules then subsequently activate 
their downstream signalling pathways, including NF-κB, p38 mitogen-activated 
protein kinase (MAPK), Erk, Akt, and mammalian target of rapamycin (mTOR) 
(Melendez et al., 2007; Nayak et al., 2010; Takabe, Paugh, Milstien, & Spiegel, 2008).  
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Figure 3. The S1P-S1PR1 signalling. Sphingolipid (derived from cell membrane) is cleaved (by 
sphingomyelinases, SMase) to ceramide. Ceramide is then deacylated by ceramidases (CERase) to 
produce sphingosine. S1P is produced by phosphorylation of sphingosine, which is mediated by SPHKs 
(SPHK1 and SPHK2, which can be activated by certain stimulus). S1P can be reversibly degraded by 
S1P phosphatases (SPPs), or irreversibly degraded by S1P lyase (SPL). On the other hand, S1P can be 
transported outside the cells and acts in the autocrine or paracrine manners to activate its receptor S1PR1. 
The S1PR1 then activates its down-stream signal cascades and therefore regulates diverse cell activities. 
S1P: Sphingosine-1-phosphate. S1PR1: Sphingosine-1-phosphate receptor 1. PLC: phospholipase C. 
PI3K: phosphoinositide 3-kinase.  NF-κB: nuclear factor kappa B. ErK: extracellular signal regulated 
kinase. mTOR: mammalian target of rapamycin. 
 
S1PR1 is considered a key player in the development of the vascular system and 
is highly expressed in differentiating endothelial cells (Liu et al., 2000). S1PR1 is 
required to maintain the integrity of endothelial cell barrier and thus regulates vascular 
permeability responses, especially under inflammatory conditions (Camerer et al., 
2009). SPHK1 is induced by inflammation and enhances S1P production of endothelial 
cells, which then acts in a feed-forward manner to stimulate more S1PR1 expression, 
counteracting the increased permeability caused by pro-inflammatory mediators e.g., 
LPS, thereby preventing otherwise lethal cell-leakage in response to inflammation. In 
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epithelial cells, S1PR1 take part in the maintenance of epithelial cell barrier integrity, 
which also initiates the immune defence against the invading pathogens (Eskan et al., 
2008). S1PR1 is expressed in MSCs and acts as a key regulator in cell migration, 
proliferation, differentiation, and survival (Pitson & Pébay, 2009), whereas in 
osteoclast- and osteoblast-precursor cells S1PR1 expression is associated with their 
differentiation (Ishii et al., 2009; Sato, et al., 2012), further testament to its role in bone 
remodelling.  
 
2.4.2   Role of the S1P-S1PR1 signalling in bone remodelling 
S1P has been found to induce both osteoclastogenesis and osteogenesis, a dual 
role that makes S1P-S1PR1 signalling all the more intriguing.  
S1P-S1PR1 signalling in osteoclastogenesis 
Together with its ligand S1P, S1PR1 directs chemotactic migration of osteoclast 
precursors in vitro and in vivo, thus having a directly involvement in 
osteoclastogenesis. S1P-S1PR1 signalling is thought to regulate osteoclast precursors 
trafficking to and from the bone surface, where the precursor cells fuse and 
differentiate into osteoclasts, which dynamically regulate bone mineral homeostasis 
and osteoclastogenesis (Ishii, et al., 2009). S1PR1-dependent chemo-attraction is only 
activated when S1P concentration is comparably low – high concentrations of S1P 
activates another receptor, S1PR2 on the precursor cells and triggers an S1PR2-
dependent chemo repulsion (Ishii, Kikuta, Shimazu, Meier-Schellersheim, & Germain, 
2010). This mechanism partially explains how these precursor cells are retained in the 
bone marrow, which has lower levels of S1P than in the peripheral blood. S1PR1 and 
S1PR2 act in a concerted manner to regulate osteoclast precursors egressing from bone 
marrow into circulation, depending on the relative concentrations of S1P. During 
RANKL-mediated osteoclast differentiation, the activity of SPHK1 (the catalyst for 
S1P synthesis) is significantly enhanced, resulting in increased production of S1P by 
the precursor cells. Conversely, inhibition of SPHK1 leads to suppression of 
osteoclastogenesis (Ryu, et al., 2006).  
S1P-S1PR1 signalling in osteogenesis 
Although S1P is considered an osteoclastogenic factor, it also plays a positive 
role in osteogenesis. In the process of BMP-2-mediated osteoblast differentiation, S1P 
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significantly induces ALP activity and the expressions of key bone formation markers, 
such as OCN and RUNX2. Enhanced BMP-2/Smad signalling is the result of MEK1/2-
Erk1/2 pathway activation (Sato, et al., 2012). Conditioned medium from osteoclasts 
can induce osteogenesis and is thought to be due to Wnt10b, BMP-6 and S1P secreted 
into the medium. And whereas S1P and BMP-6 can trigger the migration of pre-
osteoblasts towards bone resorption sites, S1P can also induced osteogenic 
differentiation of the same cells by activating S1PR1, a finding that became apparent 
when S1PR1 was blocked (Pederson, et al., 2008). These properties of S1P-S1PR1 
signalling go some way in explaining how bone formation is initiated following bone 
resorption.  
S1P-S1PR1 signalling in osteoclast-osteoblast coupling  
Interestingly, S1P, which is produced during osteoclastogenesis, also inhibits 
this process, by supressing p38-MAPK signalling, a key signalling pathway 
downstream of RANK (Fig 1). This suggests S1P targets cells other than osteoclasts, 
e.g., the coupling osteoblasts (Ryu, et al., 2006). S1P binds S1PR1–3 on osteoblasts 
which activates p38-MAPK and Erk signalling, resulting in increased levels of 
cyclooxygenase-2 (COX2). COX2 induces the expression of prostaglandin E2 (PGE2), 
which prompts the production of RANKL by osteoblasts. RANKL binds to its receptor 
RANK on the osteoclast precursors which promotes osteoclast differentiation and S1P 
secretion, thereby setting up a feedforward loop for osteoclastogenesis.  
Cathepsin K (CSTK) is an enzyme that is involved in bone degradation which, 
when specifically deleted in osteoclast lineage by targeted in vivo gene modification, 
results in mild osteopetrosis, a condition characterized by an increased number of 
osteoblasts and bone formation, as well as an increased number of dysfunctional 
osteoclasts and impaired bone resorption (Lotinun et al., 2013). In vitro analysis of 
primary osteoblasts showed enhanced ALP activity and osteogenic potential, as well 
as increased RANKL/OPG ratio. The osteoclasts of CSTK-knockout mice presented 
with up-regulated expression of SPHK1 and increased S1P production. The increased 
RANKL/OPG ratio of the primary osteoblasts explains the increased number of 
osteoclasts. The antagonist of S1PR1 and S1PR3 reduced the osteogenic ability of 
osteoblasts induced by the conditioned medium of CSTK-knock out osteoclasts, 
suggests the induced in vivo osteogenesis is due to the activation of S1PR1 and S1PR3 
(Lotinun, et al., 2013).  
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2.4.3 S1P-S1PR1 signalling and osteoimmunology 
S1P-S1PR1 signalling also regulates bone remodelling indirectly by modulating 
the immune response. S1PR1 is as a key regulator of a diverse range of immune cell 
activities, which when binding with S1P, leads to cell migration, proliferation, and 
differentiation (Rivera, et al., 2008). The key role of S1P-S1PR1 signalling in 
regulating the trafficking and egression of immune cells has been identified in both the 
innate and adaptive immune systems, affecting cells such as HSCs, DCs, macrophages 
(monocytes), neutrophils, mast cells, T and B lymphocytes, natural killer T (NKT) 
cells (Cinamon, Zachariah, Lam, Foss, & Cyster, 2008; Ishii, et al., 2009; Jenne et al., 
2009; Jolly et al., 2004; König et al., 2010; Rathinasamy, Czeloth, Pabst, Förster, & 
Bernhardt, 2010; Schwab & Cyster, 2007; Wang et al., 1999; Zachariah & Cyster, 
2010). S1P-S1PR1 signalling is required for mature thymocytes to egress from the 
thymus, and for T/B cells to egress from secondary lymphoid tissues into blood or 
lymph under homeostatic and pathological conditions (Allende et al., 2010; Sinha, 
Park, Hwang, Davis, & Kehrl, 2009; Zachariah & Cyster, 2010; Zhang et al., 2012). 
Lymphocytes with decreased S1PR1 expression have an impaired ability to egress. 
Furthermore, S1PR1 deficiency results in blocked lymphocytes egression, a condition 
known as lymphopenia (Sinha, et al., 2009). This suggests a vital role of S1P-S1PR1 
signalling in directing the timely and appropriate distribution of immune cells in 
lymphatic and non-lymphatic tissues which aids homeostasis of the immune system. 
During inflammation, there is a spike of the local concentration of S1P, which activates 
S1PR1 and leads to the recruitment of the immune cells, such as effector T cells, to 
the inflamed tissues and their in situ retention (Ledgerwood, et al., 2008).  
S1P-S1PR1 signalling is also a key modulator of immune cell differentiation and 
function. S1PR1 is required for the maturation of DCs. The functions of mature DCs 
are also regulated by S1PR1, which further affects the activation and polarization of T 
cells (Czeloth et al., 2007; Maeda et al., 2007). The lymphocyte responses are greatly 
affected by S1P. For example, S1P-S1PR1 signalling regulates the function and 
especially the polarization of CD4+T cell subsets. S1PR1 activation in CD4+T cells 
impairs the production of Th1 cells-derived IFNγ, while enhancing the production of 
Th2 cells-derived effector cytokine IL-4, thereby downregulating the Th1 cell 
response while upregulating Th2 cells (Dorsam et al., 2003; Gräler, Huang, Watson, 
& Goetzl, 2005; Song et al., 2008; Wang, Huang, & Goetzl, 2007). On the other hand, 
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S1P was found to induce the differentiation and activities of pro-inflammatory Th17 
cells, as well as the production of IL-17 (the main effector cytokine of Th17 cells) in 
vitro, accompanied by reduced production of Th1 and Th2 cells-derived cytokines, a 
process that is considered to be S1PR1-dependent (Huang, Watson, Liao, & Goetzl, 
2007; Liao, Huang, & Goetzl, 2007). Of note, signalling through S1PR1 impedes the 
differentiation and function of Treg cells, a vital regulator in immune response due to 
the special immune-suppressive activities, by activating the downstream Akt-mTOR 
signalling pathway, thereby promoting the immune response (Liu et al., 2009; Liu, 
Yang, Burns, Shrestha, & Chi, 2010).    
However, in macrophage polarization, S1P-S1PR1 signalling favours the 
differentiation of an anti-inflammatory phenotype, inducing a conversion of the pro-
inflammatory M1 macrophage subset to the anti-inflammatory M2 subset; S1PR1 is 
required for this conversion (Hughes et al., 2008). The S1P-derived induction of Th2 
response and IL-4 secretion may indirectly affect this process. Therefore, in contrast 
to its immune-inductive role in CD4+ T cell polarization, S1P-S1PR1 signalling has an 
immune-suppressive role in determining macrophage polarization, which altogether 
complicates its role in inflammation.   
S1P-S1PR1 signalling participates in bone remodelling by way of 
immunomodulation. As a key factor in immune cells migration (Thangada et al., 2010), 
S1P-S1PR1 signalling induces the recruitment of activated immune cells in the 
inflammatory tissue and therefore promotes the inflammatory response, a process that 
induces bone resorption (Takayanagi, 2007). As mentioned above, S1P-S1PR1 
signalling promotes Th17 cells differentiation and IL-17 production (Liao, et al., 2007), 
both of which promote osteoclastogenesis (Sato et al., 2006), and which impedes the 
differentiation and function of Treg cells (Liu, et al., 2009; Liu, et al., 2010), thereby 
further facilitate immune response and osteoclastogenesis (Sakaguchi, et al., 2008; 
Zaiss, et al., 2007). More importantly, S1P enhanced RANKL production of CD4+T 
cells and hence greatly inducing osteoclast differentiation (Takeshita et al., 2012). 
However, S1P-S1PR1 signalling might also act as a negative factor in 
osteoclastogenesis, as it polarizes macrophage differentiation from M1 towards the 
M2 subsets (Hughes, et al., 2008), which is thought to reduce osteoclast differentiation. 
This conversion from M1 to M2 phenotype is driven by S1P-S1PR1 signalling and 
may also take part in osteogenesis. M1 macrophage activation, it has been suggested, 
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is indispensable during the early stages of bone repair. M2 macrophages, on the other 
hand, plays a key role in the later stage of bone formation, suggesting the shift from 
M1 to M2 phenotype is a crucial process in the regulation of osteogenesis (Guihard, et 
al., 2012; Loi, et al., 2016). 
Taken together, these studies all point to S1P-S1PR1 signalling having a key role 
in osteoimmunology. Whereas at one level it directly regulates osteoclastogenesis, 
osteogenesis, and osteoclast-osteoblast coupling and, therefore, has a crucial role in 
bone remodelling; however, at another level, the immune regulation of S1P-S1PR1 
signalling suggests an indirect modulation of osteoclastogenesis and osteogenesis. 
Under certain pathological conditions, the aberrant status of S1P-S1PR1 signalling 
results in dysregulation of immune response and consequently imbalanced bone 
remodelling.    
 
Figure 4. The role of S1P-S1PR1 signalling in osteoimmunology. S1P-S1PR1 signalling is greatly 
involved in the interaction between immune system and bone remodelling. On one hand, S1PR1 directly 
affects osteoclastogenesis by inducing the migration of osteoclast-precursors. The direct effect of S1P 
on osteoclast-precursors results in reduced osteoclastogenesis; however, it induces RANKL production 
of osteoblasts and facilitating the RANKL-RANK mediated osteoclastogenesis. S1P also induces the 
migration of MSCs and osteogenesis by activating S1PR1. On the other hand, S1P-S1PR1 signalling 
participates in immune regulation, which affects the polarization and function of T-helper cells. S1P-
S1PR1 signalling induces the differentiation and function of Th17 cells (known as inducing 
osteoclastogenesis) while impedes that of Treg cells (known as reducing osteoclastogenesis); therefore 
facilitating osteoclastogenesis. S1P also induces the function of Th2 cells while reduces that of Th1 
cells, which affects the macrophage phenotype; also, S1P directly induces the transition of M1 to M2 
phenotype by activating S1PR1. This conversion of pro-inflammatory M1 macrophages to tissue-
engineering M2 macrophages therefore impedes osteoclastogenesis, which might also affect 
osteogenesis.   
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2.5 S1P-S1PR1 SIGNALLING IN BONE DESTRUCTIVE DISEASES 
Abnormally activated S1P-S1PR1 signalling has been observed in many 
diseases, such as rheumatoid arthritis (RA), multiple sclerosis and cancer, and is 
thought to have a key role in the pathogenesis of these diseases (Choi et al., 2011; Feng 
et al., 2010; Kitano, et al., 2006). The importance of S1P-S1PR1 signalling in immune 
regulation and bone remodelling makes it necessary to assess their putative roles in the 
pathogenesis of bone destructive diseases. 
 
2.5.1 S1P-S1PR1 signalling in rheumatoid arthritis 
Rheumatoid arthritis (RA) is an autoimmune disorder that feature excessive 
osteoclastogenesis resulting from an abnormally activated immune response (Kitano, 
et al., 2006). Abnormal expression of S1PR1 in inflamed RA synovial tissue and S1P-
SIPR1 signalling has been shown to play an important role in the pathogenesis of RA 
in the mechanism of promoting the COX-2-induced PGE2 secretion by rheumatoid 
synoviocytes (which was identified as a key process in RA-related osteoclastogenesis) 
(Kitano, et al., 2006). S1P-S1PR1 signalling has been found to promote RANKL 
production in CD4+T cells and synoviocytes in vitro following stimulation with TNF-
α, suggesting a role of S1P-S1PR1 signalling in RA bone destruction (Takeshita, et al., 
2012). Therapies targeting S1P or S1PR1 have shown some promise as a treatment for 
RA and further indication of the key role of S1P-S1PR1 signalling in this disease. 
Fingolimod, also known as FTY720, is an analogue of sphingosine and acts as a 
‘functional antagonist’ of S1PR1 in vivo by inducing the internalization, down-
regulation and degradation of S1PR1 (Pham, Okada, Matloubian, Lo, & Cyster, 2008; 
Thangada, et al., 2010). FTY720 has been shown to be effective in a mouse RA model 
by inhibiting the infiltration of effector CD4+ T cells. This reduced the production of 
PGE2 by the synoviocytes and induced the Th2 cells-mediated immune response 
(Tsunemi et al., 2010). S1PR1 is therefore a potential therapeutic target in RA. In a 
mouse TNF- induced chronic inflammatory arthritis model, the progression and 
severity of arthritis, as well as bone destruction in mouse with SPHK1 deficiency were 
significantly reduced. This was associated with reduced COX-2 expression and Th17 
differentiation caused by decreased S1P production, with a resulting inhibition of 
osteoclastogenesis in the inflammatory joints (Baker, Barth, Chang, Obeid, & 
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Gilkeson, 2010)–a finding that suggests SPHK1 and/or S1P can also be potential 
targets for TNF-α-related arthritis, such as RA. 
 
2.5.2 S1P-S1PR1 signalling in infection-induced bone loss 
Since the S1P-S1PR1 signalling plays such an important role in the immune 
response it is not surprising that this pathway involved in a diverse range of infections 
caused by microbial agents such as viruses, bacteria and fungi (Arish, et al., 2015). 
Although S1P-S1PR1 signalling was found to be up-regulated in most systemic 
inflammations, its status in infection-induced inflammations has been determined by 
the types of pathogens involved. A common target of pathogens is SPHK1. Pathogens 
can either induce or reduce SPHK1 activity, resulting in dysregulated S1P expression. 
This hinders the normal immune response and creates suitable conditions for pathogen 
evasion. In some cases pathogens can promote S1P signalling in the infected cells and 
prolong the survival of these cells via the activation of the PI3K/Akt and Erk signalling 
pathways, which then facilitates the replication of pathogens (Monick et al., 2004). 
However, in some cases pathogens can suppress S1P production thereby impairing the 
innate and adaptive immune response against the invading pathogen. For example, in 
Mycobacterium tuberculosis (M. tuberculosis) infections, S1P signalling is disrupted 
by bacteria-mediated reduction of SPHK1 activity. Clinical treatment of S1P results in 
significantly reduced intracellular growth of M. tuberculosis, as well as enhanced 
antigen presentation and CD4+ T cell response (Malik et al., 2003; Richmond, Lee, 
Green, Kornfeld, & Cruikshank, 2012). The way that different pathogens have a 
differential effect on S1P expression is an example of the complexities implicit in the 
infection-induced inflammatory response. Therefore, a thorough understanding of the 
S1P-S1PR1 signalling status might shed some light on the management and treatment 
of the infection-induced inflammatory diseases. 
S1P is also associated with the pathogenesis of periodontitis, an inflammatory 
oral bone-destructive disease caused by bacterial infection (Yu, Sun, & Argraves, 
2016). In a mouse periodontitis model, the ablation of SPHK1 significantly attenuated 
alveolar bone loss and is accompanied by reduction in the numbers of leukocytes and 
osteoclasts in the periodontal tissues, suggesting modulating S1P production could be 
a novel therapeutic strategy for periodontitis treatment. It could be presumed that the 
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S1P-S1PR1 signalling also takes part in other infection-induced bone destructive 
diseases, such as apical periodontitis and osteomyelitis.  
Taken together, the importance of S1P-S1PR1 signalling in bone-destructive 
diseases further confirmed the vital role of this signalling in bone remodelling, 
suggesting this signalling should be considered as a new therapeutic approach for these 
diseases. Also, the role of S1P-S1PR1 signalling in other infection-induced bone-
destructive diseases (i.e. apical periodontitis) deserves future study. 
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2.6 CONCLUSION 
In summary, the literature is replete with in vitro and in vivo studies that indicate 
that S1P acts as a key coupling factor between osteoclasts and osteoblasts, thereby 
playing a key role in immune regulation and bone remodelling via the activation of 
S1PR1. The S1P-S1PR1 signalling pathway must be considered as a crucial factor in 
osteoimmunology and, therefore, a novel therapeutic target for the treatment of 
diseases with inflammatory bone-destruction. Furthermore, the detailed mechanism of 
S1P-S1PR1 signalling in bone remodelling under inflammation is still not clear and 
needs further research. 
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The role of S1P-S1PR1 signalling in infection-induced 
inflammatory bone loss 
 
3.1 ABSTRACT 
Background: The S1P-S1PR1 signalling is crucial for the regulation of immunity and 
bone metabolism. This study aims to investigate the status of S1P-S1PR1 signalling in 
apical periodontitis lesions and its role in the infection-induced inflammatory bone 
loss in vivo. 
 
Methods: Periapical lesion samples from 10 patients were collected and examined by 
histological observation, immunohistochemistry, and double immunofluorescence 
analysis. Apical periodontitis model was created in rats to further investigate the 
correlation between S1P-S1PR1 signalling and the development of the lesion in a time 
sequence. Five rats were sacrificed on day 0, 7, 14, 21, 28, and 35, and their mandibles 
were harvested. X-ray imaging, micro-computed tomography (µCT) scanning, 
histological observation, immunohistochemistry, enzyme histochemistry, and double 
immunofluorescence analysis were performed on the harvested samples. To 
demonstrate the effect of signalling modulation on the disease progress, Fingolimod 
(FTY720; S1P-S1PR1 signalling modulator) administration was performed on 
experimental group while saline vehicle was applied as control. Five rats in each group 
were sacrificed on day 7, 14, 21, 28, and 35, respectively. The mandibles were 
harvested and subjected to the mentioned analysis for comparison. 
 
Results: The S1P-S1PR1 signalling was up-regulated in both human and rat periapical 
lesions. A correlation was found between the expressions of S1PR1 and RANKL; the 
S1PR1+ and RANKL+ cells were found in the inflammatory periapical tissues. S1P-
S1PR1 signalling was negatively modulated by FTY720, which effectively inhibited 
bone resorption and osteoclastogenesis by down-regulating RANKL production in the 
periapical lesions. 
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Conclusions: The S1P-S1PR1 signalling was abnormally up-regulated in apical 
periodontitis lesion, which enhanced RANKL production and induced 
osteoclastogenesis, thereby promoting bone loss in the lesions. The S1P-S1PR1 
signalling could be a potent target for the treatment of apical periodontitis.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Dissecting the Role of Sphingosine 1-Phosphate--Sphingosine 1-Phosphate Receptor 1 in Inflammatory Bone 
Remodelling 49 
3.2 INTRODUCTION 
Apical periodontitis is one of the most common inflammatory dental diseases. 
Mainly due to bacterial infection of (tooth) root canals, this disease usually results in 
pulp damage, lesion formation around the apex of the root, as well as alveolar bone 
destruction (Garlet et al., 2012; Stashenko, Teles, & D'Souza, 1998). The lesion 
represents the inflammatory immune response to pathogen invasion, including 
infiltration and activation of immune cells, induced production of inflammatory 
molecules, which then promote activation of osteoclastogenesis and therefore resulting 
imbalanced bone remodelling (which consists of bone resorption and formation) 
(Stashenko, Yu, & Wang, 1992).  
Osteoclasts are known as the only cells conducting bone resorption (Kini & 
Nandeesh, 2012). Previous studies have identified that the differentiation and function 
of osteoclasts are regulated by immune system-derived factors, such as immune cells, 
cytokines, receptors, and transcription factors (Takayanagi, 2007). Receptor activator 
of nuclear factor kappa B ligand (RANKL) – a tumour necrosis factor family cytokine–
is identified to be indispensable in osteoclastogenesis (Yasuda et al., 1999). On the 
other hand, osteoprotegerin (OPG), a number of the TNF receptor superfamily, acts as 
a decoy receptor for RANKL and therefore impairs RANKL-mediated 
osteoclastogenesis (Simonet, et al., 1997). The balance between RANKL and OPG is 
considered as the hallmark in determination of the balanced bone remodelling 
(Fonseca, et al., 2004). In the pathogenesis of apical periodontitis, increased RANKL 
expression has been found to be associated with osteoclast formation during periapical 
bone destruction (Zhang & Peng, 2005). Furthermore, the imbalance between RANKL 
and OPG has been identified to play a crucial role in induced apical periodontitis of 
rats (Kawashima et al., 2007). Among the immune cells, activated T cells are 
considered to be crucial during the immune process of apical periodontitis, not only 
for their role in maintaining a balanced immune defence against oral bacteria, but also 
for their ability to produce RANKL under inflammatory circumstances and thereby 
inducing osteoclastogenesis (Matsuo, Ebisu, Shimabukuro, Ohtake, & Okada, 1992; 
Theill, et al., 2002). 
Sphingosine-1-phosphate receptor 1 (S1PR1) is one of the five members of the 
endothelial differentiation gene (Edg) family of G protein-coupled receptors that are 
expressed at the cellular membrane (Chi, 2011). Its ligand, sphingosine-1-phosphate 
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(S1P) is a multifunctional bioactive lipid molecule, which binds with S1PR1 to 
mediate diverse cellular process, such as cell growth, survival, differentiation, 
migration, and cytokine production (Spiegel & Milstien, 2011). S1PR1 is expressed in 
most immune cells, the S1P-S1PR1 signalling plays a central role in regulating 
immune response, including cell movement, differentiation and functional maturation, 
under both physical and pathological circumstances (Rivera, et al., 2008; Spiegel & 
Milstien, 2011). S1P-S1PR1 signalling is also involved in directing the migration of 
osteoclast precursors; moreover, S1P is reported to induce RANKL production in 
activated T cells, which suggests that this particular signalling cue may act as a 
regulator in osteoclastogenesis and is therefore important in bone resorption (Ishii, et 
al., 2009; Takeshita, et al., 2012). Abnormally enhanced S1P-S1PR1 signalling has 
been identified in inflammatory bone destructive disease such as rheumatoid arthritis, 
leading to the speculation that this signalling plays a key role in the pathogenesis of 
inflammatory diseases (Kitano, et al., 2006). It has also been reported that S1P 
production is dysregulated in various infectious diseases (by up-/down-regulation of 
SPHK1). This dysregulation impairs the normal status of immune response and 
therefore creating a suitable circumstance for the survival and evasion of the pathogens 
(Arish, et al., 2015). Hence, the role of S1P-S1PR1 signalling in the pathogenesis of 
apical periodontitis – a special infection induced bone destructive disease–should be 
further elucidated.   
Fingolimod (FTY720) has been applied clinically as immune response 
modulator for the treatment of multiple sclerosis (MS). FTY720 has been proved to be 
effective in animal models of autoimmune diseases (Fujino et al., 2003; Kappos et al., 
2006; Rausch et al., 2004; Sanford, 2014). Reportedly, FTY720, which is an analogous 
to S1P, induces internalization and degradation of S1PR1 on lymphocytes and makes 
S1PR1 unresponsive to S1P, hence, inhibiting the S1P-S1PR1 signalling-dependent 
immune response (Pham, et al., 2008; Thangada, et al., 2010). Based on this, it is 
considered that FTY720 is a negative modulator for S1P-S1PR1 signalling.    
This study was aimed to investigate the role of S1P-S1PR1 signalling in the 
pathological development of apical periodontitis. The S1P-S1PR1 signalling was 
found to be activated in both human and rat periapical lesions. Furthermore, a strong 
positive correlation was found in the expression of S1PR1 and RANKL; moreover, 
modulating the S1P-S1PR1 signalling was found to be effective in inhibiting the bone 
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loss derived from apical periodontitis, which was partially achieved by reducing 
RANKL-mediated osteoclastogenensis. Therefore, the S1P-S1PR1 signalling plays a 
crucial role in the pathogenesis of apical periodontitis.  
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3.3 MATERIALS AND METHODS 
3.3.1 Patients and sample collection 
All experimental procedures were approved by the Institutional Review Board 
of the Ethics Committee, School and Hospital of Stomatology, Wuhan University, 
China. Periapical lesions (total n = 10) were collected from patients diagnosed with 
apical periodontitis during tooth extraction at the Department of Oral and 
Maxillofacial Surgery, School and Hospital of Stomatology, Wuhan University, 
Wuhan, China. The patients (aged from 20 to 68 years) were free of systemic diseases 
and had not taken antibiotics for at least 1 month. The periapical tissues obtained from 
10 patients underwent tooth extraction for orthodontic treatments were used as control 
samples (the teeth were healthy with no sign of inflammation in the periodontal 
tissues). The collected samples were fixed with 4% paraformaldehyde in 0.1 mol/L 
phosphate-buffered saline (PBS, pH 7.4) for 24 h at room temperature. After that they 
were dehydrated and embedded in paraffin, then cut into 4 µm-thick histologic sections. 
 
3.3.2 Induction of rat apical periodontitis model  
All experimental procedures conform to the Guiding Principles of the Animal 
Care and Use Committee in the School of Stomatology, Wuhan University. This 
experiment was performed as previously described (Stashenko, Wang, Tani-Ishii, & 
Yu, 1994). Thirty female Wistar rats, each weighing approximately 200 g, were 
purchased from the Experimental Animal Centre of Hubei Province. After being 
randomly divided into six groups, apical periodontitis models were induced by 
exposure of the dental pulp of the first lower molars under anaesthesia (intraperitoneal 
administration of ethyl urethane (0.8 mg/g)); a #1/4 round bur was used to expose the 
pulp while avoiding damages of the pulp-chamber floor. Cavities were left open to the 
oral environment during the whole procedure. Five rats from each group were 
sacrificed in 0, 7, 14, 21, 28, and 35 days after the operation. Day 0 group served as 
the negative control. The mandibles were harvested for further analysis. 
 
3.3.3 FTY720 administration to the induced apical periodontitis lesions  
All experimental procedures conform to the Guiding Principles of the Animal 
Care and Use Committee in the School of Stomatology, Wuhan University. Fifty 
 Dissecting the Role of Sphingosine 1-Phosphate--Sphingosine 1-Phosphate Receptor 1 in Inflammatory Bone 
Remodelling 53 
female Wistar rats, each weighing approximately 200 g, were purchased from the 
Experimental Animal Centre of Hubei Province. Periapical lesions were induced as 
described above. The rats were randomly and equally divided into two groups: control 
group and experimental group. Each group received injections beginning at two days 
after the periapical lesion induction and continued every two days during the entire 
experimental period. For the experimental group, intragastric administration of 
FTY720 (LC Laboratories, Woburn, USA) was applied at a dose of 3 mg/kg (diluted 
by saline) body weight every two days, whereas only saline (the vehicle) was injected 
in the control group. Five rats from each group were sacrificed at 7, 14, 21, 28, and 35 
days after the operation. The mandibles were harvested for further analysis. 
 
3.3.4 Sample preparation 
The periapical tissues were fixed with 4% paraformaldehyde in 0.1 mol/L 
phosphate-buffered saline (PBS, pH 7.4) for 24 h at room temperature. After that they 
were dehydrated in graded ethanol (70%, 90%, and 100%), cleared in xylene,  
embedded in paraffin, and then cut into 4 µm-thick histologic sections for H & E 
staining, Immunohistochemistry staining and Immunofluorescence staining. One in 
every four sections was analysed by light microscopy. 
The mandibles were fixed with 4% paraformaldehyde in 0.1 mol/L phosphate-
buffered saline (PBS, pH 7.4) for 24 h at room temperature. Samples were firstly 
photographed under X-ray (DXS PRO, BRUKER) and then scanned by µCT (samples 
were placed in suitable containers filled with 0.5% paraformaldehyde during scanning). 
All mandibles were then demineralized in 10% EDTA solution at room temperature 
for 4 to 5 weeks. The decalcified samples were then dehydrated and embedded in 
paraffin. Finally, the mandibles were cut into 4 µm frontal serial sections in the 
mesiodistal direction. The section selected for staining (H & E staining, 
immunohistochemistry staining and immunofluorescence staining) should contain the 
distal root of the first mandibular molar, as well as the apex of root canal. One in every 
four stained sections was analysed by microscopy.  
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3.3.5 High-resolution X-ray imaging and µCT analysis 
High resolution X-ray images were taken and analysed by the BRUKER 
Molecular Imaging software to assess the bone intensity around periapical lesions. 
Bone intensity of the light blue area around the distal root apex was considered to be 
relatively low. Measurement of this area was conducted using                                                                                                                                                  
the software Image-Pro Plus 6.0. The mandibles were scanned with a Scan µCT 50 
imaging system (Scanco Medical, Bassers-dorf, Switzerland) at a resolution of 20 μm, 
and then reconstructed to evaluate the bone loss around the distal root of the first molar. 
The raw data were analysed by the three-dimensional (3D) image analysis software 
(VGStudio MAX, Heidelberg, Germany) to measure the volume of the periapical 
region as previously described (Yang et al., 2014). All measurements were performed 
in a double blind manner by two trained independent observers. 
 
3.3.6 Histological analysis 
Sections were first dewaxed in xylene, then rehydrated in graded ethanol (100%, 
90%, and 70%). After rehydration, the sections were stained with hematoxylin for 2 
min, rinsed with tap water for 5 min and then dipped 3 times in acid ethanol. After 
dehydration, they were stained with eosin for 15 sec, rinsed in 100% ethanol twice, 
cleared in xylene, and then mounted with mounting medium. One in every four 
sections was analysed by light microscopy (Leica, Wetzlar, Germany). The areas of 
periapical lesions (the tissue around the lower third of the roots) were measured by 
two trained independent observers using the software Image-Pro Plus 6.0. Three 
sections of each mandible were evaluated, and the mean average was calculated to 
measure the size of the periapical lesion in each mandible. All measurements were 
performed in a double-blind manner by two trained independent observers. 
 
3.3.7 Tartrate-resistant Acid Phosphatase (TRAP) assay 
TRAP staining was performed to detect osteoclasts. All procedures were 
performed following the manufacturer’s instructions (Acid Phosphatase, Leukocyte 
(TRAP) Kit, Sigma-Aldrich, St. Louis, MO). Briefly, sections were dewaxed in xylene, 
rehydrated in graded ethanol (100%, 90%, and 70%), and washed by distilled water. 
Sections were then incubated in a solution of naphthol AS-BI phosphoric acid and Fast 
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Garnet GBC for 1 h at 37 °C. Sections incubated in a substrate-free medium served as 
TRAP controls. After incubation, sections were lightly counterstained with 
hematoxylin (15 sec), cleared in xylene, and then mounted with mounting medium by 
cover slips. The TRAP-positive cells, which coloured from dark red to purple, were 
identified as osteoclasts if they presented with two or more nuclei. 
 
3.3.8 Immunohistochemistry 
Immunohistochemical staining was performed as previously described (Yang, et 
al., 2014). Briefly, sections were dewaxed in xylene, then rehydrated in graded ethanol 
(100%, 90%, and 70%), and washed by distilled water. For antigen retrieval, pepsin 
(rat samples, Maixin, Fuzhou, China) were applied to the sections for 15 min. Sections 
were then blocked with 2.5% bovine serum albumin (diluted in PBS) for 1 h. Rabbit 
polyclonal antibodies against S1P (Abcam, Cambridge, UK), rabbit polyclonal 
antibodies against S1PR1 (Santa Cruz Biotechnology, Santa Cruz, CA), goat 
polyclonal antibodies against human RANKL and OPG (Santa Cruz Biotechnology, 
Santa Cruz, CA) at dilutions of 1:400, 1:100, 1:200 and 1:150, respectively, were used 
as primary antibodies. All the antibodies were diluted in PBS containing 0.1% BSA. 
Sections for negative controls were substituted with non-immune rabbit or goat serum 
instead of primary antibodies. After incubated with primary antibodies at 4 °C 
overnight, sections were stained with the SP kit (Maixin, Fuzhou, China) (for S1P and 
S1PR1) and PV kit (Maixin, Fuzhou, China) (for RANKL and OPG) according to the 
manufacturer’s instructions. After that, the sections were developed with 
diaminobenzidine (DAB) and then counterstained with hematoxylin, cleared in xylene, 
and mounted with cover slips. In each section, osteoclasts/S1P-positive cells/S1PR1-
positive cells/RANKL-positive cells/OPG-positive cells in five randomly selected 
regions within periapical tissue (the tissue around lower 1/3 part of the roots) were 
counted under 400× magnification by two independent observers. The average number 
of the five chosen areas was calculated. Three sections from each mandible were 
analysed for cell measurements. All measurements were performed in a double-blind 
manner by two trained independent observers. 
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3.3.9 Double immunofluorescence labelling 
This experiment was performed as previously described (Liu & Peng, 2013). 
Sections were dewaxed in xylene, rehydrated in graded ethanol (100%, 90%, and 70%), 
and washed by distilled water. Antigen retrieval was performed by incubation with 
pepsin for 15 min at 37 °C. After that, they were incubated with 2.5% bovine serum 
albumin (BSA, diluted in PBS) for 1 h and then incubated overnight with S1PR1 
antibodies (human samples: 1:25; rat samples: 1:25) and RANKL antibodies (human 
samples: 1: 100; rat samples: 1:75) at 4 °C. The sections were then washed and 
incubated with the secondary fluorescent antibodies, donkey anti-rabbit Dylight488 
(EarthOx, San Francisco, CA, USA) (1:100) and donkey anti-goat-CY3 (Proteintech 
Group, Wuhan, China) antibodies (1:250) at for 1 h. All antibodies were diluted in 1% 
BSA/PBS. Nuclei were stained with 4’, 6-diamidino-2-phenylindole. Finally, the 
sections were washed, incubated with AutoFluo Quencher (Applygen, Beijing, China) 
for 30 min, mounted and viewed under fluorescence microscope (Leica, Wetzlar, 
Germany). 
 
3.3.10 Statistical analysis 
All data were subjected to statistical analysis using one-way ANOVA, followed 
by the Student-Newman-Keul test at a = 0.05. Pearson correlation was used for 
correlation analysis on numbers of S1PR1+ cells with osteoclasts and RANKL+ cells 
(α = 0.05). A p< 0.05 was considered to significantly different. Data were analysed by 
SPSS 13.0 (SPSS Inc., Chicago, IL). All data were presented as mean ± standard 
deviation (SD). 
 
3.4 RESULTS 
3.4.1 Up-regulated S1P-S1PR1 signalling and RANKL expression in human 
periapical lesions 
In this study, firstly, general morphology of human lesion/normal periapical 
tissues was examined by histological observation. As shown in Fig 5, the periapical 
lesion was analogous to granulomatous tissue, which consisted of fibroblast-like cells 
and infiltrating immune cells; hardly any epithelial cells were observed. The control 
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tissue showed the appearance of normal periodontal ligament tissue, which mainly 
consisted of fibroblasts; no obvious immune cell infiltration was observed. 
The status of S1P-S1PR1 signalling in human periapical lesion tissues was 
examined by IHC staining. As shown in Fig 5, compared with the control tissue, the 
S1P expression was more intensive in the periapical lesions. Furthermore, S1PR1 
expression was found to be up-regulated (Fig 5). It could also be observed that the 
expression of RANKL was enhanced in the lesions (Fig 5), suggesting the cells in the 
lesion were responsible for the induced osteoclastogenesis in apical periodontitis. 
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Figure 5. Histological and immunohistochemical observation of human lesion/normal periapical 
tissues (n=10). Representative views of histological (original magnification, 200×, Scale bar = 100 μm) 
and immunohistochemical observations (original magnification, 400×, Scale bar = 50 μm) in human 
periapical tissues. Compared with normal tissue, significantly enhanced immune cell infiltration could 
be observed in the lesions. The expression of S1P, S1PR1 was found to be up-regulated in periapical 
lesion tissues, suggesting the S1P-S1PR1 signalling was abnormally activated in apical periodontitis. 
Increased RANKL expression was observed in the lesion tissues, which could result in bone loss. 
100 μm 100 μm 
50 μm 50 μm 
50 μm 50 μm 
50 μm 50 μm 
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3.4.2 Identification of S1PR1+ and RANKL+ cells in human periapical lesions 
To investigate the relation between S1P-S1PR1 signalling and RANKL 
expression, double-dye immunofluorescent staining of S1PR1 and RANKL was 
performed on the same section to detect the S1PR1+ and RANKL+ cells in periapical 
lesions. S1PR1+ cells, RANKL+ cells, as well as S1PR1+RANKL+ cells could be seen 
co-localizing in the periapical lesion tissues (arrows Fig 6). This suggested that the up-
regulated S1P-S1PR1 signalling was associated with enhanced RANKL expression in 
periapical lesion tissues. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Immunofluorescent microscopy shows colocalization of S1PR1 and RANKL on 
human periapical lesions (n=10). S1PR1 was stained with Dylight488 (green), and RANKL was 
stained with CY3 (red). Nuclei were counterstained with DAPI (blue) (Original magnification, 200×, 
Scale bar = 50 μm). S1PR1+RANKL+ cells (yellow) could be seen in the periapical lesion tissues, 
suggesting the S1P-S1PR1 signalling was possibly related with RANKL expression in periapical 
lesions. Arrows indicate the S1PR1+RANKL+ cells.  
S1PR1-RANKL-DAPI-MERGE 
50 μm 50 μm 
50 μm 50 μm 
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3.4.3 The size of rat periapical lesion at different stages 
To further study the involvement of S1P-S1PR1 signalling in the pathogenesis 
of apical periodontitis, animal model of this disease was induced on rats by pulp 
exposure (Stashenko, et al., 1994). The lesion area and volume were measured by high-
resolution X-ray imaging and µCT. As shown in Fig 7, both the measurements of High-
resolution X-ray imaging and µCT continued to increase after day 0 (Fig 7 b&d, Table 
1), indicating the periapical area and volume expanded from day 0 to day 35. The 
periapical area (0.18 mm2) and volume (0.36 mm3) of group day 0 represented the 
normal periapical space of the first molar. According to clinical X-ray diagnose criteria, 
no lesions could be observed at this stage. From day 7 to day 21, the periapical lesion 
could be observed as the light blue area which grew in size (mean area grew from 0.34 
mm2 to 0.56 mm2). Accordingly, the µCT results showed that the lesions formed and 
continuously broadened in the sagittal, horizontal, and coronal directions from day 7 
to day 21 (mean volume grew from 0.73 mm3 to 1.12 mm3). From the measurements 
(Fig 7d), it could be found that the lesions continued to expand from day 28 to day 35, 
however, no significant differences of lesion volumes could be found on days 21, 28 
and 35, indicated that the bone loss became comparably stable after day 21. A 
significant positive correlation was found between the area measured by high-
resolution X-ray imaging and the volume by µCT (r = 0.9872, p<0.01). Data are shown 
in Table 1. 
As shown in the histological slides (Fig 7a), pulp necrosis, infiltrating 
inflammatory cells, as well as alveolar bone resorption around the first molar apex 
gradually became more prominent over time following exposure of the dental pulp. 
The inflammatory cell infiltration was moderate on day 7, which became evident 
during day 14 to day 21, then turned to be less severe from day 28 to day 35.  Same 
as the result of X-ray imaging (Fig 7c), the periapical area started to grow after day 0 
(0.17 mm2), which rapidly increased from day 7 (0.26 mm2) to day 21 (0.59 mm2) and 
became comparably stable during day 28 to day 35, as there were no significant 
differences between days 28 and 35.  
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Figure 7. Identification of rat periapical lesion size on days 0, 7, 14, 21, 28, and 35 (n=5). (a) 
Histological observation of rat periapical lesions. Representative views of histological (original 
magnification, 50×, Scale bar = 500 μm) observation in rat periapical lesions on days 0, 14, 21, and 35. 
From days 7 to 35, the lesion area continuously increased, accompanied by inflammatory cell infiltration. 
(b) Periapical lesion size was analysed by high-resolution X-ray imaging and µCT. Different colours 
represented different levels of bone intensity. The intensity of the light blue area around the apex was 
comparably low. The entire mandible with the periapical lesions (marked yellow) on the first molar is 
shown in 3D. The first molar with the periapical lesions is shown in the sagittal, horizontal, and coronal 
directions. (c) Measurements of lesion size (mm2) in X-ray imaging and histological analysis (n=5). The 
lesion area grew drastically from day 0 to day 21 and became comparably stable after day 28, as no 
significant difference (p < 0.05) could be found between days 28 and 35. (d) Measurements of periapical 
lesion volume (mm3) (n=5). The lesion volume continuously grew from day 0 to day 2 and became stale 
thereafter, as no significant differences (p <0 .05) were found on day 21, day 28 and day 35. 
 
Table 1. Bone resorption volumes and areas of rat periapical lesions (mean±standard 
deviation) 
 
* p < 0.05 versus 7-day group. # p < 0.05 versus 14-day group. † p < 0.05 versus 21-day group. £ p < 
0.05 versus 28-day group. ‡ p < 0.05 versus 35-day group. & p < 0.05 versus 0-day group (control). I 
Positive correlation (r = 0.9872, p < 0.01) with lesion volume. II Positive correlation (r = 0.9852, p < 
0.01) with Lesion area (X-RAY). 
 
 
 
Group  N Lesion area (mm2)I 
(HE) 
Lesion volume(mm3) 
  
Lesion area (mm2)II 
（X-RAY ）                    
Day 0 5 0.18 ± 0.02*,#,†,£,‡ 0.36 ± 0.06*,#,†,£,‡ 0.17 ± 0.03*,#,†,£,‡ 
Day 7 5 0.34 ± 0.01#,†,£,‡,& 0.61 ± 0.07#,†,£,‡,& 0.26 ± 0.03#,†,£,‡,& 
Day 14 5 0.40 ± 0.05*,†,£,‡,& 0.75 ± 0.04*,†,£,‡,& 0.42 ± 0.06*,£,‡,& 
Day 21 5 0.61 ± 0.12*,#,‡,& 1.06 ± 0.03*,#,& 0.59 ± 0.06*,£,‡,& 
Day 28 5 0.68 ± 0.04*,#,& 1.17 ± 0.11*,#,& 0.65 ± 0.15*,#,& 
Day 35 5 0.70 ± 0.09*,#,†,& 1.26 ± 0.12*,#,& 0.73 ± 0.09*,#,†,& 
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3.4.4 Up-regulated S1PR1 expression in rat periapical lesions 
To investigate the expression of S1PR1in the pathogenesis of apical periodontitis, 
IHC staining was performed at different time points of rat periapical lesions. As shown 
in Fig 8, there were few if any S1PR1+ cells (except for endothelial cells) in the day 0 
periapical tissues, whereas S1PR1 expression became evident from day 7 to day 35. 
Similar to what was seen in the human tissues, a large quantity of S1PR1+ cells 
appeared to be lymphocytes, macrophages and leukocytes, accompanied by the 
fibroblast-like cells. The S1PR1+ endothelial cells could also be observed. 
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Figure 8. Immunohistochemical observation of S1PR1-expression in rat periapical lesions 
(original magnification, 400×, Scale bar = 50 μm, n=5). No S1PR1-positive cells were found on 
day 0. The expression of S1PR1 increased from days 7 to 14, peaked from day 14 to day 21, then 
decreased from days 28 to 35. 
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3.4.5 S1PR1, RANKL, and osteoclast expression dynamics in rat periapical 
lesions 
To detect the relation between S1PR1 and RANKL in the pathogenesis of apical 
periodontitis, IHC staining against RANKL was performed, and the expression of 
RANKL was compared with that of S1PR1. Compared to day 0, the RANKL 
expression was significantly enhanced during day 7 to day 35 (Fig 9). Cell counting 
showed the numbers of S1PR1+ cells and RANKL+ cells to be low at day 7, which 
dramatically increase from day 7 to day 14 and remain at a high level from day 14 to 
day 21, after which there was a decreased number of positive cells that persisted after 
day 28 (Fig 11, Table 2). The cell counts and the corresponding standard deviation 
values from days 0 to 35 are listed in Table 2.  
TRAP staining was performed to detect the expression of osteoclasts during the 
pathogenesis of apical periodontitis. On day 0, no osteoclasts could be observed, while 
the expression of osteoclasts became evident from day 7 to day 35 (Fig 10). According 
to the cell counting results, the number of osteoclasts was low at day 7 (Fig 11), then 
peaked on day 14, and decreased from day 21 to day 35. Data are shown in Table 2. 
To find the relation of S1PR1 with RANKL and osteoclastogenesis in apical 
periodontitis, we compared the expression of S1PR1, RANKL and osteoclasts. As 
shown in Fig 11, the dynamic expression of S1PR1 was similar to that of RANKL and 
osteoclasts. From day 0 to day 35, a significant positive correlation was found between 
S1PR1 and RANKL-positive cells (r = 0.9171, p <0.01, Fig 11). The same correlation 
was found between S1PR1+ cells and TRAP-positive cells (r = 0.9535, p < 0.01). Data 
are shown in Table 2. 
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Figure 9. Immunohistochemical observation of RANKL-expression in rat periapical lesions 
(original magnification, 400×, Scale bar = 50 μm, n=5). No RANKL-positive cells were found on 
day 0. The RANKL expression was low on day 7, then increased from day 7 to day 14, peaked from 
day 14 to day 21, decreased and became comparably stable after day 28. 
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Figure 10. Enzyme histochemical observation of rat periapical lesions (original magnification, 
400×, Scale bar = 50 μm, n=5). No TRAP-positive cells were found on day 0. TRAP-positive cells 
appeared on day 7; the expression of TRAP-positive cells peaked from day 14 to day 21 and decreased 
thereafter.   
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Figure 11. Measurements of TRAP/S1PR1/RANKL positive cells in rat periapical lesions (n=5). 
The number of osteoclasts increased from days 0 to 14 and then decreased from days 21 to 35. The 
numbers of S1PR1- and RANKL-positive cells increased from days 0 to 14 and then decreased from 
days 21 to 35. Significant differences were observed between each time point (p< 0.05), except 
between days 14 and 21 and between days 28 and 35. Positive correlation existed between the 
expression of S1PR1 and RANKL in rat periapical lesions (r = 0.9171, p<0 .01). 
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Table 2. Numbers of S1PR1+ cells, RANKL+ cells and osteoclasts per high-power field (hpf; 
400×). 
* p<0.05 versus 7-day group. # p <0.05 versus 14-day group. † p <0.05 versus 21-day group. £ p 
<0.05 versus 28-day group. ‡ p < 0.05 versus 35-day group. & p <0.05 versus 0-day group (control). I 
Positive correlation (r = 0.9171, p < 0.01) with numbers of S1P1+ cells/hpf. II Positive correlation (r 
=0.9535, p < 0.01) with numbers of S1P1+ cells/hpf. 
 
3.4.6 Immunofluorescent co-localization of S1PR1 and RANKL in rat periapical 
lesions 
To confirm the relation between S1PR1 and RANKL, double-dye 
immunofluorescent staining of S1PR1 and RANKL was performed in different time 
points of rat periapical lesions. As shown in Fig 12, a number of S1PR1+ (green) cells 
and RANKL+ (red) cells could be observed in rat periapical lesions. Similar to what 
was seen in the human tissues, a number of S1PR1+ cells overlapped with RANKL+ 
cells in the periapical region on days 14, 21, and 35 in the rat periapical lesions. This 
further suggests that S1PR1 activation is related with RANKL expression in the 
pathogenesis of apical periodontitis. 
 
 
 
 
 
 
 
Group N S1PR1+ cells/hpf RANKL+ cells/hpfI Osteoclasts/hpfII 
Day 0 5 — — — 
Day 7 5 23.70 ±1.95#,†,£,‡ 24.43 ± 2.52#,†,£‡, 5.60 ± 0.83#,†,£,‡ 
Day 14 5 50.03 ± 7.27*,£,‡ 57.03 ± 1.43*,£,‡ 9.05 ± 0.65*,£,‡ 
Day 21 5 43.56 ± 6.82*,£,‡ 53.95 ± 8.89*,£,‡ 7.34 ± 1.20*,£,‡ 
Day 28 5 31.88 ± 5.87*,#,† 34.74 ± 3.80*,#,† 6.15 ± 1.08*,#,† 
Day 35 5 30.76 ± 6.43*,#,† 33.06 ± 4.71*,#,† 5.84 ± 0.60*,#,† 
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Figure 12. Immunofluorescent colocalization of S1PR1 and RANKL on days 14, 21, and 35 (n=5). 
S1PR1 was stained with Dylight488 (green), and RANKL was stained with CY3 (red). Nuclei were 
counterstained with DAPI (blue). (Original magnification, 200×, Scale bar = 50 μm). S1PR1+RANKL+ 
cells (yellow) could be observed in different time points (days 14, 21, and 35) of rat periapical lesions, 
suggesting S1PR1 activation was related with RANKL expression in the pathogenesis of apical 
periodontitis. Arrows indicate the S1PR1+RANKL+ cells. 
 
S1PR1-RANKL-DAPI-MERGE 
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3.4.7 S1P-S1PR1 signalling modulation limited periapical lesions exacerbation 
The role of S1P-S1PR1 signalling in apical periodontitis was further studied by 
its modulation (administration of FTY720). Histological analysis (H&E staining) was 
used for general morphology and measurements of bone loss (lesion area); sections 
were observed under both fluorescence and light microscopes. As shown in Fig 12, 
periapical bone destruction and lesion formation appeared in both of the control and 
experimental groups, accompanied with pulp necrosis and inflammatory cell 
infiltration. Apart from the control group, of which lesion areas greatly grew up from 
day 7 to day 35, the lesion areas of experimental group were comparably stable and 
much smaller. As shown in Fig 12 and Table 3, since day 7, the lesions of control 
group were significantly larger than experimental group. All the data above indicated 
that the pathogenesis of periapical lesions was effectively reduced by S1P-S1PR1 
signalling intervention. 
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Figure 13. S1P-S1PR1 signalling reduced bone resorption in apical periodontitis (n=5). Periapical 
lesion size was analysed by histological staining (observed under both fluorescence and light 
microscopes) on days 7, 21, and 35 (original magnification, 50×, Scale bar = 500μm). In the control 
group, the lesion area greatly grew up from day 7 to day 35; while the lesion area of FTY720 
administration group was comparably stable and much smaller than that of control group; the 
measurements indicated that the lesion area of control group was larger than that of FTY720 group at 
each time point, especially after day 7. Significant differences were observed between two groups at 
each time point except for day 7 (*p <0.05). All the data above indicated that the bone loss in apical 
periodontitis was effectively reduced by intervening S1P-S1PR1 signalling. 
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3.4.8 S1P-S1PR1 signalling modulation reduced osteoclastogenesis in apical 
periodontitis 
The TRAP staining was performed to investigate the impacts of S1P-S1PR1 
signalling modulation on osteoclastogenesis. As shown in Fig 14 and Table 3, from 
day 7 to day 35, the osteoclast expression of experimental group was significantly 
lower than that of control group. FTY720 administration effectively restrained 
osteoclast expression and kept it on a comparably low level; while in the control group 
the osteoclast expression peaked on day 14 and then gradually decreased. 
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3.4.9 S1P-S1PR1 signalling modulation down-regulated RANKL expression, 
while caused no effect on OPG expression 
IHC staining was performed to investigate the impacts of S1P-S1PR1 signalling 
modulation on RANKL and OPG expression. After day 7, the S1PR1 and RANKL 
expression was significantly reduced following FTY720 administration (as shown in 
Fig 15, 16 and 18). The cell counting results showed that both S1PR1 and RANKL 
expression levels remained low from day 7 to day 21 and increased only slightly from 
day 28 to day 35 (Fig 18). This was in contrast to the control group, in which S1PR1 
expression along with that of RANKL reached peak expression on day 14 and 
decreased thereafter (Fig 18). The OPG expression (Fig 17), however, was almost the 
same between two groups, as there was no significant difference between the control 
and experimental groups (Fig 18). The ratio of RANKL/OPG positive cells was 
calculated; as shown in Fig 18, the ratio of RANKL/OPG was decreased after FTY720 
administration, indicated that the inhibition of S1P-S1PR1 signalling reduced the 
RANKL expression, therefore attenuated the imbalance of RANKL and OPG in the 
development of apical periodontitis.   
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Figure 14. S1P-S1PR1 signalling modulation reduced osteoclastogenesis in apical periodontitis 
(n=5). It could be observed that from day 7 to day 35, the expression of osteoclasts in control group 
was higher than that in FTY720 group; which was further confirmed by cell counting results: the 
osteoclast numbers of control group was higher than that of FTY720 group at each time point (original 
magnification, 400×, Scale bar = 50 μm); significant differences were observed between two groups 
at each time point except for day 7 (*p<0.05). All the data above indicated that the osteoclastogenesis 
in apical periodontitis was effectively reduced by intervention of S1P-S1PR1 signalling.  
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Figure 15. FTY720 down-regulated S1PR1 expression in apical periodontitis (n=5). From the IHC 
staining results, it could be observed that the expression of S1PR1 in control group was higher than that 
in FTY720 group at each time point (original magnification, 400×, Scale bar = 50 μm), indicated the 
S1P-S1PR1 signalling was successfully inhibited by FTY720 administration. 
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Figure 16. FTY720 reduced RANKL expression in apical periodontitis (n=5). From the IHC 
staining results, it could be observed that the RANKL expression of control group was higher than that 
of FTY720 group at each time point (original magnification, 400×, Scale bar = 50 μm), indicated that 
inhibiting S1P-S1PR1 signalling leaded to decreased RANKL expression in the pathogenesis of apical 
periodontitis. 
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Figure 17. FTY720 caused no effect on OPG expression in apical periodontitis (n=5). From the 
IHC staining results, no difference on OPG expression could be observed between the control group 
and FTY720 group at each time point (original magnification, 400×, Scale bar = 50 μm), indicated that 
the inhibition of S1P-S1PR1 signalling would not affect the OPG expression in the development of 
apical periodontitis. 
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Figure 18. Measurements of S1PR1/RANKL/OPG positive cells in rat periapical lesions (n=5). 
The numbers of S1PR1- and RANKL-positive cells in control group were much higher than that in 
FTY720 group at each time point, suggested that inhibited S1PR1 resulted in reduced RANKL 
expression in apical periodontitis. Significant differences were observed between two groups at each 
time point (*p< 0.05). For OPG-positive cells, no significant differences were found between two 
groups at each time point (p>0.05). The ratio of RANKL/OPG in control group was much higher than 
that in FTY720 group, indicated that the intervention of S1P-S1PR1 signalling attenuated the 
imbalanced RANKL/OPG in the pathogenesis of apical periodontitis.    
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Table 3. Numbers of S1PR1+ cells, RANKL+ cells, and osteoclasts per high-power field (hpf; 400×), 
areas of periapical lesions (mean ± standard deviation) 
 
I p< 0.05 versus control group. * p < 0.05 versus 7-day. # p < 0.05 versus 14-day. † p < 0.05 versus 21-
day. £ p < 0.05 versus 28-day. ‡ p < 0.05 versus 35-day.  
 
 
 
 
Group N S1PR1+ cells/hpf RANKL+ cells/hpf Osteoclasts/hpf Lesion area 
(mm2)  
 
Day 7 
(control) 
5 25.65±3.44#,†,£,‡ 23.70 ± 2.74#,†,£‡, 5.28 ± 0.81#,†,£,‡ 0.43 ± 0.04 #,†,£,‡ 
Day 7 
(FTY)  
5 14.50 ±1.99I 13.96 ± 1.49I, ‡ 3.93 ± 1.18 0.35 ± 0.08 £,‡ 
Day 14 
(control) 
5 51.80 ± 8.78I,*,£,‡ 64.05 ± 7.46I,*,£,‡ 10.50 ± 0.77I,*,£,‡ 0.53 ± 0.06I,*,†,£,‡ 
Day 14 
(FTY)  
5 14.01 ± 2.64I 13.62 ± 2.90I,‡ 3.65 ± 0.93# 0.39 ± 0.04I 
Day 21 
(control)  
5 43.12 ± 7.16*,£,‡ 58.03 ± 9.55*,#,† 8.75 ± 1.37*,£,‡ 0.65± 0.09*,# 
Day 21 
(FTY)  
5 14.10 ± 2.04I 14.16 ± 2.05I,‡ 3.95 ± 0.82I 0.38± 0.07I 
Day 28 
(control) 
5 32.31 ± 6.82*,#,† 33.87 ± 7.57*,#,† 7.13 ± 1.35*,#,† 0.66 ± 0.10*,# 
Day 28 
(FTY)  
5 15.63 ± 1.63I 15.99 ± 4.05I 4.25 ± 1.11I 0.39 ± 0.05I,*,#,† 
Day 35 
(control) 
5 30.51 ± 5.21*,#,† 34.61 ± 6.27*,#,† 6.53 ± 0.89*,#,† 0.68 ± 0.08*,# 
Day 35 
(FTY)  
5 18.68 ± 4.95I 19.08 ± 3.78I,*,#,† 4.36 ± 0.66I 0.45 ± 0.06I,*,#,† 
 Dissecting the Role of Sphingosine 1-Phosphate--Sphingosine 1-Phosphate Receptor 1 in Inflammatory Bone 
Remodelling 80 
3.5 DISCUSSION 
The pathogenesis of apical periodontitis, which consists of both periapical 
inflammation and alveolar bone destruction, is characterized by the infiltration of 
immune cells, such as lymphocytes, macrophages, leukocytes, plasma cells and mast 
cells (Marton & Kiss, 2000; Silva, Garlet, Fukada, Silva, & Cunha, 2007; Stashenko, 
et al., 1998). Among these cells, T cells are believed to play the pivotal role, which 
support osteoclastogenesis by producing RANKL (Kawashima, Okiji, Kosaka, & Suda, 
1996; Matsuo, et al., 1992; Theill, et al., 2002), the key osteoclastogenic cytokine in 
osteoclast differentiation and periapical lesion formation (Yasuda, et al., 1999; Zhang 
& Peng, 2005). S1P, a bioactive metabolite of plasma‑membrane sphingolipids, is of 
great importance in immune response, which regulates immune cell migration, 
function, polarization and cytokine production by binding with a family of G-protein-
coupled receptors (S1PR1-S1P5) (Maceyka, et al., 2012; Spiegel & Milstien, 2011). 
S1PR1, the main S1P receptor that facilitates the infiltration and retention of effector 
T cells in the inflammatory tissues, plays a central role in inflammatory response 
(Rivera, et al., 2008). The S1P-S1PR1 signalling also participates in modulating the 
differentiation, function, and migration of osteoclasts (Ishii, et al., 2009). Our present 
study investigated the expression of S1P-S1PR1 signalling in both human and rat 
periapical lesions and its role in apical periodontitis-derived bone loss.  
In this study, firstly, the status of S1P-S1PR1 signalling was examined in human 
periapical lesion tissues. The immunohistochemical staining results showed that 
compared with the normal periapical tissues, both S1P and S1PR1 expressions were 
enhanced in the lesion tissues, indicating that S1P-S1PR1 signalling was induced 
during the pathological development of apical periodontitis. To find out whether this 
signalling took part in the pathogenesis of bone destruction, a double-dye 
immunofluorescent staining of S1PR1 and RANKL was performed to detect the 
relationship of S1P-S1PR1 signalling to the expression of RANKL, an indispensable 
factor in osteoclastogenesis (Yasuda, et al., 1999). From the staining results, the 
expression of the S1PR1-RANKL double-positive cells in the lesion tissues was 
confirmed, suggesting there might be a possible correlation between S1PR1 activation 
and RANKL production in apical periodontitis. These investigations on human 
periapical lesions revealed that S1P-S1PR1 signalling was aberrantly enhanced in 
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apical periodontitis and might take part in the pathogenesis of bone loss in apical 
periodontitis. 
To further identify the role of S1P-S1PR1 signalling in the development of apical 
periodontitis, a rat model of this disease was created to find out the status of S1P-
S1PR1 signalling during the pathological process and its relationship with 
osteoclastogenesis. In this study, periapical lesions were induced in rats, and the lesion 
size was measured using three methods: (1) through high-resolution X-ray imaging 
and (2) histological analyses to measure the area; (3) through µCT analysis to measure 
the volume. The results of X-ray imaging and histological analysis were identical. 
From the measurements of lesion area and volume, it could be observed that the 
periapical bone loss appeared and continued to expand between days 7 and 21 after 
pulp exposure; which became comparably stable after day 28. According to this, it 
could be concluded that the time between day 7 to day 21 is the active phase (rapid 
development of apical periodontitis), while that between day 28 to day 35 is the stable 
phase. These results agrees with the previous studies (Liu & Peng, 2013; Yang, et al., 
2014), indicating that this model is reliable and effective for apical periodontitis 
research. 
The results of immunohistochemical staining of rat mandibles revealed that the 
presence of S1PR1+ cells (many of which were lymphocytes) persisted during the 
entire pathological process of apical periodontitis, accompanied with inflammatory 
cell infiltration. Compared with the control group, the expressions of S1PR1 were 
obviously much higher. These results indicated that the S1PR1 was activated during 
apical periodontitis, which could induce the migration of immune cells into 
inflammatory sites (Rivera, et al., 2008; Spiegel & Milstien, 2003). The cell counting 
results showed that the number of S1PR1-positive cells peaked on day 14 and then 
decreased during the stable phase (days 21 to 35). Of note, the numbers of osteoclasts 
and RANKL-positive cells exhibited a similar trend. The significant positive 
correlation between expression of S1PR1 and osteoclasts suggests that S1P-S1PR1 
signalling takes part in the enhanced osteoclastogenesis during apical periodontitis. 
This might be partially due to the production of RANKL, as the RANKL expression 
was also positively correlated with S1PR1 expression. 
To further verify the correlation between S1PR1 and RANKL, the double-dye 
immunofluorescent staining of S1PR1 and RANKL was also applied in different 
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stages of rat periapical lesion tissues. Same as in the human tissues, the S1PR1 + 
RANKL+ cells were observed in rat periapical lesion tissues, suggesting that the 
S1PR1 activation correlates with RANKL production in certain cells within the 
periapical lesions. Based on this, it could be presumed that the S1P-S1PR1 signalling 
participates in inducing osteoclastogenesis during apical periodontitis by enhancing 
RANKL production.  
To confirm this presumption, a modulator on this signalling was applied in the 
rat periapical lesion model. The structural analogue of S1P‒FTY720, which has been 
used in clinical treatment of multiple sclerosis (MS) (Kappos, et al., 2006), is found to 
reduce inflammation through its functional antagonistic effects on S1PR1 which 
making it unresponsive to S1P (Pham, et al., 2008; Thangada, et al., 2010); therefore 
resulting in inhibited differentiation, migration and functional maturation of immune 
cells. Thus, in this study, FTY720 treatment was used to negatively regulate the S1P-
S1PR1 signalling in induced models of apical periodontitis in rats.   
To evaluate the effectiveness of FTY720 treatment in apical periodontitis, firstly, 
its effect on bone loss was analysed. The lesion size was measured by histological 
analysis; the results showed that from day 14 to day 35, the periapical areas of 
experimental group were significantly smaller than those of control group, indicating 
that modulation of S1P-S1PR1 signalling with FTY720 effectively inhibited the 
alveolar bone destruction in apical periodontitis. This demonstrated that the S1P-
S1PR1 signalling played a crucial role in apical periodontitis-derived bone loss.  
Further experiments were conducted to investigate the mechanisms underlying 
this therapeutic effect. The results of TRAP analysis identified that the expression of 
osteoclasts was significantly down-regulated after day 14 following FTY720 
administration, which effectively restrained osteoclastogenesis and kept it at a 
comparably low level. This finding, together with the previous experiments descried 
above, indicates that the S1P-S1PR1 signalling acts as a regulator in the 
osteoclastogenesis of apical periodontitis.  
We then sought to figure out the impacts of modulating S1P-S1PR1 signalling 
on RANKL expression. As shown in Fig.8, the S1PR1 expression was significantly 
down-regulated by FTY720 during the whole pathogenesis of rat periapical lesions. 
Based on this result, it could be concluded that the S1PR1 expression was successfully 
reduced by FTY720 administration in this animal model. Following the down-
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regulated S1PR1, RANKL expression was also significantly inhibited by FTY720 
treatment, which stayed in a lower level compared to that of control group. This finding, 
together with the previous finding described above, further demonstrated that close 
correlation exits between S1PR1 and RANKL; that during the pathogenesis of apical 
periodontitis, S1PR1 activation induced by S1P could enhance the production of 
RANKL, therefore inducing the RANKL-mediated osteoclastogenesis. It is therefore 
speculated that the S1P-S1PR1-RANKL axis plays a central role in apical 
periodontitis-derived bone loss.  
As the imbalance of RANKL/OPG was considered to be essential in bone 
destruction (Fonseca, et al., 2004), the OPG expression was investigated following 
modulation of the S1P-S1PR1 signalling by immunohistochemical staining. The 
results showed that there was no significant difference between the control and 
experiment groups; hence, the ratio of RANKL and OPG was obviously lower after 
FTY720 administration, indicating that FTY720 could attenuate the imbalance of 
RANKL/OPG in apical periodontitis. So far, S1P-S1PR1 signalling has not been 
reported to be related with OPG expression. Therefore, this finding suggested that the 
S1P-S1PR1 signalling up-regulated RANKL production while causing no effect on 
that of OPG. This induced the imbalance of RANKL/OPG, which results in activated 
bone resorption in apical periodontitis. 
It should also be noted that the inhibition of S1P-S1PR1 signalling on bone loss 
was most effective during the active stage (day 7 to day 21) of apical periodontitis. 
When it came to the later stable stage (day 28 to day 35), the difference between the 
experimental and control groups became less obvious. As the S1P-S1PR1 signalling 
has also been reported to induce bone formation (Pederson, et al., 2008; Sato, et al., 
2012), it could be assumed that down-regulation of this signalling may impact the bone 
formation in apical periodontitis. This indicates the role of S1P-S1PR1 signalling in 
the inflammatory bone remodelling is far more complex than expected and should be 
further addressed.   
In summary, the results of the current study clearly demonstrate that the S1P-
S1PR1 signalling plays a crucial role in the apical periodontitis, through enhancing 
RANKL production, inducing the imbalance of RANKL/OPG, and promoting 
osteoclastogenesis. The effective outcome of the inhibition of S1P-S1PR1 signalling 
indicates that this signalling could be a potential target for the treatment of apical 
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periodontitis. Our research findings also suggest that the administration of FTY720 
should be considered as a potent therapeutic approach for treating apical periodontitis. 
It is generally accepted that root canal treatment is the best therapy for apical 
periodontitis, thus, FTY720 administration could be used as a supplementary treatment, 
especially for the acute apical periodontitis (due to its immunosuppressive functions). 
However, since humans are physically different from rats, the effect of FTY720 on 
human apical periodontitis still needs to be established in future studies. 
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The role of S1P-S1PR1 signalling in the interaction between 
macrophages and BMSCs in infection-induced inflammation 
 
4.1 ABSTRACT 
Background: The S1P-S1PR1 signalling plays a crucial role in inducing bone loss 
during the infection-induced inflammation. It is still unclear what causes this activation 
and how this signalling leads to osteoclastogenesis. This study aims to investigate the 
role of S1P-S1PR1 signalling in macrophage-BMSC interaction under infection-
induced inflammatory conditions. 
 
Methods: The in vitro co-culture system of macrophages and BMSCs was applied 
with LPS stimulation to mimic the infection-induced inflammatory condition. S1PR1-
siRNA was used to block S1PR1 in BMSCs co-cultured with macrophages. RT-qPCR, 
western blot and immunofluorescent analysis were performed to detect the expression 
levels of SPHK1, S1P, S1P1 and RANKL. 
 
Results: Under LPS stimulation, BMSCs co-cultured with macrophages showed 
significant up-regulation of SPHK1 activity and S1P production, which then activated 
S1PR1 in BMSCs. This activated S1P-S1PR1 signalling eventually led to an increase 
of RANKL production by BMSCs, which was confirmed by S1PR1-blockage. 
 
Conclusions: Under the infection-induced inflammatory conditions, macrophages 
were activated and interacted with BMSCs. This interaction induced the S1P 
production of BMSCs, which acted in an autocrine manner to activate S1PR1 of 
BMSCs. The activated S1P-S1PR1 signalling in BMSCs then induced the production 
of RANKL, therefore eventually resulted in enhanced osteoclastogenesis and bone loss.  
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4.2 INTRODUCTION 
Bone is a dynamic tissue which is constantly undergoing life-long renovation. 
This renovation, also named remodelling, is constituted by osteoclast-derived bone 
resorption and osteoblast-derived bone formation (Raggatt & Partridge, 2010). 
Osteoclasts, derived from the monocyte/macrophage lineage, are so far recognised as 
the only type of cells capable of resorbing bone (Kini & Nandeesh, 2012). Osteoblasts, 
as well as the osteoblast precursors‒BMSCs, not only direct the bone formation 
process, but also play a key role in osteoclastogenesis by producing receptor activator 
of RANKL (Udagawa, et al., 1990), which activates its receptor RANK on osteoclast-
precursors and plays an indispensable role in osteoclastogenesis (Kong, et al., 1999; 
Theill, et al., 2002). The bone resorption and formation are kept in balance under 
physical circumstances (Arron & Choi, 2000). Under pathological settings such as 
inflammation, the balanced bone remodelling is disrupted; osteoclastogenesis is 
aberrantly activated leading to bone resorption exceeding bone formation, eventually 
results in bone loss, as seen in rheumatoid arthritis (RA) (Rodan & Martin, 2000), 
periodontitis (Taubman, et al., 2005), and apical periodontitis (Wang & Stashenko, 
1993). 
The balance of remodelling is highly regulated by the immune system 
(Takayanagi, 2007). The process of osteoclastogenesis is modulated by various 
immune-related factors, such as cytokines, transcription factors, receptors and 
molecular signalling (Takayanagi, 2005; Walsh et al., 2006). Among these factors, 
macrophages, which play a central role in the innate immune response, not only serve 
as precursors of osteoclasts, but also take part in the regulation of osteoclastogenesis 
(Takeshita, et al., 2000). Macrophages are a population of cells with three kinds of 
subsets: (1) non-activated M0 macrophages; (2) pro-inflammatory M1 macrophages 
which are classically activated by microbe-derived lipopolysaccharide (LPS) or Th1 
cell-related cytokines such as IFNγ; and (3) M2 macrophages, which alternatively 
activated by Th2 cell-related cytokines such as IL-4 and IL-13, are identified as the 
anti-inflammatory macrophages (Horwood, 2015; Mantovani, et al., 2004; Mills, et al., 
2000; Murray, et al., 2014). The M1 macrophage-derived cytokines either directly act 
on osteoclast-precursors (such as TNF-α and IL-1β) to induce osteoclastogenesis or 
indirectly act on osteoblasts (such as IL-6) or osteoblast-precursors (known as BMSCs) 
to promote RANKL production (Hashizume, et al., 2008; Kobayashi, et al., 2000; 
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Kudo, et al., 2003; Kurihara, et al., 1990; Lam, et al., 2000; Wei, et al., 2005; Zwerina, 
et al., 2007). Hence, the interaction between macrophages and osteoblast-lineage cells 
greatly affects RANKL production, therefore plays a central role in regulating 
osteoclastogenesis.  
Several factors are found to be involved in the interaction between macrophages 
and BMSCs. According to recent research, S1P should also be considered as a potent 
coupling factor in the interaction between macrophages and BMSCs. S1P is the 
bioactive metabolite of sphingolipid (Maceyka, et al., 2012), which modulates diverse 
crucial cellular processes by binding with its five G protein-coupled receptors S1PR1 
‒ S1PR5 (Davis & Kehrl, 2009); among which S1PR1 is widely expressed by various 
types of cells, and the S1P-S1PR1 signalling is found to play essential roles in 
osteoclastogenesis (Ishii, et al., 2009; Rivera, et al., 2008). A recent study (Ryu, et al., 
2006) found that S1P production of osteoclast-precursors‒known as 
macrophages/monocytes‒was enhanced during osteoclastogenesis. The produced S1P 
then acted on osteoblast-precursors and induced the production of RANKL and 
therefore increasing the propensity for osteoclastogenesis. Activated S1PR1-S1PR3 
were found in osteoblast-precursors, however, it is still unknown which receptor is 
responsible for enhancing RANKL production (Ryu, et al., 2006). Based on the 
previous findings, it could be speculated that macrophages interact with BMSCs 
through the S1P-S1PR1 signalling, which induces RANKL production and hence 
improve the propensity for osteoclastogenesis. 
 In the previous chapter, abnormally activated S1P-S1PR1 signalling in the 
infection-induced inflammation (apical periodontitis) has been identified, which is 
correlated with induced RANKL production and osteoclastogenesis. However, the 
driving mechanism for the activation of S1P-S1PR1 signalling is still not clear. 
Furthermore, it is still unknown how S1P induces RANKL production. Macrophages 
are activated during microbial-infection and play a central role in the immune response 
against pathogen invasion (Mantovani, et al., 2004), which interact with BMSCs to 
regulate osteoclastogenesis; this interaction might be greatly due to the S1P-S1PR1 
activation. Hence, the aim of this study is to investigate the role of S1P-S1PR1 
signalling in the macrophages-BMSCs interaction under the infection-induced 
inflammatory conditions. 
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4.3 MATERIALS AND METHODS 
4.3.1 Cell culture 
Rat BMSCs 
BMSCs were obtained from 8-10 week old Wistar male rats (rBMSCs) as 
described in previous study (Leboy, Beresford, Devlin, & Owen, 1991). Briefly, the 
rats were sacrificed and the back limbs were then harvested. The femurs and tibias 
were dissected to remove all the skin and muscles, and then washed by phosphate 
buffered saline (PBS) with 1% (v/v) penicillin/streptomycin (P/S; Gibco®, Life 
Technologies Pty Ltd., Australia) for three times. The dissected bones were transferred 
into a 10 cm dish containing Dulbecco’s modified Eagle’s medium (DMEM; Gibco®, 
Life Technologies Pty Ltd., Australia). The two ends of the bones were cut open, and 
then the bone marrow was flushed into a 50 mL tube by syringes filled with DMEM 
(containing 1% P/S). The obtained bone marrow was then washed once with PBS 
(containing 1% P/S) and resuspended in DMEM containing 10% (v/v) fetal bovine 
serum (FBS; In Vitro Technologies, Australia) and 1% P/S. The cell suspension was 
then transferred into a culture flask and cultured in incubators with 5% CO2 at 37º C. 
After three days, the non-adherent cells were washed away by PBS. The adherent cells 
were then continually incubated in DMEM with 10% FBS and 1% P/S (culture 
medium was changed every 2-3 days). When reaching 80% confluence, the cells were 
passaged by treating with 0.25% trypsin (containing 1mM EDTA, Gibco®, Life 
Technologies Pty Ltd., Australia) for 2 min. Cells within 5 passages were used for 
experiment. All experiment procedures were approved by the Ethics Committee of 
Queensland University of Technology. 
 RAW 264.7 cells  
In this study, a mouse-derived macrophage cell line, RAW 264.7 (RAW) cells, 
were used as macrophage-like cells to study the interaction between macrophages and 
BMSCs. As a murine macrophage cell line, RAW cells have been proved to work 
reliably with BMSCs from other species (Chen, Wu, Gu, et al., 2014; Chen, Wu, Yuen, 
et al., 2014; Shi et al., 2016). RAW cells were cultured in DMEM with 10% FBS (heat-
inactivated at 60 º C for over 30 min) and 1% P/S. The culture medium was changed 
every 2 to 3 days. After reaching 80% confluence, the cells were passaged by treating 
with 0.25% trypsin (containing 1mM EDTA) for 2 min.  
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4.3.2 In vitro cell co-culture model 
LPS stimulation was used to simulate the infection-induced inflammatory 
condition as previously described (King, Fleming, Critchley, & Kelly, 2002). The 
rBMSCs were co-cultured with RAW cells under normal or infection-induced 
inflammatory conditions. Two co-culture models were established as follows: 
Co-culture model One 
To obtain conditioned medium (CM) of RAW cells from LPS stimulation, RAW 
cells were cultured in T175 flask to reach confluence. The cells were then stimulated 
with 100 ng/mL LPS for 12 h. After stimulation, the medium was removed, and the 
cells were washed twice with PBS, and then incubated with serum-free DMEM for 12 
h. The medium was harvested and subjected to centrifugation (1000×g, 10 min, 4 º 
C), then filtered with a 0.2 µm filter (Millipore Corporation, Billerica, MA, USA) to 
remove cell debris. The filtered medium was stored at -80 º C for further experiments. 
To mimic normal condition as comparison, the CM from RAW cells (without 
LPS stimulation) was mixed with culture medium (DMEM, 20% FBS, 2% P/S) in a 
ratio of 1:1. To mimic inflammatory condition, the CM from LPS-stimulated RAW 
cells was mixed with culture medium containing 200 ng/mL LPS (DMEM, 20% FBS, 
2% P/S) a 1:1 ratio. The mixed medium was then applied to rBMSCs. The rBMSCs in 
normal culture medium served as controls for the normal co-culture, while the ones in 
culture medium supplemented with 100 ng/mL LPS served as control for the LPS-
induced inflammatory co-culture (Fig 19). The cells were stimulated for 12 h, and then 
harvested for RNA/protein extraction and immunofluorescent staining.     
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Figure 19. Co-culture model (conditioned medium) of macrophages and rBMSCs. CM of 
macrophages under normal or LPS stimulation was collected and mixed with normal or LPS medium; 
the mixed medium was then applied to rBMSCs. The rBMSCs applied with normal or LPS medium 
were served as normal- or LPS-controls, respectively. CM = conditioned medium. 
 
Co-culture model Two 
A trans-well co-culture system was used to further monitor the interaction 
between macrophages and rBMSCs. The cell culture inserts for 6-well plates 
(BectonDickinson Labware, Franklin Lakes, NJ, USA) with 0.4 µm pore size were 
used to culture RAW cells. The rBMSCs were seeded onto the companion plates (the 
ratio of numbers of rBMSCs to RAW cells is roughly 1:4). After 24 h of attachment, 
the inserts were then assembled onto the companion plates. For normal co-culture, 
normal culture medium (supplemented with FBS inactivated) was applied to the inserts 
and companion plates. The singly cultured rBMSCs with normal culture medium 
served as normal controls. In the LPS-induced inflammatory condition, co-cultured 
cells were stimulated with 100 ng/mL LPS (in DMEM with 10% inactivated FBS and 
1% P/S), the singly cultured rBMSCs subjected to the same medium served as LPS-
controls (Fig 20). After 12 h of co-culture, the cells were harvested for subsequent 
experiments. 
 
Control 
 Dissecting the Role of Sphingosine 1-Phosphate--Sphingosine 1-Phosphate Receptor 1 in Inflammatory Bone 
Remodelling 93 
4.3.3 S1PR1 siRNA Transfection  
The S1PR1 siRNA (5’GAC UAU GGC AAC UAU GAU A3’, 5’UAU CAU 
AGU UGC CAU AGU C3’, Product number: PDSIRNA2D, siRNA ID: 
SASI_Rn01_00101785, Sigma-Aldrich Pty. Ltd., Sydney, Australia) was used to 
block S1PR1 in this study. The experiment was performed following the 
manufacturer’s instructions. The rBMSCs for transfection were seeded in 6-well plates 
with culture medium (DMEM, 10% FBS, no P/S). After 24 h of cell attachment, 
forward transfection of S1PR1 siRNA was performed on each well. 125 pmol S1PR1 
siRNA was diluted in 250 µL Opti-MEM® I Reduced Serum Medium (Opti-MEM, 
Gibco®, Life Technologies Pty Ltd., Australia). Also, 4 µL Lipofectamine™ 
RNAiMAX was diluted in the same amount of Opti-MEM. These two dilutions were 
gently mixed and incubated for 15 min at room temperature, and then transferred into 
the well. The cells were then incubated for 48 h in the incubator. After incubation, the 
rBMSCs were then co-cultured with RAW cells using the trans-well system as 
described above (Fig 20). The universal negative control siRNA (MISSION® siRNA 
Universal Negative Control #1, Product number: SIC001, Sigma-Aldrich Pty Ltd., 
Sydney, Australia) was used in wells without the application of S1PR1 siRNA. 
 
 
Figure 20. Co-culture model (trans-well) of macrophages and rBMSCs. S1PR1 siRNA was used 
for blockage of S1PR1, while negative control siRNA was used in wells without the application of 
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S1PR1 siRNA. RBMSCs singly cultured in normal/LPS medium were used as controls for normal or 
inflammatory co-culture, respectively. 
 
4.3.4 RNA extraction, cDNA synthesis, and real time quantitative-PCR (RT-
qPCR) 
Total RNA was extracted from rBMSCs or RAW cells using the TRIzol Reagent 
(Ambion®, Life Technologies Pty Ltd., Australia). The cDNA was then synthesized 
from 1 μg total RNA by SensiFAST™ cDNA Synthesis Kit (Bioline (Aust) Pty Ltd., 
Australia) following the manufacturer’s protocol. The real-time polymerase chain 
reaction (RT-qPCR) was carried out by the QuantStudio™ 7 Flex Real-Time PCR 
System (Applied Biosystems, Australia) with SYBR® Green reagent (Applied 
Biosystems, Australia) according to the manufacturer’s instructions. The RT-qPCR 
primers (Table 4) were designed based on cDNA sequences from the National Centre 
for Biotechnology Information (NCBI) sequence database and the primer specificity 
was confirmed by Primer-BLAST on the NCBI website. Analyses were performed on 
the following target genes: SPHK1, S1PR1, and TNFS11 (rat); CD86, TNF, iNOS, IL-
6, IL-1β, CCR7, SPHK1 and S1PR1 (mice). The house keeping gene 18S and β-actin 
were used as control. All reactions were run in triplicate for three independent 
experiments. Relative gene expression was normalized against 18S or β-actin and 
calculated as previously described (Bookout & Mangelsdorf, 2003).  
Table 4. Primer sequences for the gene investigated in this study 
Rat 
Gene  Forward sequences Reverse sequences 
SPHK1 5’AAGCTGGGCTGTCCTTCAAC3’ 5’ACAGCGTCTTCCCAATCTGG3’ 
S1PR1 5’GTTGTCCGGGATTTGGTAGG3’ 5’GATGCTCGTAGGGGTTAGAG3’ 
TNFS11 5’GGCATCATGAAACCTCAGGG3’ 5’GTTGGACACCTGGACGCTAA3’ 
18S 5’CGGAACTGAGGCCATGATTAAG3’  5’GTATCTGATCGTCTTCGAACCTCC3 
β-actin 5’ATGCAGCCTGAAGAGGACTG3’ 5’GGCTATGAAATCCAGGGCCT3’ 
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Mice 
Gene  Forward sequences Reverse sequences 
SPHK1 5’AGAGTGCTGGTGCTGCTGAA3’ 5’CATGCATCAGACCATCACCG3’ 
S1PR1 5’ACTTTGCGAGTGAGCTGGTC3’ 5’AGGAGCCTGGGGTGGTATTT3’ 
CD86 5’CTGCTCATCATTGTATGTCAC3’ 5’ACTGCCTTCACTCTGCATTTG3’ 
TNF 5’CTGAACTTCGGGGTGATCGG3’ 5’GGCTTGTCACTCGAATTTTGAGA3’ 
iNOS 5’TGGTGAAGGGACTGAGCTGT3’ 5’CTGAGAACAGCACAAGGGGT3’  
IL-6 5’GTCTTCTGGAGTACCATAGCTACCTG3’ 5’CCTTCTGTGACTCCAGCTTATCTG3’  
IL-1β 5’TGGAGAGTGTGGATCCCAAG3’ 5’GGTGCTGATGTACCAGTTGG3’ 
CCR7 5’ATGACGTCACCTACAGCCTG3’ 5’CAGCCCAAGTCCTTGAAGAG3’ 
18S 5’CGGAACTGAGGCCATGATTAAG3’ 5’GTATCTGATCGTCTTCGAACCTCC3 
β-actin 5’ACTGAGCGTGGCTATTCCTTCG3’ 5’CTAGGGCCGTGATCTCCTTCTG3’ 
 
4.3.5 Protein extraction and western blotting 
Total protein was extracted from rBMSCs by the lysis buffer (20 mM HEPES 
(pH 7.4), 10% glycerol, 1% Triton X-100, 2mM EDTA) with the protease inhibitor 
cocktail (Roche Products Pty. Ltd., Dee Why, NSW, Australia). Measurements of 
protein concentration were performed by using the BCA Protein Assay Kit (Thermo 
Fisher Scientific, VIC, Australia). For each sample, 10 µg of protein was loaded into 
a SDS-PAGE gel and then separated by running the gel. After that the protein was 
transferred to a nitrocellulose membrane (Merck Millipore, Billerica, USA). The 
membrane was blocked by the Odessy buffer (LI-COR Biosciences, Lincoln, USA) 
for 1 h at room temperature and then incubated with primary antibodies against SPHK1 
(1: 500, Abcam, Cambridge, UK), S1P (1: 800, Abcam, Cambridge, UK), S1PR1 (1: 
500, Abcam, Cambridge, UK), and RANKL (1:300, Novus Biologicals, LLC, USA); 
α-Tubulin (1: 5000, Abcam, Cambridge, UK) was used as a loading control. After 
incubated at 4 °C overnight, the membrane was washed and then incubated with Anti-
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rabbit IgG IRDye 800 conjugated secondary antibody (1: 10000, Rockland, 
Gilbertsville, Pennsylvania, USA) or Anti-mouse IgG IRDye 700 conjugated 
secondary antibody (1: 4000, Rockland, Gilbertsville, Pennsylvania, USA) for 1 h at 
room temperature. All the antibodies were diluted in the Odessy buffer. After three-
times of washing, the membranes were scanned by Odyssey® Infrared Imaging 
System (LI-COR Biosciences, Lincoln, USA) according to the manufacturer’s 
instructions. Quantification of band intensities was obtained by ImageJ software. All 
experiments were replicated by three times. 
 
4.3.6 Immunofluorescent staining   
The rMSCs were seeded on 13mm coverslips (ProSciTech, QLD, Australia) for 
immunofluorescent staining. After treatment (described in sections 4.3.5 and 4.3.6), 
the rBMSCs were washed twice by PBS, and then fixed by 4% PFA for 20 min at room 
temperature. The cells were washed three times by PBS, and then permeabilized by 
0.1% Triton X-100 (diluted in PBS) for 5 min at room temperature. After washing 
(three times in PBS), the cells were blocked in 1% BSA/PBS (60 min in room 
temperature), then incubated with primary antibodies against SPHK1 (1: 150), S1P (1: 
200), S1PR1 (1: 100), and RANKL (1: 100) at 4°C overnight. Then the cells were 
washed three times by 0.1% BSA/PBS (5 min each time) and then incubated with 
secondary antibodies, goat anti-rabbit Alexa Fluor® 488 (1:1000, Cell Signaling 
Technology, Inc, Danvers, USA), goat anti-mouse Alexa Fluor® 568 (1:1000, Life 
Technologies Pty Ltd., Australia)for 30min (protected from light). All antibodies were 
diluted in 1% BSA/PBS. After three times’ washing (0.1% BSA/PBS, 5 min), the cells 
were mounted with ProLong® Gold antifade reagent with DAPI (Life Technologies 
Pty Ltd., Australia), secured to glass slides, kept at 4°C overnight, and then analysed 
under the fluorescent microscope. In each section, S1P-positive cells/S1PR1-positive 
cells/SPHK1-positive cells/RANKL-positive cells/S1PR1-RANKL double-positive 
cells in five randomly selected regions were counted under 200× magnification; the 
percentage of positive cells in total cells was calculated. The average percentage of the 
five chosen areas was calculated. Three sections from each group were analysed for 
cell measurements. All measurements were performed in a double-blind manner by 
two trained independent observers. 
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4.3.7 Statistical analysis 
All data were subjected to statistical analysis using one-way ANOVA, followed 
by the Student-Newman-Keul test at a = 0.05. Pearson correlation was used for 
correlation analysis on numbers of S1PR1+ cells with osteoclasts and RANKL+ cells 
(a = 0.05). A p< 0.05 was considered to significantly different. Data were analysed by 
SPSS 13.0 (SPSS Inc., Chicago, IL). All data were presented as mean ± standard 
deviation (SD). 
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4.4 RESULTS       
4.4.1 SPHK1 and S1PR1 were down-regulated in macrophages stimulated by 
LPS, while up-regulated in rBMSCs stimulated by macrophage CM 
In this study, firstly, the mRNA levels of SPHK1 and S1PR1 were examined in 
RAW cells stimulated with LPS. The macrophage phenotype was also analysed by 
RT-qPCR. The mRNA expression levels of typical markers of M1 macrophages ‒ 
TNF-α, IL-1β, iNOS, IL-6, CCR7 and CD86, were found to be significantly enhanced 
in RAW cells (Fig 21), indicating the macrophages were polarized towards the M1 
phenotype by LPS stimulation. This is consistent with previous studies (Horwood, 
2015; Mantovani, et al., 2004; Mosser & Edwards, 2008; Tjiu, et al., 2009). Along 
with the increased expression of M1 markers, there was a significant decrease in the 
expression of SPHK1. Furthermore, decreased S1PR1 expression was observed. This 
suggested that S1P production of macrophages was reduced when the cells were 
stimulated by LPS; hence, macrophages would not likely be the major source of S1P 
in the infectious inflammatory condition. 
 
 
Figure 21. Changes of mRNA levels in macrophages under the stimulation of LPS (n=3). The 
mRNA levels of M1 macrophage markers (CD86, TNF-α, iNOS, IL-6, IL-1β and CCR7) were 
significantly increased in macrophages (RAW cells) stimulated by LPS; while the levels of SPHK1 and 
S1PR1 were significantly decreased (*p< 0.05), suggesting that S1P production was decreased in 
macrophages stimulated with LPS. N = normal medium. LPS = medium with LPS. 
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Next, the mRNA expression levels of SPHK1 and S1PR1 were examined in 
rBMSCs stimulated with CM derived from RAW cells. As shown in Fig 22, the 
SPHK1 expression was enhanced in rBMSCs stimulated with macrophage CM under 
both normal and LPS-induced inflammatory conditions; accordingly, the S1PR1 
expression of rBMSCs was also up-regulated when exposed to macrophage CM. It 
could also be observed that the SPHK1 and S1PR1 expression was significantly higher 
in CM-treated rBMSCs under the stimulation of LPS. This suggested that the secreted 
factors from macrophages induced SPHK1 expression in rBMSCs, especially under 
the infection-induced inflammatory condition. 
 
Figure 22. Change of mRNA levels in rBMSCs stimulated by CM derived from macrophages 
(n=3). Under both normal and LPS-stimulation conditions, the mRNA levels of SPHK1 and S1PR1 in 
rBMSCs were significantly up-regulated when stimulated by CM and macrophages (*P < .05), 
(rBMSCs in normal culture medium served as controls for the normal co-culture, while the ones in 
culture medium supplemented with LPS served as control for the LPS-induced inflammatory co-culture). 
N = normal medium. LPS = medium with LPS. CM = conditioned medium from RAW cells 
with/without LPS stimulation. M0 = M0 macrophage. M1 = M1 macrophage.  
 
4.4.2 Up-regulated SPHK1-S1P-S1PR1 axis and RANKL production in 
rBMSCs co-cultured with macrophages     
To further study the interaction between macrophages and BMSCs, these two 
kinds of cells were co-cultured by using the trans-well system. From the Result 4.4.1, 
it could be concluded that the rBMSCs should be the main source of S1P in the co-
culture under the infectious inflammatory conditions; hence, in the following study, 
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we only focused on analysing rBMSCs in the co-culture. The RT-qPCR result showed 
that, when co-cultured with macrophages (using the transwell co-culture system) in 
normal condition, the rBMSCs showed a slight increase in; while in the LPS-induced 
inflammatory condition, co-culturing with macrophages significantly induced SPHK1 
mRNA levels (Fig 23); this was consistent with the results of western blot (Fig 23) and 
immunofluorescent staining (Fig 24). Accordingly, the expression of S1P was up-
regulated in rBMSCs co-cultured with macrophages, especially under LPS stimulation 
(Fig 23, Fig 25). These results indicated that the SPHK1 activity of rBMSCs was 
activated when co-culturing macrophages, which resulted in enhanced production of 
S1P; especially under the infection-induced inflammatory condition. 
 
Figure 23. Up-regulated SPHK1 and S1P in rBMSCs co-cultured with macrophages (n=3). (a) 
Under both normal and LPS-stimulation conditions, the mRNA level of SPHK1 in rBMSCs was 
significantly increased when co-cultured with macrophages (*p< 0.05). (b) The protein levels of SPHK1 
and S1P were up-regulated in rBMSCs co-cultured with macrophages under both normal and LPS-
stimulation conditions. (c) Quantification of band intensities showed the protein levels of SPHK1 and 
S1P were significantly higher in rBMSCs co-cultured with macrophages (*p< 0.05), suggesting that 
macrophages induced the SPHK1 activity and hence S1P production in the co-cultured rBMSCs, 
(c) 
(b) (a) 
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especially under the infectious inflammatory condition. M = co-cultured with macrophages, N = normal 
medium, LPS = medium with LPS.  
 
 
 
Figure 24. Up-regulated SPHK1 in rBMSCs co-cultured with macrophages (original 
magnification, 200×, Scale bar = 100 μm, n=3). It could be observed that under both normal and LPS-
stimulation conditions, there were more SPHK1-positive cells in rBMSCs co-cultured with 
macrophages (*p< 0.05); the cell counting results indicated that the SPHK1 expression was significantly 
higher in rBMSCs co-cultured with macrophages, especially under infectious inflammatory conditions. 
Macrophage & M = co-cultured with macrophages, LPS = medium with LPS. 
SPHK1-DAPI 
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Figure 25. Up-regulated S1P in rBMSCs co-cultured with macrophages (original magnification, 
200×, Scale bar = 100 μm, n=3). It could be observed that under both normal and LPS-stimulation 
conditions, there were more S1P-positive cells in rBMSCs co-cultured with macrophages (*p< 0.05); 
the cell counting results indicated that the S1P expression was significantly higher in rBMSCs co-
cultured with macrophages, especially under infectious inflammatory conditions.. Macrophage & M = 
co-cultured with macrophages, LPS = medium with LPS. 
 
S1P-DAPI 
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As S1P production was found to be increased, the status of S1PR1 and RANKL 
was then examined in the co-cultured rBMSCs. Through the results of RT-qPCR and 
western blot, it could be observed that the expression of S1PR1 was significantly up-
regulated along with the activated SPHK1 and increased S1P production. Similar to 
S1PR1, the expression of RANKL was found to be up-regulated in rBMSCs co-
cultured with macrophages, especially with the stimulation of LPS (Fig 26). This 
further confirmed that in infection-induced inflammatory microenvironments, secreted 
factors from macrophages induced the SPHK1 activity in rBMSCs, therefore 
activating the S1P-S1PR1 signalling. Also, the accordingly increased RANKL 
production suggested that the S1P-S1PR1 signalling might be due to RANKL 
synthesis in rBMSCs. 
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Figure 26. Up-regulated S1PR1 and RANKL in rBMSCs co-cultured with macrophages (n=3). (a) 
The RT-qPCR results showed that under both normal and LPS-stimulation conditions, the mRNA levels 
of S1PR1 and RANKL in rBMSCs were significantly up-regulated when co-cultured with macrophages 
(*p<0.05). (b) From the western blot results, it could be found that the protein levels of S1PR1 and 
RANKL were significantly increased in rBMSCs co-cultured with macrophages under both normal and 
LPS-stimulation conditions. M = co-cultured with macrophages, N = normal medium, LPS = medium 
with LPS.  
(b)   
(a) 
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4.4.3 The S1P-S1PR1 signalling regulated RANKL production in rBMSCs co-
cultured with macrophages  
To figure out whether S1PR1 acted as a regulator for rBMSCs RANKL 
production in the co-culture system,  S1PR1 activity was blocked in rBMSCs using 
S1PR1 siRNA. As shown in Fig 27, S1PR1 siRNA successfully down-regulated the 
mRNA and protein expression of S1PR1. Accordingly, the RANKL expression 
decreased in rBMSCs with S1PR1 blockage. The double-dye immunofluorescent 
staining of S1PR1 and RANKL further confirmed the correlation of S1PR1 and 
RANKL in rBMSCs; as shown in Fig 28, S1PR1+RANKL+ cells were found in 
rBMSCs co-cultured with macrophages, especially when stimulated by LPS. The 
numbers of S1PR1+RANKL+ cells, as well as the RANKL+ cells were decreased when 
S1PR1 was inactivated. This indicated that the S1P-S1PR1 signalling was responsible 
for the enhanced RANKL production in rBMSCs. 
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Figure 27. S1PR1 acted as the regulator for RANKL production of rBMSCs co-cultured with 
macrophages (n=3). (a) Under both normal and LPS-stimulation conditions, S1PR1-blockage led to 
decreased RANKL mRNA levels in rBMSCs co-cultured with macrophages (*p< 0.05). (b) The protein 
levels of RANKL were down-regulated by S1PR1 blockage in rBMSCs co-cultured with macrophages 
under both normal and LPS-stimulation conditions (*p< 0.05). M = co-cultured with macrophages, N = 
normal medium, LPS = medium with LPS, S1PR1 -/- = S1PR1 siRNA application.  
 
(a) 
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M - + + 
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Figure 28. S1PR1 acted as the regulator for RANKL production of rBMSCs co-cultured with 
macrophages (n=3). Under both normal and LPS-stimulation conditions, there were more 
S1PR1+RANKL+ cells in rBMSCs co-cultured with macrophages; the RANKL+ and S1PR1+ RANKL+ 
cells were significantly decreased in rBMSCs when S1PR1 was inactivated (original magnification, 
200×, Scale bar = 100 μm) (*p< 0.05). M = co-cultured with macrophages, LPS = medium with LPS, 
S1PR1 -/- = S1PR1 siRNA application. 
S1PR1 RANKL MERGE 
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4.5 DISCUSSION 
In this study, to investigate the interaction between macrophages and BMSCs, 
co-culture systems were established under normal or infection-induced inflammatory 
conditions. LPS was used to mimic infection induced inflammation as previously 
described (King, et al., 2002). Firstly, the possible effect of macrophage-derived 
secreted factors on rBMSCs was examined. To modulate the co-culture under normal 
condition or infectious inflammation, M0 macrophages were stimulated with/without 
LPS. In the normal co-culture group, the CM derived from macrophages without LPS 
stimulation was applied to rBMSCs cultured in normal culture medium; while in the 
inflammation group, the CM derived from LPS activated macrophages was applied to 
rBMSCs cultured in medium containing LPS.  
The phenotype of macrophages was examined by RT-qPCR. The results showed 
that the M0 macrophages differentiated into typical M1 macrophages under the 
stimulation of LPS, which was consistent with previous studies (Mosser & Edwards, 
2008). It was then found out that when compared with M0 macrophages, the SPHK1 
expression was significantly down-regulated in M1 macrophages, indicating that in 
macrophages, the ability of S1P production reduced when they differentiated into the 
M1 phenotype. Surprisingly, significantly activated S1PR1 was found in rBMSCs 
applied with the M1 macrophage CM, suggesting that rBMSCs might be the source of 
S1P. The SPHK1 expression of rBMSCs was then examined. The CM derived from 
macrophages was found to increase the SPHK1 expression of rBMSCs under both 
normal and inflammatory conditions. Especially in inflammatory condition, the M1 
macrophage derived-CM greatly increased the SPHK1 expression of rBMSCs. This 
indicated that the secreted factors derived from macrophages activated the SPHK1 
activity of rBMSCs, therefore resulted in up-regulation of the S1P-S1PR1 signalling 
in rBMSCs; especially in the LPS-induced inflammatory condition. 
To further confirm this finding, macrophages were co-cultured with rBMSCs 
using the trans-well system. The co-cultured cells were stimulated with or without LPS 
to mimic the normal or inflammatory conditions. Macrophages were found to induce 
the SPHK1 activity in the co-cultured rBMSCs, especially under LPS stimulation; 
which therefore resulted in enhanced S1P production and activated S1PR1 in rBMSCs. 
Therefore, it could be concluded that under the infection-induced inflammation, 
macrophages interacted with rBMSCs by producing secreted factors and inducing 
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SPHK1 activity in rBMSCs, which promoted S1P production. S1P acted in an 
autocrine manner to induce S1PR1 in rBMSCs, hence, the S1P-S1PR1 signalling was 
activated by the interaction between macrophages and rBMSCs. 
As S1P was found to induce RANKL production, the RANKL expression of 
rBMSCs in the co-culture system was then examined. Same as the trend of S1PR1 
activity, the mRNA and protein expression levels were found to be up-regulated in 
rBMSCs co-cultured with macrophages, especially under LPS-induced inflammation. 
It is yet to be confirmed which receptor that S1P acts on to induce RANKL. As 
demonstrated in Chapter 3, there was a correlation between S1PR1 and RANKL, 
which reflects on the interplay between rBMSCs and macrophages in the co-culture 
system. Therefore, it could be stated that the enhanced RANKL production is due to 
the activation of S1PR1. S1PR1 siRNA was then used to block S1PR1 in the co-culture 
system, and this S1PR1-silencing was found to result in reduced RANKL production 
in rBMSCs co-cultured with macrophages. This indicated that in rBMSCs, S1P-
mediated RANKL induction was at least partially through S1PR1 activation. Hence, 
under infection-induced inflammation, the S1P-S1PR1 signalling, induced by the 
macrophage-BMSC interaction, acted as a key regulator in osteoclastogenesis by 
inducing RANKL production in BMSCs. Therefore, this is the first time that the S1P-
S1PR1-RANKL axis is confirmed.   
In the present study, up-regulated S1P-S1PR1 signalling in BMSCs was 
confirmed, which was due to the secreted factors derived from the co-cultured 
macrophages. The S1P-S1PR1 signalling was also found to be responsible for 
enhanced RANKL production in BMSCs. Under LPS-induced inflammatory condition, 
macrophages greatly activated the S1P-S1PR1 signalling in BMSCs, leading to an 
over-production of RANKL; hence, the interaction between macrophages and BMSCs 
played a significant role in osteoclastogenesis in infection-induced inflammatory 
disease, such as apical periodontitis. Moreover, the BMSC-derived S1P could also 
attract the migration of osteoclast-precursors (Ishii, et al., 2009), therefore greatly 
facilitating osteoclastogenesis. The macrophages also activated the S1P-S1PR1 
signalling in BMSCs under normal condition. Although this up-regulation was 
comparably moderate, it suggests that the S1P-S1PR1-RANKL axis might be 
responsible for the physical bone remodelling. This study firstly proves that under the 
infection-induced inflammatory condition, the macrophages are activated and 
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polarized towards M1 phenotype while losing the ability of producing S1P. The 
interaction of macrophages and BMSCs activates SPHK1 of BMSCs, which 
eventually results in activation of the S1P-S1PR1 signalling and increase RANKL 
production. It is yet to be confirmed what kind of secreted factors derived from 
macrophages are responsible for activating SPHK1 in BMSCs. As TNF-α and IL-1 
have been identified to induce SPHK1 activity (Pettus, et al., 2003; Xia, et al., 1998), 
it could be presumed that these pro-inflammatory cytokines take part in the activation 
of SPHK1 in BMSCs. One of the limitations of this study is that LPS could not fully 
simulate microbial infection; instead, it only partially mimic the infection-induced 
inflammation derived from Gram-negative microbes, such as the infection in apical 
periodontitis. In addition, as RAW cells are macrophage-like cells, it would be better 
to investigate if the similar results could be found in the primary human macrophages 
and BMSCs, which will be the future work of this study.  
In conclusion, it is demonstrated that the interaction between macrophages and 
BMSCs is associated with the activation of S1P-S1PR1 signalling. Macrophages act 
as a regulator to trigger the SPHK1 activation of BMSCs, especially in infection-
derived inflammatory condition. This interaction plays a crucial role by increasing the 
rate of osteoclastogenesis and bone loss, by activated S1PR1 inducing the expression 
of RANKL. 
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Macrophages induce osteogenesis under infection-induced 
inflammatory conditions in a S1P-S1PR1 signalling dependent 
manner 
5.1 ABSTRACT 
Background: Abnormal osteogenesis has been observed in infection-induced 
inflammatory diseases, such as apical periodontitis, and the mechanism underlying this 
phenomenon remains unknown. Previous research has shown that S1PR1 can induce 
osteogenesis, therefore, the aim of this study is to investigate the role of S1P-S1PR1 
signalling in the osteogenesis under condition of infection-induced inflammation. 
    
Methods: In vitro co-culture system of macrophages and rBMSCs was applied with 
the stimulation of LPS. S1PR1-siRNA or a S1PR1-specific inhibitor was applied to 
block S1PR1 in rBMSCs co-cultured with macrophages. RT-qPCR, and western blot 
analysis were performed to detect the expression levels of osteogenic markers. Alizarin 
Red S staining was performed to evaluate the extent of osteogenesis.  
 
Results: Following LPS stimulation the macrophages responded by significantly 
enhanced expression of osteogenic markers in the co-cultured rBMSCs, as well as 
increased mineral deposition. Blocking of S1PR1 reduced this enhancement, 
suggesting that S1P-S1PR1 signalling plays a significant role in induced osteogenesis 
in these conditions.   
 
Conclusions: Under infection-induced inflammatory conditions, macrophages 
became stimulated and responded by interacting with BMSCs to activate the S1P-
S1PR1 signalling pathway, which subsequently stimulated osteogenesis. S1P-S1PR1 
signalling may, therefore, be responsible for the abnormal bone formation seen in 
infection-induced inflammatory diseases.  
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5.2 INTRODUCTION  
There is ample evidence to show that the immune and skeletal systems are 
closely related and have many regulatory factors in common, such as cytokines, 
transcription factors, and signalling pathways (Takayanagi, 2007; Walsh, et al., 2006). 
A case in point is the immunomodulation of bone remodelling (Arron & Choi, 2000), 
a life-long process that consists of bone resorption (mediated by osteoclasts) and 
formation (mediated by osteoblasts) and a key function of bone metabolism 
(Hadjidakis & Androulakis, 2006; Raggatt & Partridge, 2010). Under normal 
physiological conditions, bone remodelling is a balanced process; the amount of 
resorption equals that of formation (Arron & Choi, 2000). However, during 
pathological conditions, such as inflammation, the balance between resorption and 
formation is disrupted by the inflammatory immune response, resulting in aberrantly 
stimulated bone resorption and a net bone loss, such as that seen in rheumatoid arthritis 
(RA) (Rodan & Martin, 2000), periodontitis (Taubman, et al., 2005), and apical 
periodontitis (Wang & Stashenko, 1993). Paradoxically, inflammation, which is 
generally considered as a destructive factor for bone (Redlich & Smolen, 2012), has 
been found to induce osteogenesis under certain conditions. Inflammation is necessary 
as an initial response in the healing injuries such as bone fractures (Mountziaris & 
Mikos, 2008). Also, excessive bone formation (such as osteophyte or bone spurs) has 
been found in chronical inflammations, such as arthritis (Oettmeier & Abendroth, 
1989), and spondylarthrosis (Nathan, Pope, & Grobler, 1994). Similar phenomena are 
also seen in infection-induced inflammation, such as chronic osteomyelitis (Lew & 
Waldvogel, 2004) and apical periodontitis (Eliasson, Halvarsson, & Ljungheimer, 
1984). However, the mechanism of this immune response-mediated bone formation 
has not been fully established. 
Among the many and various types of immune cells, macrophages is the main 
cell type involved in the innate immune response (Mosser & Edwards, 2008) and is 
also considered a crucial regulator in osteogenesis. Macrophages encompass three 
main subpopulations of cells, consisting of non-activated M0 macrophages, pro-
inflammatory M1 macrophages (induced by LPS or INF-γ), and immune-suppressive 
M2 macrophages (induced by IL-4 and IL-13) (Mantovani, et al., 2004). The M1 
macrophages, in particular, have been shown to interact with BMSC‒the precursor of 
osteoblast‒via secreted factors and to induce the production of RANKL, a key factor 
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in osteoclastogenesis. Consequently, M1 macrophages are generally considered a 
negative factor in bone healing (Hashizume, et al., 2008; Kobayashi, et al., 2000; Lam, 
et al., 2000; Wei, et al., 2005; Zwerina, et al., 2007). However, recent studies have 
found that the M1 macrophages actually play a positive role in bone regeneration with 
macrophage infiltration during the early stage inflammation considered a critical factor 
in bone fracture repair. M1 macrophages have been shown to induce bone formation 
by producing OSM (Guihard, et al., 2012), and another M1 macrophage-derived factor, 
IL-6, also promotes bone formation (Bellido, et al., 1997; Blanchard, et al., 2009; Cho, 
et al., 2007; Itoh, et al., 2006; Sammons, et al., 2004). There is conflicting evidence as 
to the effects on osteogenesis of TNF-α and IL-1, both also derived from M1 
macrophages (Hess, et al., 2009; Nanes, 2003; Perrien, et al., 2002), which suggests 
that the mechanisms of M1 macrophage-mediated bone formation is still far from fully 
resolved.  
The bioactive lipid sphingosine-1-phosphate (S1P) has been identified to play a 
central role in immunoregulation by activating its five G-protein coupled receptors, 
termed sphingosine-1-phosphate receptor 1 (S1PR1)-S1PR5 (Rivera, et al., 2008). The 
S1P-S1PR1 signalling is a key modulator in the migration, differentiation and 
functionalized maturation of immune cells, which promotes inflammation by inducing 
the infiltration of activated immune cells (Rivera, et al., 2008; Spiegel & Milstien, 
2011). S1P-S1PR1 signalling is involved in the interaction between cells from the 
monocyte/macrophage-lineage and osteoblast-lineage. This interaction is not only 
related with osteoclastogenesis by increasing RANKL production (Ryu, et al., 2006), 
but also osteogenesis under physical conditions by triggering the recruitment of 
osteoblast-precursors and enhancing the survival rate and mineralization of osteoblasts. 
Furthermore, the activation of MEK1/2-Erk1/2 and BMP-2/Smad signalling may be 
the tell-tale signs of osteogenesis induction (Pederson, et al., 2008; Sato, et al., 2012). 
Considering the complexity nature of the relationship between immune cells and bone-
forming cells, the role of S1P-S1PR1 signalling in induced-osteogenesis during 
inflammation still warrants further investigation.  
In the previous chapter, we demonstrated that macrophages interact with BMSCs 
to activation of S1P-S1PR1 signalling in BMSCs, especially under infection-induced 
inflammatory conditions. Since macrophages activated by inflammation have been 
found to induce bone formation and activated S1P-S1PR1 signalling can induce 
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osteogenesis, a testable hypothesis could be that the interaction between macrophages 
and BMSCs may affect osteogenesis via S1P-S1PR1 signalling under infection-
derived inflammatory conditions. Hence, in this study we investigated the role of 
macrophages in infection-induced inflammatory bone formation, as well as its possible 
relation with the S1P-S1PR1 signalling.  
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5.3 MATERIALS AND METHODS 
5.3.1 Cell culture 
Rat BMSCs 
The rat BMSCs (rBMSCs) were obtained from 8-10 week old Wistar male rats 
as described in previous study (Leboy, et al., 1991). Briefly, the rats were sacrificed 
and the back limbs were harvested. The femurs and tibias were dissected to remove all 
the skin and muscles, and then washed by PBS with 1% (v/v) penicillin/streptomycin 
(P/S; Gibco®, Life Technologies Pty Ltd., Australia) for three times. The dissected 
bones were transferred into a 10 cm petri dish containing Dulbecco’s modified Eagle’s 
medium (DMEM; Gibco®, Life Technologies Pty Ltd., Australia). The two ends of 
the bones were cut open and the bone marrow was flushed into a 50 mL tube by 
syringes filled with DMEM (containing 1% P/S). The obtained bone marrow was then 
washed once with PBS (containing 1% P/S) and resuspended in DMEM containing 
10% (v/v) fetal bovine serum (FBS; In Vitro Technologies, Australia) and 1% P/S. 
The cell suspension was then transferred into a culture flask and cultured in incubators 
with 5% CO2 at 37º C. After three days, the non-adherent cells were washed away by 
PBS, the adherent cells were then continually incubated in DMEM with 10% FBS and 
1% P/S (culture medium was changed every 2-3 days). When reaching 80% 
confluence, the cells were passaged with 0.25% trypsin (containing 1mM EDTA, 
Gibco®, Life Technologies Pty Ltd., Australia) for 2 min. Cells within 5 passages were 
used for experiment. All experiment procedures were approved by the Ethics 
Committee of Queensland University of Technology. 
 RAW 264.7 cells  
The murine-derived macrophage cell line, RAW 264.7 (RAW) cells were used 
to represent macrophage-like cells in this study. As a murine macrophage cell line, 
RAW cells have been proved to work reliably with BMSCs form other species (Chen, 
Wu, Gu, et al., 2014; Chen, Wu, Yuen, et al., 2014; Shi, et al., 2016). The RAW cells 
were cultured in DMEM with 10% FBS (heat-inactivated at 60 º C for over 30 min) 
and 1% P/S. The culture medium was changed every 2 to 3 days. After reaching 80% 
confluence, the cells were passaged by treating with 0.25% trypsin (containing 1mM 
EDTA) for 2 min.  
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5.3.2 In vitro cell co-culture  
The rBMSCs were co-cultured with RAW cells under normal or LPS-induced 
inflammatory conditions (as seen in Fig 4.1B). A trans-well co-culture system was 
applied in this study. The cell culture inserts for 6-well plates (Becton Dickinson 
Labware, Franklin Lakes, NJ, USA) with 0.4 µm pore size were used to culture RAW 
cells. The rBMSCs were cultured in the companion plates (the ratio of numbers of 
rBMSCs to RAW cells is roughly 1:4). After 24 h of attachment, the inserts were then 
assembled onto the companion plates. Normal culture medium (supplemented with 
inactivated FBS) was used in the normal co-culture group. The RAW cells and 
rBMSCs cultured in normal culture medium served as normal-controls. In the LPS-
induced inflammatory condition, co-cultured cells were stimulated with 100 ng/mL 
LPS (DMEM supplemented with 10% inactivated FBS and 1% P/S), the RAW cells 
and rBMSCs cultured in LPS-supplemented medium served as LPS-controls. After 
12h of co-culture, rBMSCs were harvested for RNA and protein extraction. 
 
5.3.3 S1PR1 siRNA Transfection  
The S1PR1 siRNA ((5’GAC UAU GGC AAC UAU GAU A3’, 5’UAU CAU 
AGU UGC CAU AGU C3’, Product number: PDSIRNA2D, siRNA ID: 
SASI_Rn01_00101785, Sigma-Aldrich Pty. Ltd., Sydney, Australia) was used to 
block S1PR1 activity in this study (as seen in Fig 4.1B). The experiment was 
performed following the manufacturer’s instructions. The rBMSCs for transfection 
were seeded in 6-well plates with culture medium (DMEM, 10% FBS, no P/S). After 
24 h of cell attachment, forward transfection of S1PR1 siRNA was performed. 125 
pmol S1PR1 siRNA was diluted in 250 ul Opti-MEM® I Reduced Serum Medium 
(Opti-MEM, Gibco®, Life Technologies Pty Ltd., Australia). Also, 4 µL 
Lipofectamine™ RNAiMAX (Life Technologies Pty Ltd., Australia) was diluted in 
the same amount of Opti-MEM. These two dilutions were gently mixed and incubated 
for 15 min at room temperature, and then transferred into the well. The cells were then 
incubated for 48 h in the incubator. After incubation, the rBMSCs were co-cultured 
with RAW cells using the trans-well system as described above. The universal 
negative control siRNA (MISSION® siRNA Universal Negative Control #1, Product 
number: SIC001, Sigma-Aldrich Pty Ltd., Sydney, Australia) was used in wells 
without S1PR1 siRNA. 
 Dissecting the Role of Sphingosine 1-Phosphate--Sphingosine 1-Phosphate Receptor 1 in Inflammatory Bone 
Remodelling 118 
5.3.4 Preparation of conditioned medium 
Conditioned medium (CM) derived from RAW cells was obtained. Briefly, 
RAW cells were cultured in T175 flak to reach confluence, and then stimulated with 
100 ng/mL LPS for 12 h. For co-culture under normal condition, cells were treated 
with normal culture medium for 12 h. After that, the medium was removed the cells 
were washed twice with PBS, and then incubated with serum-free DMEM for 12 h. 
The medium was collected and subjected to centrifugation (1000 g, 10 min, 4º C), then 
filtrated with a 0.2 µm filter (Millipore Corporation, Billerica, MA, USA) to remove 
cell debris. The filtered medium was stored at -80ºC for the further experiment. 
 
5.3.5 Osteogenic differentiation of rBMSCs under normal / inflammation 
conditions 
To investigate osteogenesis in the co-culture system under normal condition, the 
CM derived from RAW 264.7 cells (without LPS stimulation) was mixed with the 
osteogenic medium (DMEM, 20% FBS, 2% P/S, 20 mM β-glycerophosphate, 100 µM 
ascorbic acid and 200 nM dexamethasone; Sigma-Aldrich Pty Ltd., Sydney, Australia) 
in a ratio of 1:1. To investigate osteogenesis in co-culture system under LPS-induced 
inflammation (Fig 5.1), the CM derived from LPS-stimulated RAW 264.7 cells was 
mixed with osteogenic medium containing 200 ng/mL LPS (DMEM, 20% FBS, 2% 
P/S, 20 mM β-glycerophosphate, 100 µM ascorbic acid and 200 nM dexamethasone) 
in a ratio of 1:1. The mixed medium was then applied to culture rBMSCs. The rBMSCs 
cultured in normal osteogenic medium (DMEM, 10% FBS, 1% P/S, 10 mM β-
glycerophosphate, 50 µM ascorbic acid and 100 nM dexamethasone) served as control 
for the normal co-culture, while the ones cultured in osteogenic medium (DMEM, 10% 
FBS, 1% P/S, 10 mM β-glycerophosphate, 50 µM ascorbic acid and 100 nM 
dexamethasone) supplemented with 100 ng/mL LPS served as control for the LPS-
induced inflammatory co-culture. S1PR1 blockage was performed by application with 
the S1PR1-specific inhibitor, W146 hydrate (100 ng/ml, Sigma-Aldrich Pty Ltd., 
Sydney, Australia). The cells were stimulated for 1 day, and then harvested for RNA 
extraction or ALP activity assay. The cells stimulated for 10 days were harvested for 
Alizarin Red S staining and immunofluorescent staining.   
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Figure 29. Osteogenic differentiation of rBMSCs co-cultured with macrophages (by conditioned 
medium) under normal / inflammation conditions. CM of macrophages under normal or LPS 
stimulation was collected and mixed with osteogenic medium or osteogenic medium with LPS; the 
mixed medium was then applied to rBMSCs. The rBMSCs applied with osteogenic medium or 
osteogenic medium with LPS were served as normal- or LPS-controls, respectively. S1PR1 was blocked 
by S1PR1-specific inhibitor, while vehicle was used in wells without S1PR1 siRNA. CM = conditioned 
medium. 
 
5.3.6 RNA extraction, cDNA synthesis, and real time quantitative-PCR (RT-
qPCR) 
Total RNA was extracted from rBMSCs using the TRIzol Reagent (Ambion®, 
Life Technologies Pty Ltd., Australia). The cDNA was then synthesized from 1 μg 
total RNA by SensiFAST™ cDNA Synthesis Kit (Bioline (Aust) Pty Ltd., Australia) 
following the manufacturer’s protocol. The real-time polymerase chain reaction (RT-
qPCR) was carried out by the QuantStudio™ 7 Flex Real-Time PCR System (Applied 
Biosystems, Australia) with SYBR® Green reagent (Applied Biosystems, Australia) 
according to the manufacturer’s instructions. The RT-qPCR primers (Table 4.1) were 
designed based on cDNA sequences from the National Centre for Biotechnology 
Information (NCBI) sequence database and the primer specificity was confirmed by 
Primer-BLAST on the NCBI website. Analyses were performed on the following 
target genes: S1PR1, ALP, COL-1, RUNX2 and OCN. The house keeping gene 18S  
and β-actin were used as control. All reactions were run in triplicate for three 
independent experiments. Relative gene expression was normalized against 18S or β-
actin and calculated as previously described (Bookout & Mangelsdorf, 2003).  
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Table 5. Primer sequences for the gene (rat) investigated in this study 
Gene 
name 
Forward sequences Reverse sequences 
S1PR1 5’GTTGTCCGGGATTTGGTAGG3’ 5’GATGCTCGTAGGGGTTAGAG3’ 
ALP 5’CCATTTCAGCCTCAGGATCG3’ 5’ TGGCCACGTTGGTGTTGAGT3’ 
COL-1 5’CCCCAAGGAGAAGAAGCATG3’ 5’GAATCGACTGTTGCCTTCGC3’ 
RUNX2 5’TCTTTTGGGATCCGAGCACC3’ 5’ATCTCCACCATGGTGCGGTT3’ 
OCN 5’GCCCTGACTGCATTCTGCCTCT3’ 5’TCACCACCTTACTGCCCTCCTG3’ 
18S 5’CGGAACTGAGGCCATGATTAAG3’ 5’GTATCTGATCGTCTTCGAACCTCC3’ 
β-actin 5’ATGCAGCCTGAAGAGGACTG 5’GGCTATGAAATCCAGGGCCT 
 
5.3.7 Protein extraction and western blotting 
Total protein was extracted from rBMSCs by the lysis buffer (20 mM HEPES 
(pH 7.4), 10% glycerol, 1% Triton X-100, 2mM EDTA) with the protease inhibitor 
cocktail (Roche Products Pty. Ltd., Dee Why, NSW, Australia). Measurements of 
protein concentration were performed by the BCA Protein Assay Kit (Thermo Fisher 
Scientific, VIC, Australia). For each sample, 10 µg of protein was loaded into a SDS-
PAGE gel and then separated by running the gel. After that the protein was transferred 
to a nitrocellulose membrane (Merck Millipore, Billerica, USA). The membrane was 
blocked by the Odessy buffer (LI-COR Biosciences, Lincoln, USA) for 1 h at room 
temperature and then incubated with primary antibodies against ALP (1: 1000, Abcam, 
Cambridge, UK) and COL-1 (1:3000, Invitrogen Pty Ltd., Australia); α-Tubulin (1: 
5000, Abcam, Cambridge, UK) was used as a loading control. After incubated at 4°C 
overnight, the membrane was washed and then incubated with Anti-rabbit IgG IRDye 
800 conjugated secondary antibody (1: 10000, Rockland, Gilbertsville, Pennsylvania, 
USA) for 1 h at room temperature. After three-times of washing, the membranes were 
scanned by Odyssey® Infrared Imaging System (LI-COR Biosciences, Lincoln, USA) 
according to the manufacturer’s instructions. Quantification of band intensities was 
obtained by ImageJ software. All experiments were replicated by three times. 
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5.3.8 ALP activity assay 
The ALP activity of rBMSCs was tested by Alkaline Phosphatase Assay kit 
(Colorimetric) (Abcam, Cambridge, UK) according to the manufacture’s instruction. 
The rBMSCs were harvested by the ALP Assay Buffer. The protein concentration was 
measured by the BCA Protein Assay Kit (Thermo Fisher Scientific, VIC, Australia). 
The cell samples were diluted by the Assay Buffer in a ratio of 1:3, and then transferred 
to a 96-well plate. The pNPP solution was added to the sample wells. ALP Enzyme 
Solution was added to the pNPP standard wells. The plate was then incubated at 25°C 
for 60 min in the dark. After incubation, reactions were stopped by the Stop Solution. 
The measurement was performed immediately by a microplate reader (SpectraMax, 
Plus 384, Molecular Devices, Inc., USA) at OD 405 nm. For each sample, the test was 
performed in triplicate, and the ALP activities were calculated according to the 
manufacture’s instruction. All the results were expressed as the calculated ALP 
activity / protein concentration. 
 
5.3.9 Alizarin Red S staining 
After 10 days of osteogenic differentiation, the rBMSCs were washed twice with 
PBS and fixed with 4% PFA for 20 min at room temperature. After that, the cells were 
rinsed with distilled water, and then stained in the 1% Alizarin Red S (Sigma-Aldrich 
Pty Ltd., Sydney, Australia) solution (pH: 4.1-4.3) for 20 min at room temperature. 
After washing with distilled water, the samples were air-dried and observed under the 
microscope (Eclipse TS100, Nikon Australia Pty Ltd.).  
 
5.3.10 Statistical analysis 
All data were subjected to statistical analysis using one-way ANOVA, followed 
by the Student-Newman-Keul test at a = 0.05. Pearson correlation was used for 
correlation analysis on numbers of S1PR1+ cells with osteoclasts and RANKL+ cells 
(a = 0.05). A p< 0.05 was considered to significantly different. Data were analysed by 
SPSS 13.0 (SPSS Inc., Chicago, IL). All data were presented as mean ± standard 
deviation (SD). 
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5.4 RESULTS 
5.4.1 Macrophages induced the osteogenic differentiation of rBMSCs  
A trans-well co-culture system was used to determine the impact of macrophages 
on rBMSCs under normal or infection-induced inflammatory conditions and LPS 
stimulation used to simulate infection-mediated inflammation. After 12 h of co-culture 
under inflammatory conditions (Fig 30), we found significantly increased mRNA 
levels of the osteogenic markers, ALP, COL-1, RUNX2, and OCN in rBMSCs co-
cultured with macrophages, whereas in the LPS negative (normal) co-cultures only 
COL1 showed significantly increased expression. The western blot results (Fig 31) 
also showed that early stage osteogenic markers were induced in rBMSCs co-cultured 
with macrophages under both conditions. These results suggested that in conditions 
mimicking infection induced inflammation, macrophages induced osteogenic 
differentiation and gene expression. 
 
Figure 30. Up-regulated osteogenic markers in rBMSCs co-cultured with macrophages (n=3). 
Under both normal and LPS-stimulation conditions, the mRNA levels of osteogenic markers (COL-1, 
RUNX2, ALP and OCN) in rBMSCs were significantly up-regulated when co-cultured with 
macrophages (*p<0.05). M = co-cultured with macrophages, N = normal medium, LPS = medium with 
LPS. 
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Figure 31. Up-regulated osteogenic markers in rBMSCs co-cultured with macrophages (n=3). 
Under both normal and LPS-stimulation conditions, the protein levels of early stage osteogenic markers 
(COL-1 and ALP) in rBMSCs were significantly up-regulated when co-cultured with macrophages 
(*p<0.05), indicating that macrophages induced the differentiation and activation of osteoblasts, 
especially under the LPS-induced inflammatory conditions. M = co-cultured with macrophages, N = 
normal medium, LPS = medium with LPS. 
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5.4.2 The macrophage-induced osteoblast differentiation was due to the 
activation of S1P-S1PR1 signalling 
S1PR1 was blocked by the S1PR1-siRNA in order to assess the role of S1P-
S1PR1 signalling in the activation of osteoblasts. S1PR1-siRNA treatment 
significantly reduced the mRNA expression levels of osteogenic markers (COL-1, 
RUNX2, ALP and OCN) in the rBMSCs co-cultured with macrophages (Fig 32). The 
rBMSCs also showed decreased protein expression levels of the early stage osteogenic 
markers (Fig 33). Hence, the S1P-S1PR1 signalling played an essential role in the 
activation of osteoblasts in the inflammatory co-culture. 
 
 
Figure 32. The impacts of S1PR1 regulation on osteogenic markers expression (n=3). Under LPS-
stimulation conditions, the mRNA levels of osteogenic markers (RUNX2, ALP, COL-1, and OCN) in 
rBMSCs co-cultured with macrophages were significantly down-regulated when S1PR1 was inhibited 
(*p<0.05). M = co-cultured with macrophages, N = normal medium, LPS = medium with LPS, S1PR1 
-/- = S1PR1 siRNA. 
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Figure 33. The impacts of S1PR1 regulation on osteogenic markers expression (n=3). Under both 
normal and LPS-stimulation conditions, the protein levels of early stage osteogenic markers (COL-1 
and ALP) in rBMSCs co-cultured with macrophages were significantly down-regulated when applied 
S1PR1 was inhibited (*p<0.05), suggesting that the activation of osteoblasts in the inflammatory co-
culture was due to the S1P-S1PR1 signalling. M = co-cultured with macrophages, N = normal medium, 
LPS = medium with LPS, S1PR1 -/- = S1PR1 siRNA. 
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5.4.3 Macrophages induced osteogenesis through activation of the S1P-S1PR1 
signalling 
To confirm whether macrophages induce osteogenesis under LPS-induced 
inflammation, and whether the S1P-S1PR1 signalling plays a role in the induced 
osteogenesis, we tested the effect of macrophages on osteogenesis under normal and 
LPS-induced inflammatory conditions. Macrophage CM was used to stimulate the 
rBMSCs. CM derived from LPS-stimulated macrophages was applied to rBMSCs in 
osteogenic medium with the supplementation of LPS (inflammatory co-culture), 
whereas CM derived from un-stimulated macrophages was applied to rBMSCs in 
normal osteogenic medium (normal co-culture). The S1PR1 specific antagonist W146 
hydrate was used to block S1PR1. As shown in Fig 34a to f, CM derived from 
macrophages significantly enhanced the mRNA levels of the osteogenic markers, as 
well as ALP activity under both normal and inflammatory conditions. Furthermore, 
when S1PR1 was inhibited, the enhanced expressions of the osteogenic markers and 
ALP activity were reduced. The Alizarin Red S staining was performed to identify 
mineralization nodules. As shown in Fig 34g, after ten days of osteogenic 
differentiation, the macrophages CM had a significant inductive effect on 
mineralization of rBMSCs under both conditions, which was reduced by the S1PR1 
antagonist. Thus, macrophages induced osteogenesis under both normal and LPS- 
induced inflammatory conditions, which was achieved by activating the S1P-S1PR1 
signalling. 
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Figure 34. The role of S1P-S1PR1 signalling in macrophage-induced osteogenesis (n=3). (a) – (e): 
Under both normal and LPS-stimulation conditions, the mRNA levels of osteogenic markers (RUNX2, 
ALP, COL-1, and OCN) in rBMSCs  were significantly up-regulated when co-cultured with 
macrophages (by CM). This up-regulation was significantly down-regulated when S1PR1 was blocked 
(*p<0.05). (f): ALP activity in rBMSCs co-cultured with macrophages was significantly enhanced 
under both normal and LPS-stimulation conditions; this enhancement was significantly reduced after 
S1PR1 blockage. (g): Induced mineralization could be found in rBMSCs co-cultured with macrophages 
(by CM) under both conditions; which was reduced by S1PR1 blockage. All these data suggested that 
macrophages induced osteogenesis under LPS- induced inflammatory conditions in a S1P-S1PR1 
signalling dependent manner. M = co-cultured with macrophages (by stimulation with CM derived from 
macrophages), N = normal medium, LPS = medium with LPS, S1PR1 -/- = S1PR1 inhibitor.  
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5.5 DISCUSSION     
Inflammation has long been recognised as being partially responsible for bone 
destruction. The evidence for this is that activated immune response under 
inflammation has been shown to trigger RANKL-RANK signalling directed 
osteoclastogenesis (Arron & Choi, 2000), resulting in the enhanced bone resorption 
and bone loss that is seen in inflammatory bone destructive diseases such as 
rheumatoid arthritis (RA) (Rodan & Martin, 2000), periodontitis (Taubman, et al., 
2005), and apical periodontitis (Wang & Stashenko, 1993). However, in some cases, 
inflammation may also result in aberrantly-induced bone formation. A typical case is 
osteophyte formation ‒ abnormally formed bone tissue found around damaged joints 
such as arthritic tissues (Oettmeier & Abendroth, 1989). The similar phenomenon also 
happens in infection-induced bone destructive diseases such as osteomyelitis  (Lew 
& Waldvogel, 2004) and apical condensing osteitis (Eliasson, et al., 1984) ‒ a special 
subset of apical periodontitis, which features with over-induced bone formation. 
Compared with osteoclastogenesis, the role and mechanisms of inflammation in 
osteogenesis, especially under the condition of infection, are poorly understood.  
Recent studies have found that macrophages – the major effector cells in the 
innate immune response that are generally considered to induce osteoclastogenesis – 
also play a key role in inducing osteogenesis (Wei, et al., 2005; Zwerina, et al., 2007). 
The main macrophage phenotype in inflammation, the pro-inflammatory M1 type, 
have been found to interact with osteoblast-precursors (known as BMSCs) and induce 
osteogenesis by the secreted factor OSM (Guihard, et al., 2012). Furthermore, another 
M1 macrophage-derived factor, IL-6, is also found to promote osteogenesis (Bellido, 
et al., 1997; Blanchard, et al., 2009; Cho, et al., 2007; Itoh, et al., 2006; Sammons, et 
al., 2004). As M1 macrophage differentiation and activation have been identified in 
infection-induced disease (Mantovani, et al., 2004), it could be presumed that the M1 
macrophages might interact with BMSCs and play a role in the infection-induced 
inflammatory osteogenesis. In Chapter 4, we found that the interaction between 
macrophages and rBMSCs resulted in activation of S1P-S1PR1 signalling. Some 
studies have found that this signalling pathway is associated with osteogenesis, which 
prompted the hypothesis that the S1P-S1PR1 signalling should affect osteogenesis 
under this infection-induced inflammatory condition (Pederson, et al., 2008). 
Therefore, this study aimed to investigate the effect of macrophages in osteogenesis 
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under infection-induced inflammation, and the role of S1P-S1PR1 signalling in this 
process.  
To investigate the impact of macrophages in the infection-induced inflammatory 
osteogenesis, the trans-well co-culture system of macrophages and rBMSCs was 
stimulated with or without the supplementation of LPS to mimic the interacted 
macrophages and rBMSCs under normal or infection-induced inflammatory 
conditions. The expressions of osteogenic markers were examined in the co-cultured 
rBMSCs. Increased mRNA levels were found in the rBMSCs co-cultured with 
macrophages, which was more obvious in the LPS co-culture. At the same time, 
protein levels of the early stage markers in these co-cultured rBMSCs were also 
observed. These results indicated that the rBMSCs were induced by the co-cultured 
macrophages to initiate differentiation towards osteoblasts. This induction was more 
obvious in the LPS co-culture, suggesting macrophages greatly induce the osteoblast 
phenotype in the infection-induced inflammation. 
To determine if the activated osteoblast differentiation was due to the up-
regulated S1P-S1PR1 signalling (as was demonstrated in Chapter 4), the effect of 
S1PR1-inhibition on the expression of osteogenic markers was then investigated. 
S1PR1 silencing led to a significant downregulation of mRNA and protein expression 
of osteogenic markers in rBMSCs co-cultured with macrophages in the infection-
induced inflammatory conditions, indicating the S1PR1 could be a key factor in the 
macrophage-induced osteoblast activation; therefore, the macrophage-induced 
osteoblast differentiation was partially achieved through the activated S1P-S1PR1 
signalling in rBMSCs. 
To assess whether macrophages could induce osteogenesis through the S1P-
S1PR1 signalling pathway, a similar macrophage-BMSC co-culture system was 
established to simulate the osteogenic differentiation. To avoid the possible impact of 
the osteogenic medium on macrophages, an in-direct co-culture system using 
macrophage CM was applied. The rBMSCs were stimulated with M1 macrophage-
derived CM and then supplemented with LPS and osteogenic medium to mimic the 
situation of LPS co-culture (in the transwell system); while the normal co-culture (in 
the transwell system) was simulated by culturing rBMSCs with CM of M0 
macrophages mixed with normal osteogenic medium. The S1PR1 specific antagonist 
W146 hydrate was used to block S1PR1 instead of S1PR1 siRNA, since the RNA 
 Dissecting the Role of Sphingosine 1-Phosphate--Sphingosine 1-Phosphate Receptor 1 in Inflammatory Bone 
Remodelling 130 
silencing effect could not last for 10 days. Similar to the findings in trans-well co-
culture system, the rBMSCs in the inflammatory conditions resulted in the up-
regulation of osteogenic markers when stimulated with the M1 macrophage-derived 
CM; however, this effect was reduced following S1PR1 inhibition with W146. CM 
derived from M0 macrophages also resulted in slightly increased expression of 
osteogenic markers in rBMSCs and this effect was also reduced by S1PR1 inhibition. 
Accordingly, rBMSCs cultured in macrophage CM showed enhanced ALP activity 
under both normal and inflammatory conditions. After ten days of osteogenic 
differentiation, the Alizarin Red S staining ultimately showed that the macrophage CM 
enhanced the osteogenesis under both normal and infection-induced inflammatory 
conditions, which was also reduced by S1PR1 inhibition. Therefore, these results are 
firm evidence that macrophages induce osteogenesis by up-regulation of the S1P-
S1PR1 signalling in rBMSCs under infection-induced inflammatory conditions.  
An intriguing finding is the observation that the pro-inflammatory M1 
macrophages resulted in a more robust osteogenic response than did the M2 
macrophages, the phenotype which is considered more beneficial for tissue 
regeneration (Guihard, et al., 2012). A possible explanation for this is that during the 
early stages of bone healing, which is characterized by an acute inflammatory phase, 
the M1 macrophages act as a key factor in the differentiation of osteoblasts, whereas 
M2 macrophages take part in the later stage of osteogenesis by inducing the maturation 
and terminal mineralization of osteoblasts. The transition from the M1 to M2 
phenotype is, therefore, considered to be crucial aspect of bone healing and de novo 
bone formation (Loi, et al., 2016). In the preceding chapter, it was found that the 
macrophages were capable of inducing the SPHK1 activity in the co-cultured BMSCs, 
thereby promoting the S1P production. S1P has been identified to play a regulatory 
role in macrophage polarization, which induces the transition of M1 to M2 phenotype 
by activating S1PR1 in macrophages (Hughes, et al., 2008). It is, therefore, likely that 
during the process of bone healing, the early stage inflammation induces the activation 
of M1 macrophages, which signals via the SHPK1-S1P-S1PR1 axis in BMSCs, 
thereby initiating osteogenesis. It is also possible that secreted S1P could act on the 
macrophages and lead to the gradual conversion of M1 to M2 phenotype, thereby 
creating suitable conditions for later stage osteogenesis. Further research is required to 
test this hypothesis. Also, the inflammatory osteogenesis induced by M1 macrophages 
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may result in abnormal bone formation, as exemplified by the dysfunctional de novo 
bone found in osteomyelitis (Lew & Waldvogel, 2004). Hence, further research on the 
chemical constitution and structure of bone tissues formed under infectious 
inflammation should be performed.   
Taken together, it is demonstrated that LPS-stimulated macrophages are capable 
of inducing osteogenesis in infection-induced inflammatory conditions, by activating 
the S1P-S1PR1 signalling in BMSCs in vitro. These findings go some way towards 
explaining a molecular mechanism for the bone formation seen in infection-related 
inflammatory diseases. 
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Chapter 6:  Conclusions 
6.1 SUMMARY 
Skeletal bones undergo a lifelong process termed bone remodelling, which 
consists of osteoclasts-driven bone resorption and osteoblasts-driven bone formation 
(Raggatt & Partridge, 2010). Bone remodelling is highly regulated by immune 
modulators to keep the balance between bone resorption and formation. This is a 
fundamental interaction between the immune and skeletal systems and describes a 
physiological process known as osteoimmunology (Arron & Choi, 2000). The immune 
response under pathological conditions, such as inflammation, results in an imbalance 
between bone resorption and formation, which eventually leads to bone diseases, as 
seen in rheumatoid arthritis (RA) (Rodan & Martin, 2000), chronic osteomyelitis (Lew 
& Waldvogel, 2004), periodontitis (Taubman, et al., 2005), apical periodontitis (Wang 
& Stashenko, 1993). A better understanding of how the immune system modulates 
bone remodelling under the inflammatory conditions will help us develop better 
treatments to target inflammatory bone-destructive diseases. 
The immune and skeletal systems are integrated through number of factors. Key 
among these factors is the multifunctional sphingolipid metabolite-S1P which, not 
only acts as a key factor in immune-regulation, but also directly regulates the process 
of bone remodelling and as such plays an essential role in osteoimmunology. The 
function of S1P is achieved by binding with cognate receptors, the S1PRs, of which 
five separate ones have been identified (Spiegel & Milstien, 2011). S1PR1, which is 
widely expressed in the immune and skeletal system (Aarthi, et al., 2011), is found to 
be greatly involved in the S1P-derived regulation in osteoimmunology (Rivera, et al., 
2008). The role of S1P-S1PR1 signalling in osteoimmunology has intrigued 
researchers since, besides being capable of inducing inflammatory response and 
therefore facilitating osteoclastogenesis, it also acts as a positive factor in osteogenesis. 
This makes its role in bone remodelling far from straight forward, especially under 
pathological conditions such as inflammation.  
Within the local-inflammatory tissues of bone-destructive disease, such as RA, 
increased S1P concentration and enhanced S1PR1 expression has been identified. It 
has also been shown that modulating S1P-S1PR1 signalling can have therapeutic 
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effects on bone loss (Maceyka, et al., 2012). However, the role of this signalling in the 
infection-induced bone loss (e.g. apical periodontitis, osteomyelitis) has not been well 
studied. Compared with non-infectious inflammation, the status of S1P-S1PR1 
signalling in infection-induced inflammation may be different, since the invading 
pathogens affect the tissues in a number of ways. Hence, the role of S1P-S1PR1 
signalling in the infection-induced bone loss is a subject worthy of research. The aim 
of this project was to reveal the functions and mechanisms of S1P-S1PR1 signalling 
in infection-induced inflammatory bone remodelling.  
The study chose to focus on apical periodontitis–one of the most common oral 
diseases caused by infection–as the model condition in which to study the role of S1P-
S1PR1 signalling in pathogenic bone loss. In Chapter 3 we report a study in which we 
examined and compared the expression levels of S1P-S1PR1 signalling in periapical 
lesion tissues and normal periapical tissues isolated from human subjects. Up-
regulation of S1P-S1PR1 signalling was identified in the lesion tissues, which was 
accompanied by up-regulated expression of RANKL (the key factor in 
osteoclastogenesis) in the same tissues. Double staining of S1PR1 and RANKL 
support the notion of a possible connection between the S1P-S1PR1 signalling and 
RANKL, which precipitate the bone-destruction seen in apical periodontitis. To further 
investigate this connection, an induced rat periapical lesion model was applied to study 
the relationship between S1P-S1PR1 signalling, RANKL, and osteoclasts. The results 
from this study indicated that there were positive correlations among these three 
factors and that the up-regulated S1P-S1PR1 signalling might result in increased 
RANKL expression and subsequent osteoclastogenesis. To test this hypothesis, the 
S1P-S1PR1 signalling was modulated by FTY720 (an inhibitory S1P analogue) in an 
induced periapical lesion models in rats. This approach strongly reduced RANKL 
expression and was associated with a significant reduction of osteoclastogenesis and 
bone destruction in the apical periodontitis model. Hence, in this report, it is identified 
that aberrant up-regulation of S1P-S1PR1 signalling leads to the bone loss associated 
with infection-induced apical periodontitis, and the results support the view that 
suppression of RANKL reduces osteoclastogenesis and, consequently, bone loss.  
Although S1P-S1PR1 signalling activation is known to be associated with apical 
periodontitis, it is yet unknown what activates this signalling. Macrophages, which are 
activated and played a central role in the innate immune response against pathogen 
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invasion, not only act as precursors for osteoclasts, but also interact with pre-
osteoblasts (known as BMSCs) to regulate the RANKL production and hence 
modulate osteoclastogenesis (Takeshita, et al., 2000). Also, since cells from the 
macrophage-monocyte lineage have been identified as important sources of S1P and, 
further, that S1PR1 is expressed by macrophages and BMSCs, it was hypothesised that 
S1P-S1PR1 signalling was involved in the macrophage-BMSC interaction. In Chapter 
4, this hypothesis was tested using a macrophage-BMSC co-culture system that was 
stimulated with LPS in order to mimic a bacterial infection. S1P expression of 
macrophages fell significantly following LPS stimulation; however, other secreted 
factors from the macrophage significantly up-regulated the SPHK1 activity of BMSCs 
and, therefore, resulted in increased S1P production of BMSCs which were likely to 
activate S1PR1 in an autocrine manner. Therefore, under infection-induced 
inflammatory conditions, activated macrophages interacted with BMSCs, which 
resulted in up-regulated S1P expression in BMSCs and ultimately an autocrine S1PR1 
activation. 
It was also observed that RANKL expression was induced in BMSCs with 
activated S1PR1. Although S1P has been found to induce RANKL expression in pre-
osteoblasts, it was still unknown which particular receptor (e.g. S1PR1, S1PR2 and 
S1PR3) was required for this effect. To test whether S1PR1 was necessary for in S1P-
induced RANKL production, S1PR1 was down-regulated in BMSCs in the 
macrophage-BMSC co-culture and showed a significant reduction of RANKL 
expression associated with the S1PR1 down-regulation. This is strong evidence for an 
essential role of S1PR1 in S1P-induced RANKL expression. Taken together, in 
Chapter 4, it is found that macrophages, in response to LPS stimulation, interacted 
with BMSCs to induce the S1P production. Subsequently, S1P activated S1PR1 in 
BMSCs which induced the RANKL expression, and ultimately promoted 
osteoclastogenesis.     
Since bone remodelling is the net result of bone resorption versus bone formation, 
it is necessary to know how the S1P-S1PR1 signalling affects osteogenesis. In Chapter 
5, canonical osteogenic markers were found to be up-regulated in BMSCs co-cultured 
with macrophages (especially when stimulated with LPS). Osteogenic marker 
expression, ALP activity, and calcification nodule formation all decreased following 
S1PR1 blockage, which suggest a major role for S1P-S1PR1 signalling in suppressing 
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osteogenesis in response to infection-induced inflammatory conditions. Therefore, 
under infection-induced inflammation, the interaction between macrophages and 
BMSCs leads to the activation of S1P-S1PR1 signalling in BMSCs, which then induce 
osteogenesis. Although inflammation is generally thought to lead to bone loss (Redlich 
& Smolen, 2012), it has also been shown to induce abnormal osteogenesis under 
chronical inflammations, as exemplified by bone spurs in arthritis (Oettmeier & 
Abendroth, 1989) and spondylarthrosis (Nathan, et al., 1994). Excessive bone 
formation has also been found in infection-induced inflammation, such as chronic 
osteomyelitis (Lew & Waldvogel, 2004) and apical periodontitis (Eliasson, et al., 
1984). However, the mechanism behind this inflammatory bone formation is not fully 
established. Hence, this is the first study of its kind to elucidate the role of S1P-S1PR1 
signalling in the interaction between the immune and skeletal systems that results in 
abnormal osteogenesis under infection-induced inflammation, and provides new 
insights into osteoimmunology. 
 
6.2 LIMITATIONS AND FUTURE DIRECTIONS 
In this thesis, the role of S1P-S1PR1 signalling in macrophage-BMSC 
interaction was mainly studied in vitro. One can only draw a limited number of 
conclusions from such data and the logical next step will be to verify these results in 
vivo, ideally in genetically modified mouse models, such as a conditional S1PR1-
knock down in osteoblast lineage cells. Also, in Chapter 3, the S1P-S1PR1 signalling 
modulation in vivo was achieved by the application of S1P analogue. Only in vitro data 
has been confirmed in Chapter 4 that S1P-derived RANKL production was due to the 
expression of S1PR1. It would be better if we could use S1PR1-specific inhibitor to 
further confirm its role in osteoclastogenesis in vivo.  
In Chapter 4, we found macrophage-derived factors were induced by activated 
SPHK1 activity in the co-cultured BMSCs. However, it is still unknown what factors 
are responsible for this activation. This will be confirmed in the future research. Still, 
in Chapter 4, the relation of S1PR1 and RANKL was verified by S1PR1 regulation. 
To ultimately prove the S1PR1 is correlated with RANKL expression, the Co-
immunoprecipitation will be performed in our future study.  
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In Chapter 5 of this project, the main focus was on how S1P-S1PR1 signalling 
affected BMSCs under the conditions mimicking infection-induced inflammation. 
However, as there is strong evidence that S1P takes part in macrophage polarization, 
it could be hypothesised that the BMSCs-derived S1P may in turn affect the phenotype 
of macrophages in the co-culture. Further research will be performed to establish if 
this is the case. Also, all the in vitro experiments in Chapter 4 and 5 were done on rat 
primary BMSCs and the RAW 264.7 macrophage cell line. Ideally it would be better 
to explore the role of S1P-S1PR1 signalling in macrophage-BMSC interaction and 
bone remodelling using human primary cells, and this will be done in future work. 
Moreover, although enhanced osteogenesis has been found in infection-induced 
inflammation, it is still unknown whether or not the structure and components of this 
bone is equal to that of bone formed under normal conditions. Future work will be 
performed to compare the chemical components, structure and mechanics of the bone 
formed under physical and infectious inflammatory conditions.   
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Figure 35. Summary of the whole study. In the infection-induced inflammation, the components of 
the invading bacteria (i.e.: LPS) activates macrophages and induces the M1 phenotype. The secreted 
factors from M1 macrophages then induce SPHK1 activity in BMSCs and therefore results in over-
production of S1P. S1P acts its receptor S1PR1 in BMSCs in an autocrine manner. The activated S1P-
S1PR1 signalling results in multiple affections on bone remodelling. On one hand, it induces the 
osteoblast differentiation and osteogenesis; on the other hand, it enhances the RANKL production of 
the osteoblast-lineage cells, which eventually induces osteoclastogenesis. Moreover, the over-produced 
S1P might affect the phenotype of macrophages by inducing a shift from the M1 to M2 phenotype.  
 
A summary of the findings is shown in the above figure (Fig 35). The S1P-
S1PR1 signalling is abnormally activated in an infection-induced inflammatory 
disease, i.e. apical periodontitis and this activation partially resulted from the 
interaction between macrophages and BMSCs in response to infection. The S1P-
S1PR1 signalling plays a crucial role in the inflammatory bone remodelling, where on 
one hand, it stimulates the RANKL production of BMSCs, therefore facilitating 
osteoclastogenesis, and on the other hand, it induces the differentiation of osteoblasts 
and inducing osteogenesis. The imbalanced bone remodelling in inflammatory 
conditions could be induced from the interplay between immune cells and bone cells 
(osteoclasts and osteoblasts) through the S1P-S1PR1 signalling in regulating both 
osteoclastogenesis and osteogenesis. This may, therefore, be responsible for both the 
bone loss and aberrant bone formation seen in inflammatory diseases. These findings 
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contribute to our knowledge of osteoimmunology, and may also provide new insights 
that could lead to novel treatment options against bone-destructive diseases. 
 
 
 
 
 
 
 
 
 
 Bibliography 141 
Bibliography 
Aarthi, J., Darendeliler, M., & Pushparaj, P. (2011). Dissecting the role of the 
S1P/S1PR axis in health and disease. Journal of dental research, 90(7), 841-
854.  
 
Abu-Amer, Y. (2001). IL-4 abrogates osteoclastogenesis through STAT6-dependent 
inhibition of NF-κB. The Journal of clinical investigation, 107(11), 1375-1385.  
 
Aggarwal, S., & Pittenger, M. F. (2005). Human mesenchymal stem cells modulate 
allogeneic immune cell responses. Blood, 105(4), 1815-1822.  
 
Allende, M. L., Tuymetova, G., Lee, B. G., Bonifacino, E., Wu, Y.-P., & Proia, R. L. 
(2010). S1P1 receptor directs the release of immature B cells from bone 
marrow into blood. The Journal of experimental medicine, 207(5), 1113-1124.  
 
Alvarez, S. E., Milstien, S., & Spiegel, S. (2007). Autocrine and paracrine roles of 
sphingosine-1-phosphate. Trends in Endocrinology & Metabolism, 18(8), 300-
307.  
 
Arish, M., Husein, A., Kashif, M., Saleem, M., Akhter, Y., & Rub, A. (2015). 
Sphingosine-1-phosphate signaling: unraveling its role as a drug target against 
infectious diseases. Drug discovery today.  
 
Arron, J. R., & Choi, Y. (2000). Osteoimmunology: bone versus immune system. 
Nature, 408(6812), 535-536.  
 
Augello, A., Tasso, R., Negrini, S. M., Amateis, A., Indiveri, F., Cancedda, R., & 
Pennesi, G. (2005). Bone marrow mesenchymal progenitor cells inhibit 
lymphocyte proliferation by activation of the programmed death 1 pathway. 
European journal of immunology, 35(5), 1482-1490.  
 
Auletta, J. J., Deans, R. J., & Bartholomew, A. M. (2012). Emerging roles for 
multipotent, bone marrow–derived stromal cells in host defense. Blood, 119(8), 
1801-1809.  
 
Baker, D. A., Barth, J., Chang, R., Obeid, L. M., & Gilkeson, G. S. (2010). Genetic 
sphingosine kinase 1 deficiency significantly decreases synovial inflammation 
and joint erosions in murine TNF-α–induced arthritis. The Journal of 
Immunology, 185(4), 2570-2579.  
 
Bellido, T., Borba, V. Z., Roberson, P., & Manolagas, S. C. (1997). Activation of the 
Janus Kinase/STAT (Signal Transducer and Activator of Transcription) Signal 
Transduction Pathway by Interleukin-6-Type Cytokines Promotes Osteoblast 
Differentiation 1. Endocrinology, 138(9), 3666-3676.  
 
Billich, A., Bornancin, F., Mechtcheriakova, D., Natt, F., Huesken, D., & Baumruker, 
T. (2005). Basal and induced sphingosine kinase 1 activity in A549 carcinoma 
 Bibliography 142 
cells: function in cell survival and IL-1β and TNF-α induced production of 
inflammatory mediators. Cellular signalling, 17(10), 1203-1217.  
 
Blanchard, F., Duplomb, L., Baud’huin, M., & Brounais, B. (2009). The dual role of 
IL-6-type cytokines on bone remodeling and bone tumors. Cytokine & growth 
factor reviews, 20(1), 19-28.  
 
Bonewald, L., & Dallas, S. (1994). Role of active and latent transforming growth 
factor β in bone formation. Journal of cellular biochemistry, 55(3), 350-357.  
 
Bookout, A., & Mangelsdorf, D. J. (2003). Quantitative real-time PCR protocol for 
analysis of nuclear receptor signaling pathways. Nuclear receptor signaling, 1, 
e012.  
 
Boyle, W. J., Simonet, W. S., & Lacey, D. L. (2003). Osteoclast differentiation and 
activation. Nature, 423(6937), 337-342.  
 
Bunnell, B. A., Betancourt, A. M., & Sullivan, D. E. (2010). New concepts on the 
immune modulation mediated by mesenchymal stem cells. Stem Cell Res Ther, 
1(5), 34.  
 
Cahalan, S. M., Gonzalez-Cabrera, P. J., Sarkisyan, G., Nguyen, N., Schaeffer, M.-T., 
Huang, L., . . . Rosen, H. (2011). Actions of a picomolar short-acting S1P1 
agonist in S1P1-eGFP knock-in mice. Nature chemical biology, 7(5), 254-256.  
 
Camerer, E., Regard, J. B., Cornelissen, I., Srinivasan, Y., Duong, D. N., Palmer, D., . . . 
Coughlin, S. R. (2009). Sphingosine-1-phosphate in the plasma compartment 
regulates basal and inflammation-induced vascular leak in mice. The Journal 
of clinical investigation, 119(7), 1871-1879.  
 
Chae, S.-S., Proia, R. L., & Hla, T. (2004). Constitutive expression of the S1P 1 
receptor in adult tissues. Prostaglandins & other lipid mediators, 73(1), 141-
150.  
 
Chen, K., Wang, D., Du, W. T., Han, Z.-B., Ren, H., Chi, Y., . . . Han, Z. C. (2010). 
Human umbilical cord mesenchymal stem cells hUC-MSCs exert 
immunosuppressive activities through a PGE 2-dependent mechanism. 
Clinical immunology, 135(3), 448-458.  
 
Chen, Z., Wu, C., Gu, W., Klein, T., Crawford, R., & Xiao, Y. (2014). Osteogenic 
differentiation of bone marrow MSCs by β-tricalcium phosphate stimulating 
macrophages via BMP2 signalling pathway. Biomaterials, 35(5), 1507-1518.  
 
Chen, Z., Wu, C., Yuen, J., Klein, T., Crawford, R., & Xiao, Y. (2014). Influence of 
osteocytes in the in vitro and in vivo β‐tricalcium phosphate‐stimulated 
osteogenesis. Journal of Biomedical Materials Research Part A, 102(8), 2813-
2823.  
 
Chi, H. (2011). Sphingosine-1-phosphate and immune regulation: trafficking and 
beyond. Trends in pharmacological sciences, 32(1), 16-24.  
 Bibliography 143 
 
Cho, T.-J., Kim, J., Chung, C., Yoo, W., Gerstenfeld, L., Einhorn, T., & Choi, I. (2007). 
Expression and role of interleukin-6 in distraction osteogenesis. Calcified 
tissue international, 80(3), 192-200.  
 
Choi, J. W., Gardell, S. E., Herr, D. R., Rivera, R., Lee, C.-W., Noguchi, K., . . . 
Kennedy, G. (2011). FTY720 (fingolimod) efficacy in an animal model of 
multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) 
modulation. Proceedings of the National Academy of Sciences, 108(2), 751-
756.  
 
Cinamon, G., Zachariah, M. A., Lam, O. M., Foss, F. W., & Cyster, J. G. (2008). 
Follicular shuttling of marginal zone B cells facilitates antigen transport. 
Nature immunology, 9(1), 54-62.  
 
Croes, M., Öner, F. C., van Neerven, D., Sabir, E., Kruyt, M. C., Blokhuis, T. J., . . . 
Alblas, J. (2016). Proinflammatory T cells and IL-17 stimulate osteoblast 
differentiation. Bone.  
 
Czeloth, N., Schippers, A., Wagner, N., Müller, W., Küster, B., Bernhardt, G., & 
Förster, R. (2007). Sphingosine-1 phosphate signaling regulates positioning of 
dendritic cells within the spleen. The Journal of Immunology, 179(9), 5855-
5863.  
 
Davis, M. D., & Kehrl, J. H. (2009). The influence of sphingosine-1-phosphate 
receptor signaling on lymphocyte trafficking: how a bioactive lipid mediator 
grew up from an “immature” vascular maturation factor to a “mature” mediator 
of lymphocyte behavior and function. Immunologic research, 43(1-3), 187-197.  
 
Dewhirst, F. E., Stashenko, P. P., Mole, J. E., & Tsurumachi, T. (1985). Purification 
and partial sequence of human osteoclast-activating factor: identity with 
interleukin 1 beta. The Journal of Immunology, 135(4), 2562-2568.  
 
Dorsam, G., Graeler, M. H., Seroogy, C., Kong, Y., Voice, J. K., & Goetzl, E. J. (2003). 
Transduction of multiple effects of sphingosine 1-phosphate (S1P) on T cell 
functions by the S1P1 G protein-coupled receptor. The Journal of Immunology, 
171(7), 3500-3507.  
 
Duque, G., Huang, D. C., Macoritto, M., Rivas, D., Yang, X. F., Ste‐Marie, L. G., & 
Kremer, R. (2009). Autocrine regulation of interferon γ in mesenchymal stem 
cells plays a role in early osteoblastogenesis. Stem Cells, 27(3), 550-558.  
 
Eliasson, S., Halvarsson, C., & Ljungheimer, C. (1984). Periapical condensing osteitis 
and endodontic treatment. Oral Surgery, Oral Medicine, Oral Pathology, 57(2), 
195-199.  
 
Eskan, M. A., Rose, B. G., Benakanakere, M. R., Zeng, Q., Fujioka, D., Martin, M. 
H., . . . Kinane, D. F. (2008). TLR4 and S1P receptors cooperate to enhance 
inflammatory cytokine production in human gingival epithelial cells. European 
journal of immunology, 38(4), 1138-1147.  
 Bibliography 144 
 
Feng, H., Stachura, D. L., White, R. M., Gutierrez, A., Zhang, L., Sanda, T., . . . 
Langenau, D. M. (2010). T-lymphoblastic lymphoma cells express high levels 
of BCL2, S1P1, and ICAM1, leading to a blockade of tumor cell intravasation. 
Cancer cell, 18(4), 353-366.  
 
Fibbe, W. E., Nauta, A. J., & Roelofs, H. (2007). Modulation of immune responses by 
mesenchymal stem cells. Annals of the New York Academy of Sciences, 
1106(1), 272-278.  
 
Firestein, G. S. (2003). Evolving concepts of rheumatoid arthritis. Nature, 423(6937), 
356-361.  
 
Fonseca, J., Cortez-Dias, N., Francisco, A., Sobral, M., Canhao, H., Resende, C., . . . 
Saraiva, F. (2004). Inflammatory cell infiltrate and RANKL/OPG expression 
in rheumatoid synovium: comparison with other inflammatory arthropathies 
and correlation with outcome. Clinical and experimental rheumatology, 23(2), 
185-192.  
 
Fujino, M., Funeshima, N., Kitazawa, Y., Kimura, H., Amemiya, H., Suzuki, S., & Li, 
X.-K. (2003). Amelioration of experimental autoimmune encephalomyelitis in 
Lewis rats by FTY720 treatment. Journal of Pharmacology and Experimental 
Therapeutics, 305(1), 70-77.  
 
Galvin, R. J. S., Gatlin, C. L., Horn, J. W., & Fuson, T. R. (1999). TGF-β enhances 
osteoclast differentiation in hematopoietic cell cultures stimulated with 
RANKL and M-CSF. Biochemical and biophysical research communications, 
265(1), 233-239.  
 
Garlet, G. P., Horwat, R., Ray, H. L., Garlet, T. P., Silveira, E. M., Campanelli, A. 
P., . . . Silva, R. M. (2012). Expression analysis of wound healing genes in 
human periapical granulomas of progressive and stable nature. Journal of 
endodontics, 38(2), 185-190.  
 
Gräler, M. H., Huang, M.-C., Watson, S., & Goetzl, E. J. (2005). Immunological 
effects of transgenic constitutive expression of the type 1 sphingosine 1-
phosphate receptor by mouse lymphocytes. The Journal of Immunology, 
174(4), 1997-2003.  
 
Guihard, P., Danger, Y., Brounais, B., David, E., Brion, R., Delecrin, J., . . . Heymann, 
D. (2012). Induction of osteogenesis in mesenchymal stem cells by activated 
monocytes/macrophages depends on oncostatin M signaling. Stem cells, 30(4), 
762-772.  
 
Gur-Wahnon, D., Borovsky, Z., Beyth, S., Liebergall, M., & Rachmilewitz, J. (2007). 
Contact-dependent induction of regulatory antigen-presenting cells by human 
mesenchymal stem cells is mediated via STAT3 signaling. Experimental 
hematology, 35(3), 426-433.  
 
 Bibliography 145 
Hadjidakis, D. J., & Androulakis, I. I. (2006). Bone remodeling. Annals of the New 
York Academy of Sciences, 1092(1), 385-396.  
 
Hait, N. C., Allegood, J., Maceyka, M., Strub, G. M., Harikumar, K. B., Singh, S. 
K., . . . Milstien, S. (2009). Regulation of histone acetylation in the nucleus by 
sphingosine-1-phosphate. Science, 325(5945), 1254-1257.  
 
Hammad, S. M., Crellin, H. G., Wu, B. X., Melton, J., Anelli, V., & Obeid, L. M. 
(2008). Dual and distinct roles for sphingosine kinase 1 and sphingosine 1 
phosphate in the response to inflammatory stimuli in RAW macrophages. 
Prostaglandins & other lipid mediators, 85(3), 107-114.  
 
Hannun, Y. A., & Obeid, L. M. (2008). Principles of bioactive lipid signalling: lessons 
from sphingolipids. Nature reviews Molecular cell biology, 9(2), 139-150.  
 
Hashizume, M., Hayakawa, N., & Mihara, M. (2008). IL-6 trans-signalling directly 
induces RANKL on fibroblast-like synovial cells and is involved in RANKL 
induction by TNF-α and IL-17. Rheumatology, 47(11), 1635-1640.  
 
Hess, K., Ushmorov, A., Fiedler, J., Brenner, R. E., & Wirth, T. (2009). TNFα 
promotes osteogenic differentiation of human mesenchymal stem cells by 
triggering the NF-κB signaling pathway. Bone, 45(2), 367-376.  
 
Ho, V. W., & Sly, L. M. (2009). Derivation and characterization of murine 
alternatively activated (M2) macrophages. Macrophages and Dendritic Cells: 
Methods and Protocols, 173-185.  
 
Horwood, N. J. (2015). Macrophage Polarization and Bone Formation: A review. 
Clinical reviews in allergy & immunology, 1-8.  
 
Huang, H., Kim, H., Chang, E., Lee, Z., Hwang, S., Kim, H., . . . Kim, H. (2009). IL-
17 stimulates the proliferation and differentiation of human mesenchymal stem 
cells: implications for bone remodeling. Cell Death & Differentiation, 16(10), 
1332-1343.  
 
Huang, M.-C., Watson, S. R., Liao, J.-J., & Goetzl, E. J. (2007). Th17 augmentation 
in OTII TCR plus T cell-selective type 1 sphingosine 1-phosphate receptor 
double transgenic mice. The Journal of Immunology, 178(11), 6806-6813.  
 
Hughes, J. E., Srinivasan, S., Lynch, K. R., Proia, R. L., Ferdek, P., & Hedrick, C. C. 
(2008). Sphingosine-1-phosphate induces an antiinflammatory phenotype in 
macrophages. Circulation research, 102(8), 950-958.  
 
Ishii, M., Egen, J. G., Klauschen, F., Meier-Schellersheim, M., Saeki, Y., Vacher, J., . . . 
Germain, R. N. (2009). Sphingosine-1-phosphate mobilizes osteoclast 
precursors and regulates bone homeostasis. Nature, 458(7237), 524-528.  
 
Ishii, M., Kikuta, J., Shimazu, Y., Meier-Schellersheim, M., & Germain, R. N. (2010). 
Chemorepulsion by blood S1P regulates osteoclast precursor mobilization and 
 Bibliography 146 
bone remodeling in vivo. The Journal of experimental medicine, 207(13), 
2793-2798.  
 
Ito, K., Anada, Y., Tani, M., Ikeda, M., Sano, T., Kihara, A., & Igarashi, Y. (2007). 
Lack of sphingosine 1-phosphate-degrading enzymes in erythrocytes. 
Biochemical and biophysical research communications, 357(1), 212-217.  
 
Itoh, S., Udagawa, N., Takahashi, N., Yoshitake, F., Narita, H., Ebisu, S., & Ishihara, 
K. (2006). A critical role for interleukin-6 family-mediated Stat3 activation in 
osteoblast differentiation and bone formation. Bone, 39(3), 505-512.  
 
Jenne, C. N., Enders, A., Rivera, R., Watson, S. R., Bankovich, A. J., Pereira, J. P., . . . 
Banerjee, A. (2009). T-bet–dependent S1P5 expression in NK cells promotes 
egress from lymph nodes and bone marrow. The Journal of experimental 
medicine, 206(11), 2469-2481.  
 
Jolly, P. S., Bektas, M., Olivera, A., Gonzalez-Espinosa, C., Proia, R. L., Rivera, J., . . . 
Spiegel, S. (2004). Transactivation of sphingosine-1–phosphate receptors by 
FcεRI triggering is required for normal mast cell degranulation and chemotaxis. 
The Journal of experimental medicine, 199(7), 959-970.  
 
Kappos, L., Antel, J., Comi, G., Montalban, X., O'Connor, P., Polman, C. H., . . . 
Radue, E. W. (2006). Oral fingolimod (FTY720) for relapsing multiple 
sclerosis. New England Journal of Medicine, 355(11), 1124-1140.  
 
Kawashima, N., Okiji, T., Kosaka, T., & Suda, H. (1996). Kinetics of macrophages 
and lymphoid cells during the development of experimentally induced 
periapical lesions in rat molars: a quantitative immunohistochemical study. 
Journal of Endodontics, 22(6), 311-316.  
 
Kawashima, N., Suzuki, N., Yang, G., Ohi, C., Okuhara, S., Nakano-Kawanishi, H., 
& Suda, H. (2007). Kinetics of RANKL, RANK and OPG expressions in 
experimentally induced rat periapical lesions. Oral Surgery, Oral Medicine, 
Oral Pathology, Oral Radiology, and Endodontology, 103(5), 707-711.  
 
Kim, M. S., Day, C. J., & Morrison, N. A. (2005). MCP-1 is induced by RANKL, 
promotes osteoclast fusion and rescues GM-CSF suppression of osteoclast 
formation. Journal of Biological Chemistry.  
 
Kim, Y.-G., Park, J.-W., Lee, J.-M., Suh, J.-Y., Lee, J.-K., Chang, B.-S., . . . Lee, Y. 
(2014). IL-17 inhibits osteoblast differentiation and bone regeneration in rat. 
Archives of oral biology, 59(9), 897-905.  
 
Kimura, A., Naka, T., & Kishimoto, T. (2007). IL-6-dependent and-independent 
pathways in the development of interleukin 17-producing T helper cells. 
Proceedings of the National Academy of Sciences, 104(29), 12099-12104.  
 
King, A. E., Fleming, D. C., Critchley, H. O., & Kelly, R. W. (2002). Regulation of 
natural antibiotic expression by inflammatory mediators and mimics of 
 Bibliography 147 
infection in human endometrial epithelial cells. Molecular human reproduction, 
8(4), 341-349.  
 
Kini, U., & Nandeesh, B. (2012). Physiology of bone formation, remodeling, and 
metabolism. In Radionuclide and hybrid bone imaging (pp. 29-57): Springer.  
 
Kitano, M., Hla, T., Sekiguchi, M., Kawahito, Y., Yoshimura, R., Miyazawa, K., . . . 
Sano, H. (2006). Sphingosine 1 ‐ phosphate/sphingosine 1 ‐ phosphate 
receptor 1 signaling in rheumatoid synovium: Regulation of synovial 
proliferation and inflammatory gene expression. Arthritis & Rheumatism, 
54(3), 742-753.  
 
Kitaura, H., Sands, M. S., Aya, K., Zhou, P., Hirayama, T., Uthgenannt, B., . . . Silva, 
M. J. (2004). Marrow stromal cells and osteoclast precursors differentially 
contribute to TNF-α-induced osteoclastogenesis in vivo. The Journal of 
Immunology, 173(8), 4838-4846.  
 
Kobayashi, K., Takahashi, N., Jimi, E., Udagawa, N., Takami, M., Kotake, S., . . . 
Shima, N. (2000). Tumor necrosis factor α stimulates osteoclast differentiation 
by a mechanism independent of the ODF/RANKL–RANK interaction. The 
Journal of experimental medicine, 191(2), 275-286.  
 
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., . . . Itie, A. 
(1999). OPGL is a key regulator of osteoclastogenesis, lymphocyte 
development and lymph-node organogenesis. Nature, 397(6717), 315-323.  
 
König, K., Diehl, L., Rommerscheidt-Fuss, U., Golletz, C., Quast, T., Kahl, P., . . . 
Heukamp, L. C. (2010). Four-and-a-half LIM domain protein 2 is a novel 
regulator of sphingosine 1-phosphate receptor 1 in CCL19-induced dendritic 
cell migration. The Journal of Immunology, 185(3), 1466-1475.  
 
Kono, M., & Proia, R. L. (2015). Imaging S1P1 activation in vivo. Experimental cell 
research, 333(2), 178-182.  
 
Kono, M., Tucker, A. E., Tran, J., Bergner, J. B., Turner, E. M., & Proia, R. L. (2014). 
Sphingosine-1-phosphate receptor 1 reporter mice reveal receptor activation 
sites in vivo. The Journal of clinical investigation, 124(5), 2076.  
 
Korn, T., Mitsdoerffer, M., Croxford, A. L., Awasthi, A., Dardalhon, V. A., Galileos, 
G., . . . Waisman, A. (2008). IL-6 controls Th17 immunity in vivo by inhibiting 
the conversion of conventional T cells into Foxp3+ regulatory T cells. 
Proceedings of the National Academy of Sciences, 105(47), 18460-18465.  
 
Kudo, O., Sabokbar, A., Pocock, A., Itonaga, I., Fujikawa, Y., & Athanasou, N. (2003). 
Interleukin-6 and interleukin-11 support human osteoclast formation by a 
RANKL-independent mechanism. Bone, 32(1), 1-7.  
 
Kurihara, N., Bertolini, D., Suda, T., Akiyama, Y., & Roodman, G. D. (1990). IL-6 
stimulates osteoclast-like multinucleated cell formation in long term human 
 Bibliography 148 
marrow cultures by inducing IL-1 release. The Journal of Immunology, 
144(11), 4226-4230.  
 
Lacey, D., Timms, E., Tan, H.-L., Kelley, M., Dunstan, C., Burgess, T., . . . Scully, S. 
(1998). Osteoprotegerin ligand is a cytokine that regulates osteoclast 
differentiation and activation. cell, 93(2), 165-176.  
 
Lam, J., Takeshita, S., Barker, J. E., Kanagawa, O., Ross, F. P., & Teitelbaum, S. L. 
(2000). TNF-α induces osteoclastogenesis by direct stimulation of 
macrophages exposed to permissive levels of RANK ligand. The Journal of 
clinical investigation, 106(12), 1481-1488.  
 
Lari, R., Fleetwood, A. J., Kitchener, P. D., Cook, A. D., Pavasovic, D., Hertzog, P. J., 
& Hamilton, J. A. (2007). Macrophage lineage phenotypes and 
osteoclastogenesis—Complexity in the control by GM-CSF and TGF-β. Bone, 
40(2), 323-336.  
 
Leboy, P. S., Beresford, J. N., Devlin, C., & Owen, M. E. (1991). Dexamethasone 
induction of osteoblast mRNAs in rat marrow stromal cell cultures. Journal of 
cellular physiology, 146(3), 370-378.  
 
Ledgerwood, L. G., Lal, G., Zhang, N., Garin, A., Esses, S. J., Ginhoux, F., . . . Ding, 
Y. (2008). The sphingosine 1-phosphate receptor 1 causes tissue retention by 
inhibiting the entry of peripheral tissue T lymphocytes into afferent lymphatics. 
Nature immunology, 9(1), 42-53.  
 
Lew, D. P., & Waldvogel, F. A. (2004). Osteomyelitis. The Lancet, 364(9431), 369-
379.  
 
Liao, J.-J., Huang, M.-C., & Goetzl, E. J. (2007). Cutting edge: Alternative signaling 
of Th17 cell development by sphingosine 1-phosphate. The Journal of 
Immunology, 178(9), 5425-5428.  
 
Liu, G., Burns, S., Huang, G., Boyd, K., Proia, R. L., Flavell, R. A., & Chi, H. (2009). 
The receptor S1P1 overrides regulatory T cell–mediated immune suppression 
through Akt-mTOR. Nature immunology, 10(7), 769-777.  
 
Liu, G., Yang, K., Burns, S., Shrestha, S., & Chi, H. (2010). The S1P1-mTOR axis 
directs the reciprocal differentiation of TH1 and Treg cells. Nature 
immunology, 11(11), 1047-1056.  
 
Liu, L., & Peng, B. (2013). The expression of macrophage migration inhibitory factor 
is correlated with receptor activator of nuclear factor kappa B ligand in induced 
rat periapical lesions. Journal of endodontics, 39(8), 984-989.  
 
Liu, Y., Wada, R., Yamashita, T., Mi, Y., Deng, C.-X., Hobson, J. P., . . . Lee, M.-J. 
(2000). Edg-1, the G protein–coupled receptor for sphingosine-1-phosphate, is 
essential for vascular maturation. The Journal of clinical investigation, 106(8), 
951-961.  
 
 Bibliography 149 
Liu, Y., Wang, L., Kikuiri, T., Akiyama, K., Chen, C., Xu, X., . . . Shi, S. (2011). 
Mesenchymal stem cell-based tissue regeneration is governed by recipient T 
lymphocytes via IFN-[gamma] and TNF-[alpha]. [10.1038/nm.2542]. Nat Med, 
17(12), 1594-1601. Retrieved from http://dx.doi.org/10.1038/nm.2542. 
doi:http://www.nature.com/nm/journal/v17/n12/abs/nm.2542.html#suppleme
ntary-information 
 
Logan, C. Y., & Nusse, R. (2004). The Wnt signaling pathway in development and 
disease. Annu. Rev. Cell Dev. Biol., 20, 781-810.  
 
Loi, F., Córdova, L. A., Zhang, R., Pajarinen, J., Lin, T.-h., Goodman, S. B., & Yao, 
Z. (2016). The effects of immunomodulation by macrophage subsets on 
osteogenesis in vitro. Stem Cell Research & Therapy, 7(1), 1-11.  
 
Lotinun, S., Kiviranta, R., Matsubara, T., Alzate, J. A., Neff, L., Lüth, A., . . . Vuorio, 
E. (2013). Osteoclast-specific cathepsin K deletion stimulates S1P-dependent 
bone formation. The Journal of clinical investigation, 123(2), 666-681.  
 
Lubberts, E., van den Bersselaar, L., Oppers-Walgreen, B., Schwarzenberger, P., 
Coenen-de Roo, C. J., Kolls, J. K., . . . van den Berg, W. B. (2003). IL-17 
promotes bone erosion in murine collagen-induced arthritis through loss of the 
receptor activator of NF-κB ligand/osteoprotegerin balance. The Journal of 
Immunology, 170(5), 2655-2662.  
 
Ma, T., Miyanishi, K., Trindade, M. C., Genovese, M., Regula, D., Smith, R. L., & 
Goodman, S. B. (2003). Interleukin 1 receptor antagonist inhibits localized 
bone formation in vivo. The Journal of rheumatology, 30(12), 2547-2552.  
 
Maceyka, M., Harikumar, K. B., Milstien, S., & Spiegel, S. (2012). Sphingosine-1-
phosphate signaling and its role in disease. Trends in cell biology, 22(1), 50-
60.  
 
Maeda, Y., Matsuyuki, H., Shimano, K., Kataoka, H., Sugahara, K., & Chiba, K. 
(2007). Migration of CD4 T cells and dendritic cells toward sphingosine 1-
phosphate (S1P) is mediated by different receptor subtypes: S1P regulates the 
functions of murine mature dendritic cells via S1P receptor type 3. The Journal 
of Immunology, 178(6), 3437-3446.  
 
Maggini, J., Mirkin, G., Bognanni, I., Holmberg, J., Piazzón, I. M., Nepomnaschy, 
I., . . . Vermeulen, M. (2010). Mouse bone marrow-derived mesenchymal 
stromal cells turn activated macrophages into a regulatory-like profile. PloS 
one, 5(2), e9252.  
 
Malik, Z. A., Thompson, C. R., Hashimi, S., Porter, B., Iyer, S. S., & Kusner, D. J. 
(2003). Cutting edge: Mycobacterium tuberculosis blocks Ca2+ signaling and 
phagosome maturation in human macrophages via specific inhibition of 
sphingosine kinase. The Journal of Immunology, 170(6), 2811-2815.  
 
 Bibliography 150 
Mantovani, A., Sica, A., Sozzani, S., Allavena, P., Vecchi, A., & Locati, M. (2004). 
The chemokine system in diverse forms of macrophage activation and 
polarization. Trends in immunology, 25(12), 677-686.  
 
Marton, I., & Kiss, C. (2000). Protective and destructive immune reactions in apical 
periodontitis. Oral microbiology and immunology, 15(3), 139-150.  
 
Matsuo, T., Ebisu, S., Shimabukuro, Y., Ohtake, T., & Okada, H. (1992). Quantitative 
analysis of immunocompetent cells in human periapical lesions: correlations 
with clinical findings of the involved teeth. Journal of endodontics, 18(10), 
497-500.  
 
Mechtcheriakova, D., Wlachos, A., Sobanov, J., Kopp, T., Reuschel, R., Bornancin, 
F., . . . Stingl, G. (2007). Sphingosine 1-phosphate phosphatase 2 is induced 
during inflammatory responses. Cellular signalling, 19(4), 748-760.  
 
Melendez, A. J., Harnett, M. M., Pushparaj, P. N., Wong, W. F., Tay, H. K., McSharry, 
C. P., & Harnett, W. (2007). Inhibition of Fc&epsi; RI-mediated mast cell 
responses by ES-62, a product of parasitic filarial nematodes. Nature medicine, 
13(11), 1375-1381.  
 
Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J., & Hill, A. M. (2000). M-1/M-2 
macrophages and the Th1/Th2 paradigm. The Journal of Immunology, 164(12), 
6166-6173.  
 
Miyamoto, T., Ohneda, O., Arai, F., Iwamoto, K., Okada, S., Takagi, K., . . . Suda, T. 
(2001). Bifurcation of osteoclasts and dendritic cells from common progenitors. 
Blood, 98(8), 2544-2554.  
 
Monick, M. M., Cameron, K., Powers, L. S., Butler, N. S., McCoy, D., Mallampalli, 
R. K., & Hunninghake, G. W. (2004). Sphingosine Kinase Mediates Activation 
of Extracellular Signal–Related Kinase and Akt by Respiratory Syncytial Virus. 
American journal of respiratory cell and molecular biology, 30(6), 844-852.  
 
Moreno, J. L., Kaczmarek, M., Keegan, A. D., & Tondravi, M. (2003). IL-4 suppresses 
osteoclast development and mature osteoclast function by a STAT6-dependent 
mechanism: irreversible inhibition of the differentiation program activated by 
RANKL. Blood, 102(3), 1078-1086.  
 
Mosser, D. M., & Edwards, J. P. (2008). Exploring the full spectrum of macrophage 
activation. Nature reviews immunology, 8(12), 958-969.  
 
Mountziaris, P. M., & Mikos, A. G. (2008). Modulation of the inflammatory response 
for enhanced bone tissue regeneration. Tissue Engineering Part B: Reviews, 
14(2), 179-186.  
 
Murray, P. J., Allen, J. E., Biswas, S. K., Fisher, E. A., Gilroy, D. W., Goerdt, S., . . . 
Lawrence, T. (2014). Macrophage activation and polarization: nomenclature 
and experimental guidelines. Immunity, 41(1), 14-20.  
 
 Bibliography 151 
Nagata, N., Kitaura, H., Yoshida, N., & Nakayama, K. (2003). Inhibition of RANKL-
induced osteoclast formation in mouse bone marrow cells by IL-12: 
involvement of IFN-γ possibly induced from non-T cell population. Bone, 
33(4), 721-732.  
 
Nanes, M. S. (2003). Tumor necrosis factor-α: molecular and cellular mechanisms in 
skeletal pathology. Gene, 321, 1-15.  
 
Nathan, M., Pope, M., & Grobler, L. (1994). Osteophyte formation in the vertebral 
column: a review of the etiologic factors--Part II. Contemporary orthopaedics, 
29(2), 113-119.  
 
Nauta, A. J., & Fibbe, W. E. (2007). Immunomodulatory properties of mesenchymal 
stromal cells. Blood, 110(10), 3499-3506.  
 
Nayak, D., Huo, Y., Kwang, W., Pushparaj, P., Kumar, S., Ling, E.-A., & Dheen, S. 
(2010). Sphingosine kinase 1 regulates the expression of proinflammatory 
cytokines and nitric oxide in activated microglia. Neuroscience, 166(1), 132-
144.  
 
Németh, K., Leelahavanichkul, A., Yuen, P. S., Mayer, B., Parmelee, A., Doi, K., . . . 
Brown, J. M. (2009). Bone marrow stromal cells attenuate sepsis via 
prostaglandin E2–dependent reprogramming of host macrophages to increase 
their interleukin-10 production. Nature medicine, 15(1), 42-49.  
 
O’Brien, C. A., Gubrij, I., Lin, S.-C., Saylors, R. L., & Manolagas, S. C. (1999). 
STAT3 activation in stromal/osteoblastic cells is required for induction of the 
receptor activator of NF-κB ligand and stimulation of osteoclastogenesis by 
gp130-utilizing cytokines or interleukin-1 but not 1, 25-dihydroxyvitamin D3 
or parathyroid hormone. Journal of Biological Chemistry, 274(27), 19301-
19308.  
 
Oettmeier, R., & Abendroth, K. (1989). Osteoarthritis and bone: osteologic types of 
osteoarthritis of the hip. Skeletal radiology, 18(3), 165-174.  
 
Ono, T., Okamoto, K., Nakashima, T., Nitta, T., Hori, S., Iwakura, Y., & Takayanagi, 
H. (2016). IL-17-producing [gamma][delta] T cells enhance bone regeneration. 
Nature communications, 7.  
 
Pappu, R., Schwab, S. R., Cornelissen, I., Pereira, J. P., Regard, J. B., Xu, Y., . . . 
Cyster, J. G. (2007). Promotion of lymphocyte egress into blood and lymph by 
distinct sources of sphingosine-1-phosphate. Science, 316(5822), 295-298.  
 
Park-Min, K.-H., Ji, J.-D., Antoniv, T., Reid, A. C., Silver, R. B., Humphrey, M. B., . . . 
Ivashkiv, L. B. (2009). IL-10 suppresses calcium-mediated costimulation of 
receptor activator NF-κB signaling during human osteoclast differentiation by 
inhibiting TREM-2 expression. The Journal of Immunology, 183(4), 2444-
2455.  
 
 Bibliography 152 
Pederson, L., Ruan, M., Westendorf, J. J., Khosla, S., & Oursler, M. J. (2008). 
Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and 
the chemokine sphingosine-1-phosphate. Proceedings of the National 
Academy of Sciences, 105(52), 20764-20769.  
 
Peest, U., Sensken, S. C., Andréani, P., Hänel, P., Van Veldhoven, P. P., & Gräler, M. 
H. (2008). S1P‐lyase independent clearance of extracellular sphingosine 1‐
phosphate after dephosphorylation and cellular uptake. Journal of cellular 
biochemistry, 104(3), 756-772.  
 
Perrien, D. S., Brown, E. C., Fletcher, T. W., Irby, D. J., Aronson, J., Gao, G. G., . . . 
Suva, L. J. (2002). Interleukin-1 and tumor necrosis factor antagonists 
attenuate ethanol-induced inhibition of bone formation in a rat model of 
distraction osteogenesis. Journal of Pharmacology and Experimental 
Therapeutics, 303(3), 904-908.  
 
Pettus, B. J., Bielawski, J., Porcelli, A. M., Reames, D. L., Johnson, K. R., Morrow, 
J., . . . Hannun, Y. A. (2003). The sphingosine kinase 1/sphingosine-1-
phosphate pathway mediates COX-2 induction and PGE2 production in 
response to TNF-α. The FASEB Journal, 17(11), 1411-1421.  
 
Pham, T. H., Okada, T., Matloubian, M., Lo, C. G., & Cyster, J. G. (2008). S1P 1 
receptor signaling overrides retention mediated by Gα i-coupled receptors to 
promote T cell egress. Immunity, 28(1), 122-133.  
 
Pitson, S. M. (2011). Regulation of sphingosine kinase and sphingolipid signaling. 
Trends in biochemical sciences, 36(2), 97-107.  
 
Pitson, S. M., & Pébay, A. (2009). Regulation of stem cell pluripotency and neural 
differentiation by lysophospholipids. Neurosignals, 17(4), 242-254.  
 
Quinn, J. M., Itoh, K., Udagawa, N., Häusler, K., Yasuda, H., Shima, N., . . . Suda, T. 
(2001). Transforming growth factor β affects osteoclast differentiation via 
direct and indirect actions. Journal of Bone and Mineral Research, 16(10), 
1787-1794.  
 
Raggatt, L. J., & Partridge, N. C. (2010). Cellular and molecular mechanisms of bone 
remodeling. Journal of Biological Chemistry, 285(33), 25103-25108.  
 
Raicevic, G., Rouas, R., Najar, M., Stordeur, P., Boufker, H. I., Bron, D., . . . Lagneaux, 
L. (2010). Inflammation modifies the pattern and the function of Toll-like 
receptors expressed by human mesenchymal stromal cells. Human 
immunology, 71(3), 235-244.  
 
Rathinasamy, A., Czeloth, N., Pabst, O., Förster, R., & Bernhardt, G. (2010). The 
origin and maturity of dendritic cells determine the pattern of sphingosine 1-
phosphate receptors expressed and required for efficient migration. The 
Journal of Immunology, 185(7), 4072-4081.  
 
 Bibliography 153 
Rausch, M., Hiestand, P., Foster, C. A., Baumann, D. R., Cannet, C., & Rudin, M. 
(2004). Predictability of FTY720 efficacy in experimental autoimmune 
encephalomyelitis by in vivo macrophage tracking: Clinical implications for 
ultrasmall superparamagnetic iron oxide ‐ enhanced magnetic resonance 
imaging. Journal of Magnetic Resonance Imaging, 20(1), 16-24.  
 
Redlich, K., & Smolen, J. S. (2012). Inflammatory bone loss: pathogenesis and 
therapeutic intervention. Nature reviews Drug discovery, 11(3), 234-250.  
 
Richmond, J. M., Lee, J., Green, D. S., Kornfeld, H., & Cruikshank, W. W. (2012). 
Mannose-Capped Lipoarabinomannan from Mycobacterium tuberculosis 
Preferentially Inhibits Sphingosine-1-Phosphate–Induced Migration of Th1 
Cells. The Journal of Immunology, 189(12), 5886-5895.  
 
Rivera, J., Proia, R. L., & Olivera, A. (2008). The alliance of sphingosine-1-phosphate 
and its receptors in immunity. Nature Reviews Immunology, 8(10), 753-763.  
 
Rodan, G. A., & Martin, T. J. (2000). Therapeutic approaches to bone diseases. Science, 
289(5484), 1508-1514.  
 
Rosen, H., Gonzalez-Cabrera, P. J., Sanna, M. G., & Brown, S. (2009). Sphingosine 
1-phosphate receptor signaling. Annual review of biochemistry, 78, 743-768.  
 
Ross, F. P., & Teitelbaum, S. L. (2005). αvβ3 and macrophage colony‐stimulating 
factor: partners in osteoclast biology. Immunological reviews, 208(1), 88-105.  
 
Ryu, J., Kim, H. J., Chang, E. J., Huang, H., Banno, Y., & Kim, H. H. (2006). 
Sphingosine 1‐phosphate as a regulator of osteoclast differentiation and 
osteoclast–osteoblast coupling. The EMBO journal, 25(24), 5840-5851.  
 
Sakaguchi, S., Yamaguchi, T., Nomura, T., & Ono, M. (2008). Regulatory T cells and 
immune tolerance. Cell, 133(5), 775-787.  
 
Sammons, J., Ahmed, N., El-Sheemy, M., & Hassan, H. (2004). The role of BMP-6, 
IL-6, and BMP-4 in mesenchymal stem cell-dependent bone development: 
effects on osteoblastic differentiation induced by parathyroid hormone and 
vitamin D3. Stem cells and development, 13(3), 273-280.  
 
Sanchez, T., & Hla, T. (2004). Structural and functional characteristics of S1P 
receptors. Journal of cellular biochemistry, 92(5), 913-922.  
 
Sanford, M. (2014). Fingolimod: a review of its use in relapsing-remitting multiple 
sclerosis. Drugs, 74(12), 1411-1433.  
 
Sato, C., Iwasaki, T., Kitano, S., Tsunemi, S., & Sano, H. (2012). Sphingosine 1-
phosphate receptor activation enhances BMP-2-induced osteoblast 
differentiation. Biochemical and biophysical research communications, 423(1), 
200-205.  
 
 Bibliography 154 
Sato, K., Suematsu, A., Okamoto, K., Yamaguchi, A., Morishita, Y., Kadono, Y., . . . 
Iwakura, Y. (2006). Th17 functions as an osteoclastogenic helper T cell subset 
that links T cell activation and bone destruction. The Journal of experimental 
medicine, 203(12), 2673-2682.  
 
Schwab, S. R., & Cyster, J. G. (2007). Finding a way out: lymphocyte egress from 
lymphoid organs. Nature immunology, 8(12), 1295-1301.  
 
Schwab, S. R., Pereira, J. P., Matloubian, M., Xu, Y., Huang, Y., & Cyster, J. G. (2005). 
Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P 
gradients. Science, 309(5741), 1735-1739.  
 
Shi, M., Chen, Z., Farnaghi, S., Friis, T., Mao, X., Xiao, Y., & Wu, C. (2016). Copper-
doped mesoporous silica nanospheres, a promising immunomodulatory agent 
for inducing osteogenesis. Acta biomaterialia, 30, 334-344.  
 
Silva, T., Garlet, G., Fukada, S., Silva, J., & Cunha, F. (2007). Chemokines in oral 
inflammatory diseases: apical periodontitis and periodontal disease. Journal of 
Dental Research, 86(4), 306-319.  
 
Simonet, W., Lacey, D., Dunstan, C., Kelley, M., Chang, M.-S., Lüthy, R., . . . Boone, 
T. (1997). Osteoprotegerin: a novel secreted protein involved in the regulation 
of bone density. Cell, 89(2), 309-319.  
 
Sinha, R. K., Park, C., Hwang, I.-Y., Davis, M. D., & Kehrl, J. H. (2009). B 
lymphocytes exit lymph nodes through cortical lymphatic sinusoids by a 
mechanism independent of sphingosine-1-phosphate-mediated chemotaxis. 
Immunity, 30(3), 434-446.  
 
Song, H. Y., Jeon, E. S., Kim, J. I., Jung, J. S., & Kim, J. H. (2007). Oncostatin M 
promotes osteogenesis and suppresses adipogenic differentiation of human 
adipose tissue ‐ derived mesenchymal stem cells. Journal of cellular 
biochemistry, 101(5), 1238-1251.  
 
Song, J., Matsuda, C., Kai, Y., Nishida, T., Nakajima, K., Mizushima, T., . . . Ito, T. 
(2008). A novel sphingosine 1-phosphate receptor agonist, 2-amino-2-
propanediol hydrochloride (KRP-203), regulates chronic colitis in interleukin-
10 gene-deficient mice. Journal of Pharmacology and Experimental 
Therapeutics, 324(1), 276-283.  
 
Sonomoto, K., Yamaoka, K., Oshita, K., Fukuyo, S., Zhang, X., Nakano, K., . . . 
Tanaka, Y. (2012). Interleukin ‐ 1β  induces differentiation of human 
mesenchymal stem cells into osteoblasts via the Wnt‐5a/receptor tyrosine 
kinase–like orphan receptor 2 pathway. Arthritis & Rheumatism, 64(10), 3355-
3363.  
 
Spiegel, S., & Milstien, S. (2003). Sphingosine-1-phosphate: an enigmatic signalling 
lipid. Nature reviews Molecular cell biology, 4(5), 397-407.  
 
 Bibliography 155 
Spiegel, S., & Milstien, S. (2011). The outs and the ins of sphingosine-1-phosphate in 
immunity. Nature Reviews Immunology, 11(6), 403-415.  
 
Stashenko, P., Teles, R., & D'Souza, R. (1998). Periapical inflammatory responses and 
their modulation. Critical Reviews in Oral Biology & Medicine, 9(4), 498-521.  
 
Stashenko, P., Wang, C.-Y., Tani-Ishii, N., & Yu, S. M. (1994). Pathogenesis of 
induced rat periapical lesions. Oral Surgery, Oral Medicine, Oral Pathology, 
78(4), 494-502.  
 
Stashenko, P., Yu, S. M., & Wang, C.-Y. (1992). Kinetics of immune cell and bone 
resorptive responses to endodontic infections. Journal of endodontics, 18(9), 
422-426.  
 
Steele, D. G., & Bramblett, C. A. (1988). The anatomy and biology of the human 
skeleton: Texas A&M University Press. 
 
Taichman, R. S. (2005). Blood and bone: two tissues whose fates are intertwined to 
create the hematopoietic stem-cell niche. Blood, 105(7), 2631-2639.  
 
Takabe, K., Paugh, S. W., Milstien, S., & Spiegel, S. (2008). “Inside-out” signaling of 
sphingosine-1-phosphate: therapeutic targets. Pharmacological reviews, 60(2), 
181-195.  
 
Takayanagi, H. (2005). Mechanistic insight into osteoclast differentiation in 
osteoimmunology. Journal of molecular medicine, 83(3), 170-179.  
 
Takayanagi, H. (2007). Osteoimmunology: shared mechanisms and crosstalk between 
the immune and bone systems. Nature Reviews Immunology, 7(4), 292-304.  
 
Takayanagi, H., Ogasawara, K., Hida, S., Chiba, T., Murata, S., Sato, K., . . . Tanaka, 
K. (2000). T-cell-mediated regulation of osteoclastogenesis by signalling 
cross-talk between RANKL and IFN-γ. Nature, 408(6812), 600-605.  
 
Takeshita, H., Kitano, M., Iwasaki, T., Kitano, S., Tsunemi, S., Sato, C., . . . Hla, T. 
(2012). Sphingosine 1-phosphate (S1P)/S1P receptor 1 signaling regulates 
receptor activator of NF-κB ligand (RANKL) expression in rheumatoid 
arthritis. Biochemical and biophysical research communications, 419(2), 154-
159.  
 
Takeshita, S., Kaji, K., & Kudo, A. (2000). Identification and characterization of the 
new osteoclast progenitor with macrophage phenotypes being able to 
differentiate into mature osteoclasts. Journal of Bone and Mineral Research, 
15(8), 1477-1488.  
 
Taubman, M. A., Valverde, P., Han, X., & Kawai, T. (2005). Immune response: the 
key to bone resorption in periodontal disease. Journal of periodontology, 
76(11-s), 2033-2041.  
 
 Bibliography 156 
Thangada, S., Khanna, K. M., Blaho, V. A., Oo, M. L., Im, D.-S., Guo, C., . . . Hla, T. 
(2010). Cell-surface residence of sphingosine 1-phosphate receptor 1 on 
lymphocytes determines lymphocyte egress kinetics. The Journal of 
experimental medicine, 207(7), 1475-1483.  
 
Theill, L. E., Boyle, W. J., & Penninger, J. M. (2002). RANK-L and RANK: T cells, 
bone loss, and mammalian evolution. Annual review of immunology, 20(1), 
795-823.  
 
Tjiu, J.-W., Chen, J.-S., Shun, C.-T., Lin, S.-J., Liao, Y.-H., Chu, C.-Y., . . . Inoue, H. 
(2009). Tumor-associated macrophage-induced invasion and angiogenesis of 
human basal cell carcinoma cells by cyclooxygenase-2 induction. Journal of 
Investigative Dermatology, 129(4), 1016-1025.  
 
Tsunemi, S., Iwasaki, T., Kitano, S., Imado, T., Miyazawa, K., & Sano, H. (2010). 
Effects of the novel immunosuppressant FTY720 in a murine rheumatoid 
arthritis model. Clinical Immunology, 136(2), 197-204.  
 
Udagawa, N., Takahashi, N., Akatsu, T., Tanaka, H., Sasaki, T., Nishihara, T., . . . 
Suda, T. (1990). Origin of osteoclasts: mature monocytes and macrophages are 
capable of differentiating into osteoclasts under a suitable microenvironment 
prepared by bone marrow-derived stromal cells. Proceedings of the national 
academy of sciences, 87(18), 7260-7264.  
 
Urist, M. R. (1965). Bone: formation by autoinduction. Science, 150(3698), 893-899.  
 
Van Den Berg, W. B., & Miossec, P. (2009). IL-17 as a future therapeutic target for 
rheumatoid arthritis. Nature Reviews Rheumatology, 5(10), 549-553.  
 
Venkataraman, K., Lee, Y.-M., Michaud, J., Thangada, S., Ai, Y., Bonkovsky, H. 
L., . . . Hla, T. (2008). Vascular endothelium as a contributor of plasma 
sphingosine 1-phosphate. Circulation research, 102(6), 669-676.  
 
Verreck, F. A., de Boer, T., Langenberg, D. M., van der Zanden, L., & Ottenhoff, T. 
H. (2006). Phenotypic and functional profiling of human proinflammatory 
type-1 and anti-inflammatory type-2 macrophages in response to microbial 
antigens and IFN-γ-and CD40L-mediated costimulation. Journal of leukocyte 
biology, 79(2), 285-293.  
 
Walsh, M. C., Kim, N., Kadono, Y., Rho, J., Lee, S. Y., Lorenzo, J., & Choi, Y. (2006). 
Osteoimmunology: interplay between the immune system and bone 
metabolism. Annu. Rev. Immunol., 24, 33-63.  
 
Wang, C.-Y., & Stashenko, P. (1993). Characterization of bone-resorbing activity in 
human periapical lesions. Journal of endodontics, 19(3), 107-111.  
 
Wang, F., Van Brocklyn, J. R., Hobson, J. P., Movafagh, S., Zukowska-Grojec, Z., 
Milstien, S., & Spiegel, S. (1999). Sphingosine 1-Phosphate Stimulates Cell 
Migration through a Gi-coupled Cell Surface Receptor POTENTIAL 
 Bibliography 157 
INVOLVEMENT IN ANGIOGENESIS. Journal of Biological Chemistry, 
274(50), 35343-35350.  
 
Wang, W., Huang, M.-C., & Goetzl, E. J. (2007). Type 1 sphingosine 1-phosphate G 
protein-coupled receptor (S1P1) mediation of enhanced IL-4 generation by 
CD4 T cells from S1P1 transgenic mice. The Journal of Immunology, 178(8), 
4885-4890.  
 
Waterman, R. S., Tomchuck, S. L., Henkle, S. L., & Betancourt, A. M. (2010). A new 
mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory 
MSC1 or an Immunosuppressive MSC2 phenotype. PloS one, 5(4), e10088.  
 
Wei, S., Kitaura, H., Zhou, P., Ross, F. P., & Teitelbaum, S. L. (2005). IL-1 mediates 
TNF-induced osteoclastogenesis. The Journal of clinical investigation, 115(2), 
282-290.  
 
Wu, B., Sondag, G., Malcuit, C., Kim, M. H., & Safadi, F. F. (2015). Macrophage‐
Associated Osteoactivin/GPNMB Mediates Mesenchymal Stem Cell Survival, 
Proliferation, and Migration via a CD44‐Dependent Mechanism. Journal of 
cellular biochemistry.  
 
Xia, P., Gamble, J. R., Rye, K.-A., Wang, L., Hii, C. S., Cockerill, P., . . . Vadas, M. 
A. (1998). Tumor necrosis factor-α induces adhesion molecule expression 
through the sphingosine kinase pathway. Proceedings of the National Academy 
of Sciences, 95(24), 14196-14201.  
 
Xiao, L., Zhu, L., Yang, S., Lei, D., Xiao, Y., & Peng, B. (2015). Different Correlation 
of Sphingosine-1-Phosphate Receptor 1 with Receptor Activator of Nuclear 
Factor Kappa B Ligand and Regulatory T Cells in Rat Periapical Lesions. 
Journal of endodontics, 41(4), 479-486.  
 
Yang, S., Zhu, L., Xiao, L., Shen, Y., Wang, L., Peng, B., & Haapasalo, M. (2014). 
Imbalance of interleukin-17+ T-cell and Foxp3+ regulatory T-cell dynamics in 
rat periapical lesions. Journal of endodontics, 40(1), 56-62.  
 
Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Goto, M., . . . 
Udagawa, N. (1999). A novel molecular mechanism modulating osteoclast 
differentiation and function. Bone, 25(1), 109-113.  
 
Yoshida, H., Hayashi, S.-I., Kunisada, T., Ogawa, M., Nishikawa, S., Okamura, H., . . . 
Nishikawa, S.-I. (1990). The murine mutation osteopetrosis is in the coding 
region of the macrophage colony stimulating factor gene.  
 
Yu, H., Sun, C., & Argraves, K. (2016). Periodontal inflammation and alveolar bone 
loss induced by Aggregatibacter actinomycetemcomitans is attenuated in 
sphingosine kinase 1‐deficient mice. Journal of periodontal research, 51(1), 
38-49.  
 
 Bibliography 158 
Zachariah, M. A., & Cyster, J. G. (2010). Neural crest–derived pericytes promote 
egress of mature thymocytes at the corticomedullary junction. Science, 
328(5982), 1129-1135.  
 
Zaiss, M. M., Axmann, R., Zwerina, J., Polzer, K., Gückel, E., Skapenko, A., . . . Schett, 
G. (2007). Treg cells suppress osteoclast formation: a new link between the 
immune system and bone. Arthritis & Rheumatism, 56(12), 4104-4112.  
 
Zhang, L., Orban, M., Lorenz, M., Barocke, V., Braun, D., Urtz, N., . . . Gaertner, F. 
(2012). A novel role of sphingosine 1-phosphate receptor S1pr1 in mouse 
thrombopoiesis. The Journal of experimental medicine, 209(12), 2165-2181.  
 
Zhang, X., & Peng, B. (2005). Immunolocalization of receptor activator of NF kappa 
B ligand in rat periapical lesions. Journal of endodontics, 31(8), 574-577.  
 
Zou, W., Hakim, I., Tschoep, K., Endres, S., & Bar‐Shavit, Z. (2001). Tumor 
necrosis factor ‐α  mediates RANK ligand stimulation of osteoclast 
differentiation by an autocrine mechanism. Journal of cellular biochemistry, 
83(1), 70-83.  
 
Zwerina, J., Redlich, K., Polzer, K., Joosten, L., Krönke, G., Distler, J., . . . Hoffmann, 
O. (2007). TNF-induced structural joint damage is mediated by IL-1. 
Proceedings of the National Academy of Sciences, 104(28), 11742-11747.  
 
 
 
 Appendices (ethics) 159 
Appendices (ethics) 
 
 
 
 Appendices (ethics) 160 
 
 
